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ABSTRACT 
 
Mammalian cells have evolved highly regulated defence pathways, which are 
activated in response to stress. The transcription factor Nrf2 is activated in 
response to chemical and oxidative stress and induces the expression of 
antioxidants and detoxification enzymes. Nrf2 activity is regulated by its 
cysteine-rich repressor protein Keap1, which facilitates Nrf2 degradation. In 
the presence of electrophilic compounds and/or oxidative stress, Keap1-
mediated repression of Nrf2 is hindered, allowing the nuclear localisation of 
Nrf2 and the up-regulation of cell defence gene expression. The 
dysregulation of the Nrf2 pathway has been associated with many disease 
pathologies, and is a promising therapeutic target. Furthering our 
understanding of the chemico-biological triggers for Nrf2 activation may 
inform the design of novel Nrf2-inducers with increased efficacy and reduced 
toxicity. The modification of one or more cysteine residues in Keap1 by 
electrophiles is believed to be central to Nrf2 activation. Therefore, the aims 
of the studies in this thesis were to investigate the chemical modification of 
Keap1 cysteine residues by Nrf2-inducers and identify novel Keap1 binding 
proteins, which may play a role in the regulation of Nrf2 activity.  
  
Previous work carried out in this lab identified cysteine residues in Keap1 that 
are covalently modified by a panel of Nrf2-inducing compounds in 
recombinant Keap1 protein and in cells. Additionally, Nrf2 can be induced by 
glutathione (GSH) depletion in the absence of Keap1 adduct formation. We 
hypothesised that GSH depletion permits reactive oxygen species (ROS) to 
accumulate and oxidise Keap1 cysteine residues, thereby inducing Nrf2. To 
address this, we treated Keap1-V5 expressing HEK293T cells with Nrf2-
inducing compounds. We used liquid chromatography tandem mass 
spectrometry (LC-MS/MS) to investigate the ability of these compounds to 
form adducts with Keap1 cysteine residues, or induce reversible/irreversible 
redox modifications of these residues. We show that compounds which form 
covalent adducts with Keap1 and deplete GSH (i.e. 2,4-dinitrochlorobenzene) 
or do not deplete GSH (i.e. dexamethasone 2,1-mesylate) induce 
modifications of Keap1 that could be representative of oxidation. However 
compounds which do not form covalent adducts with Keap1 but cause 
oxidative stress (i.e. hydrogen peroxide), or GSH depletion (i.e. L-buthionine-
sulfoximine), do not appear to cause oxidative-like modification of Keap1 
cysteines. We therefore show that some Nrf2 inducers promote the formation 
of reversible and/or irreversible redox modifications of Keap1 which could be 
due to thiol oxidation, although this is not dependent on GSH depletion.  
 
To further explore the modification of Keap1 cysteine residues by Nrf2 
inducers, we investigated the ability of triterpenoids (TPs) to modify Keap1. 
TPs, in particular methyl 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate 
(CDDO-Me), are potent inducers of Nrf2 and are potential therapeutic agents. 
   
ii 
 
However, the mechanism of Nrf2 activation by TPs has not been fully 
elucidated using LC-MS/MS. We identify key cysteine residues in Keap1 
which are adducted by a chemically-tuned TP (CDDO-Epoxide) in 
recombinant Keap1 and in cells expressing Keap1-V5. Additionally, we use 
an in silico modelling approach to visualise the binding orientations of CDDO-
Epoxide with key Keap1 cysteine residues. Correlating the potency of a panel 
of TPs towards the Nrf2 pathway with their in silico propensity to bind 
covalently to the identified residues showed no relationship. However, we 
show significant positive correlation between the potency of these TPs 
towards Nrf2 and their in silico propensity to bind non-covalently in two 
cysteine-containing pockets (Cys-273, -288) in Keap1. These data reveal the 
specific sites of interactions between potent TP Nrf2 inducers and Keap1, 
and highlight the non-covalent binding of Keap1 by electrophiles as a 
potential mechanism of Nrf2 activation.  
 
The function of Keap1 is regulated by interactions with binding partners, such 
as sequestosome1 (p62) which targets it for autophagic degradation, or 
PGAM5 which localises Keap1 to the mitochondria. We previously used an 
LC-MS/MS approach to identify p62 as a novel Keap1-binding partner in 
cells. Therefore, we reasoned that using the same experimental approach 
with a more sensitive MS system, we could identify additional Keap1-binding 
proteins. Specifically, we identified a large number of proteins that co-purified 
with Keap1-V5 from HEK293T cell lysates, of which 55 were found to contain 
a known Keap1 binding motif, such as the one found in Nrf2, p62 and 
PGAM5. Network analysis highlighted the potential link between Keap1/Nrf2 
and the p53 cell survival pathway. We validated the LC-MS/MS data using a 
yeast 2-hybrid screen, which reveals HBS1L, RIC8A and PSMD3 as novel 
Keap1 binding partners, although the functional relevance of the interaction 
of these proteins with Keap1 requires further investigation. 
 
In summary, the data presented in this thesis demonstrates that whilst the 
covalent modification of Keap1 cysteines is an important aspect of Nrf2 
induction, the oxidation of Keap1 thiols may be an alternative mechanism. 
We identify key cysteine residues in Keap1 covalently modified by a potent 
TP Nrf2 inducer in recombinant protein and cells, but show that non-covalent 
modification of Keap1 may be involved in the process of Nrf2 activation by 
this class of compound. It will be important in future studies to determine how 
the modification of Keap1 cysteine residues is translated to the activation of 
Nrf2. Additionally, we identify putative novel Keap1 binding partners which 
may serve to regulate the activity of the Nrf2 pathway. Overall, these findings 
expand our understanding of the chemical and molecular interactions that 
govern the activity of Nrf2, and will therefore contribute to the ongoing efforts 
to target this pathway as a novel therapeutic strategy in numerous diseases. 
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1.1 INTRODUCTION 
 
In order for cells to function efficiently and synergistically, they must be 
maintained in a homeostatic state. Deviation from this homeostatic state may 
lead to an increase in the susceptibility of the cells to damage. The loss of 
homeostatic conditions can be brought about by chemical and/or oxidative 
stress, which can originate from external sources (i.e. via the ingestion of a 
pharmacological agent), or internal sources, such as the accumulation of 
reactive oxygen species (ROS). To adapt to the stress and limit damage, 
cells have evolved multi-faceted, highly-regulated defence mechanisms to 
respond to varying levels and types of stress, and initiate defence pathways 
accordingly. Indeed, numerous pathways are activated simultaneously to 
confer survival and limit the spread of stress or damage to neighbouring cells 
and surrounding tissue. If these defence mechanisms become defective, 
cells can be vulnerable to damage and disease pathologies. These defence 
pathways are often regulated by transcription factors which activate the 
transcription of genes involved in cell defence. 
 
The most important defence pathway employed by cells to defend against 
chemical and oxidative stress is coordinated by the transcription factor 
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) (Park et al. 2010, 
Motohashi and Yamamoto 2004, Lewis et al. 2010, Ishii et al. 2000). Nrf2 
mediates the basal and inducible expression of cytoprotective genes 
including detoxification enzymes and antioxidants. The up-regulation of this 
pathway enhances the removal of stressors from the cell, limiting the 
potential for damage and reducing the risk of toxicity. Nrf2 is ubiquitously 
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expressed, however, it is more prominent in organs of the body that are 
exposed to the environment, such as the skin, the gastrointestinal tract, and 
the liver, the main drug metabolising organ of the body(J. M. Lee et al. 2005). 
The regulation of this pathway has been attributed toKeap1 (Kelch-like ECH-
associated Protein 1), a cysteine rich protein which can “sense” the presence 
of chemical or oxidative stress such as electrophilic activators of Nrf2 
(Wakabayashi et al. 2004). This pathway is activated by many compounds, 
including naturally occurring phytochemicals (Jaramillo and Zhang 2013) and 
reactive metabolites generated by drug metabolism processes, many of 
which activate Nrf2 via the modification of cysteine residues in Keap1 
(Jaramillo and Zhang 2013, Copple et al. 2008a). 
 
The Nrf2 pathway is protective against drug-induced toxicities (Copple et al. 
2008b) and its dysregulation has been linked to a variety of diseases 
(Hybertson et al. 2011, Jaramillo and Zhang 2013, Ramsey et al. 2007), thus, 
Nrf2 is a promising therapeutic target. Increasing our knowledge regarding 
the mechanism of action of Nrf2 inducers, and furthering our understanding 
ofKeap1 as the point of interaction between a cell’s chemical environment 
and Nrf2 activation will be important for developing therapeutic agents that 
target this pathway in a safe and efficacious manner. Therefore, the focus of 
this thesis is to investigate the mechanisms whereby molecular interactions 
with Keap1 are capable of regulating the activity of Nrf2, in particular via the 
modification of its redox-sensing cysteine residues. 
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1.2 CELL DEFENCE 
 
Cells can respond to stress in numerous ways, from activating survival 
pathways, to the initiation of cell death. The path taken by the cell often 
depends on the nature and severity of the stress being encountered. Often, 
there is interplay between the pathways activated, to ensure cell survival and 
limit damage. Upon initial exposure to stress, the cell will activate pathways 
which aim to defend against the stress being encountered, thus encouraging 
cell survival. However, if the stress is sustained or the initial cell defence 
mechanisms become overwhelmed, cell death may be initiated. Under 
conditions whereby cells are exposed to chemical or oxidative stress, such 
as in the presence of reactive drug metabolites in the liver, a carefully 
regulated set of protective pathways function synergistically to couple the 
bioactivation and bioinactivation of compounds which allows a therapeutic 
effect to occur, whilst limiting exposure and the potential for damage. These 
cell defence mechanisms can be grouped into three tiers (Figure 1.1). The 
first is the basal, constitutive expression of detoxification enzymes and 
antioxidants, and the second is the activation of cytoprotective genes by 
transcription factors to enhance basal defences. The third tier is the 
activation of programmed cell death (apoptosis), in an attempt to limit the 
spread of damage to neighbouring cells. 
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Figure 1.1. The tiers of cell defence. Cell defence consists of 3 main tiers, 
their activity determined by the level of stress in the cell. Basally, cells 
express constitutive levels of non-protein antioxidants and detoxification 
enzymes. The second tier is activated by transcription factors such as Nrf2 to 
up-regulate the expression of antioxidants and detoxification enzymes. If 
these defence mechanisms are overwhelmed, toxicity occurs and apoptosis 
is activated to limit the spread of damage. (Adapted from Nel et al. (2006) 
 
 
1.2.1 Tier I of cell defence- basal 
 
Under basal conditions, there are constitutive levels of non-protein 
antioxidants and enzymes present in the cell. These are capable of 
detoxifying a range of reactive species including electrophiles and free 
radicals, generated via aerobic metabolic transformations(Yu 1994). This tier 
also includes drug metabolising enzymes which facilitate the bioactivation of 
bioinactivation of xenobiotics. Non-protein antioxidants include α-Tocopherol, 
ascorbic acid, β-carotene, bilirubin and glutathione (GSH). α-Tocopherol is a 
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potent antioxidant found in vegetable oils,and is primarily involved in breaking 
chain reactions involving oxygen and lipid peroxyl free radicals, resulting in a 
relatively stable form of vitamin E(Engin 2009). Thus, it protects against 
membrane lipid peroxidation (Yu 1994). Ascorbic acid (vitamin C), is a 
naturally occurring compound which can recycle oxidised vitamin E and 
scavenge ROS(Yu 1994). β-Carotene, the pre-cursor of retinol (Vitamin 
A)found in plants and fruits, scavenges ROS and protects lipids against 
peroxidation (Yu 1994).Additionally, bilirubin, the breakdown product of 
heme, scavenges peroxyl radicals, protecting from lipid peroxidation (Sedlak 
et al. 2009). The most vital non-protein thiol is GSH, discussed in Section 
1.4.2. 
 
1.2.2 Tier II of cell defence- adaptive response 
 
The second tier of cell defence involves the up-regulation of cytoprotective 
pathways via the induction of cell defence genes, such antioxidants and drug 
metabolising enzymes. This up-regulation is facilitated by redox-sensitive 
transcription factors which recognise and bind to distinct, specific 
deoxyribonucleic acid (DNA) regions, recruiting co-factors and ribonucleic 
acid (RNA) polymerase to facilitate the transcription and translation of target 
genes. One of the key transcription factors involved in the adaptive response 
to cell defence is Nrf2, which aims to restore cellular redox homeostasis, and 
is activated by the presence of chemical and oxidative stress in the cell. At 
higher levels of oxidative stress, the pro-inflammatory signalling pathways 
take over, facilitated by the activation of the mitogen activated protein kinase 
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(MAPK) and the nuclear factor κB (NF-κB) pathways (Nel et al. 2006). When 
cells are exposed to low levels of ROS, NF-κB encourages cell survival, 
however when higher levels of ROS are encountered, NF-κB is inhibited, 
promoting cell death (Trachootham et al. 2008).Additionally, the redox 
sensitive transcription factor activator protein 1 (AP-1) promotes either cell 
survival or cell death dependent on the tissue type or developmental stage 
(Trachootham et al. 2008). Under conditions of increased temperature and 
other stresses, heat shock factor protein 1 (HSF1) transcription factors 
induce the expression of heat-shock proteins (HSP), which act as molecular 
chaperones to restore protein function or facilitate the degradation of 
irreparably damaged proteins (Kiang and Tsokos 1998). 
 
1.2.3 Tier III of cell defence-toxicity and apoptosis 
 
Should efforts to detoxify and eliminate a stress be overcome, toxicity ensues 
and the cell will initiate the apoptotic pathway. This can be considered a 
“breaking point”, i.e. sufficient damage has accumulated in the cell so much 
that it will no longer be able to return to a homeostatic state. Apoptosis, or 
programmed cell death, is a mechanism whereby the cell can prevent the 
spread of damage to neighbouring cells by facilitating its own death. 
Oxidative stress-induced apoptosis often stems from damage to the 
mitochondria, such as the loss of mitochondrial membrane potential, the 
release of cytochrome c into the cytosol, and the degradation of 
mitochondrial enoded DNA (Davies 2000). The characteristics of apoptosis 
include cell shrinkage and membrane blebbing, although the integrity of the 
membrane is maintained(Elmore 2007). Components of the cell are formed 
into membrane bound apoptotic bodies which are engulfed by neighbouring 
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phagocytic cells(Elmore 2007), thus there is no release of cellular contents 
into the surrounding tissue, and no inflammatory response (Elmore 2007). 
Apoptosis is characteristically distinct from necrosis as in the latter, cells 
swell, resulting in a loss of membrane integrity and leaking of cellular 
contents, inducing an inflammatory response (Elmore 2007). Apoptosis, 
rather than necrosis, is considered a cell defence mechanism as it is induced 
to protect the tissue, whilst necrosis is an uncontrollable consequence of 
cellular damage (Davies 2000). Apoptosis is partly regulated by the cellular 
redox state, and oxidative stress is central to apoptotic pathways induced by 
toxicity (Franco et al. 2009). 
 
1.3  REDOX REGULATION OF CELL DEFENCE 
 
ROS play an important role in cell survival, and many cell defence 
mechanisms are redox-sensitive (Trachootham et al. 2008). Whilst moderate 
levels of ROS can encourage cell proliferation and survival, severe ROS 
accumulation can trigger cell death. Thus, the balance between the 
generation and elimination of ROS maintains cellular homeostasis and the 
function of redox sensitive proteins (Trachootham et al. 2008). Redox-
sensitivity is commonly conferred by the presence of sulphydryl groups found 
in cysteine residues. These groups can regulate protein function via 
reversible or irreversible redox reactions such as the loss of electrons 
(oxidation), or the gain of electrons (reduction). The possible redox changes 
of sulphydryl groups are outlined in Fig 1.2. If a cysteine residue is located 
adjacent to a basic amino acid (arginine, lysine, histidine), it can be stabilised 
in a thiolate form (-S-), which is more nucleophilic and reacts more readily 
with oxidants and nucleophiles than a protonated thiol (-SH; a) (Snyder et al. 
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1981). The thiol can undergo oxidation to yield sulphenic acid (-SOH; b), 
which can be further oxidised to sulphinic acid (-SO2H; c) and subsequently 
the terminal oxidation state, sulphonic acid (SO3H; d)(Paget and Buttner 
2003). Primary oxidation can also lead to the formation of disulphide bonds 
(S-S), either intramolecular (e), intermolecular (f), or with non-protein thiols 
such as GSH via S-glutathiolylation (g) (Paget and Buttner 2003). 
Furthermore, thiol-disulphide exchange reactions occur between thiols and 
disulphides (h), and thiols can be modified by reactive nitrogen species (NO) 
or peroxinitrite (ONOO-), yielding S-nitrothiols (-SNO;i /-SNO2; j) (Cooper et 
al. 2002). 
Figure 1.2.Overview of the states of cysteine oxidation. Details of each 
oxidation state are in the main text. Adapted from Paget and Buttner (2003).  
  Chapter 1 
- 12 - 
 
 
1.4 THE ANTIOXIDANT RESPONSE PATHWAY 
 
Mammalian cells have evolved numerous cell defence pathways in order to 
maintain cellular homeostasis. One such pathway is termed the antioxidant 
response pathway. This pathway facilitates the up-regulation of an array of 
cytoprotective enzymes which enhance the metabolism of electrophilic 
moieties and oxidants in the cell, thus reducing the presence of stress. This 
pathway is comprised of three main components, which are; a) the 
antioxidant response element (ARE), a DNA sequence within the promoter 
region of cytoprotective genes, b) Nrf2, the transcription protein that binds to 
the ARE and c) Keap1, the cysteine-rich, redox-sensitive repressor of Nrf2. 
 
1.4.1 Nuclear Factor Erythroid 2 (NF-E2) -Related Factor 2 (Nrf2) 
 
Nrf2 was first isolated in a screen of a hemin-induced complimentary DNA 
(cDNA) library for proteins which could bind to the AP1-nuclear factor 
erythroid 2 (NF-E2) repeat promoter sequence(Moi et al. 1994).It is a 
cap’n’collar bZip transcription factor primarily responsible for the adaptive 
response to chemical and oxidative stress by up-regulating the expression of 
ARE-containing genes which are involved in drug metabolism, the oxidative 
stress response and cytoprotection (Miao et al. 2005). Nrf2 is ubiquitously 
expressed, both in humans and mice, and is highly expressed in organs 
which are involved in detoxification (the liver and kidneys), and those 
exposed to the external environment (the skin, gastrointestinal tract, and 
lungs) (Motohashi et al. 2002, Moi et al. 1994).  
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Nrf2 was shown to up-regulate the expression of target genes by binding to 
the ARE (Venugopal and Jaiswal 1996, Nguyen et al. 2000), a cis-acting 
DNA enhancer motif, as identified in with a consensus sequence as follows: 
 
5’-gagTcACaGTgAGtCggCAaaatt-3’ 
(Essential nucleotides in capitals and the core in bold) (Nioi et al. 2003). 
 
Nrf2 binds to this consensus sequence with high affinity only when in a 
homodimer with small Maf proteins (MafF, MafK, MafG) (Itoh et al. 1997). 
Maf proteins interact with other bZip proteins, however lack transactivation 
domains, therefore are reliant on Nrf2 to promote transcription (Kataoka et al. 
1993, Motohashi et al. 2002). The comparison of the human Nrf2 amino acid 
sequence with that of the chicken Nrf2 sequence revealed six highly-
conserved regions, the Nrf2-ECH (erythroid-derived CNC homology protein) 
homology (Neh) domains, which are important for Nrf2 function (Itoh et al. 
1999) (Fig 1.3, Table 1.1). The binding of Nrf2 to the ARE is reliant on a 
conserved cysteine residue (Cys-506) within the Neh1 domain (Bloom et al. 
2002). Co-activator proteins, such as cAMP responsive element binding 
protein (CREB)–binding protein (CBP) are recruited to enhance 
transcriptional activity (Kalkhoven 2004, Katoh et al. 2001). 
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Figure. 1.3. Structure and Functional domains of Nrf2. Schematic 
overview of the six Neh domains of Nrf2. See table 1.1 for the functions of 
each domain. The names of the domains are shown in the green boxes, with 
the amino acid residue at the beginning of each domain shown below. 
 
Domain Residues Function Reference(s) 
Neh2 1-96 Facilitates interaction with 
Keap1 via DLG/ETGE motif. 
Point of lysine ubiquitination 
Point of serine 
phosphorylation by PKC 
Itoh et al. (1999) 
Katoh et al. (2005) 
McMahon et al. 
(2006) 
McMahon et al. 
(2004) 
Tong et al. (2006) 
(Numazawa et al. 
2003) 
Neh4 111-141 Transactivation domain 
Interaction with CBP 
Point of phosphorylation by 
CK2 in vitro 
Katoh et al. (2001) 
Apopa et al. (2008) 
Neh5 172-201 As Neh4 
Contains nuclear export 
signal 
Interacts with caveolin-1 
Katoh et al. (2001) 
Li et al. (2006) 
Zhang et al. (2007) 
(W. Li et al. 2012) 
Neh6 330-380 Facilitates Nrf2 regulation 
under stress conditions 
Facilitates interaction with β-
TrCp 
McMahon et al. 
(2004) 
Chowdhry et al. 
(2013) 
Neh1 427-560 Facilitates binding to ARE 
and small Maf proteins 
Contains nuclear 
localisation/export signals 
Point of acetylation 
byp300/CBP 
Bloom et al. (2002) 
Itoh et al. (1999) 
Sun et al. (2009) 
Neh3 561-597 Transactivation 
Interaction with other co-
activator proteins 
Nioi et al. (2005) 
Table 1.1.Functional domains of Nrf2. 
 
Neh2
Keap1 binding DNA binding
N C
1 605
Neh4 Neh5 Neh6 Neh1 Neh3
Neh2
29DLG31 79ETGE82α helix
111 172 330 427 561
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The genes regulated by Nrf2 can be categorised as; drug-metabolizing 
enzymes; antioxidants; molecular chaperones; DNA repair enzymes; and 
anti-inflammatory proteins (Table 1.2) (Hayes and McLellan 1999, Nguyen et 
al. 2003b). Their co-ordinated up-regulation by Nrf2 enhances removal of the 
insult, thereby restoring the cell to a basal state and conferring resistance to 
stress. This prevents damage to cellular components which are sensitive to 
changes in the redox state of the cell, such as proteins, lipids and DNA, 
which, if damaged, can promote cell death. 
 
Nrf2 has been linked to a diverse array of cellular mechanisms including, but 
not limited to differentiation, proliferation, apoptosis (Y. Li et al. 2012)and lipid 
metabolism in the liver(Kitteringham et al. 2010). As expected, Nrf2knockout 
(Nrf2-/-) animals show reduced basal and/or inducible expression of 
detoxification and antioxidant genes across tissues (liver, lung, skin) (Ramos-
Gomez et al. 2001, Rangasamy et al. 2005, Xu et al. 2006, Walsh et al. 
2014). This has knock-on effects, in that the animals are more susceptible to 
toxicity by xenobiotics and environmental stresses (Copple et al. 2008b). 
TheNrf2-/- animals exhibit no characteristic phenotype, in that they exhibit no 
growth or developmental issues (Chan et al. 1996). However, these mice do 
develop vacuolar leukoencephalopathy characterised by myelin degeneration 
and the presence of cavities in the brain (Hubbs et al. 2007). Moreover, these 
animals develop lupus-like symptoms including nephritis (inflammation of the 
kidney) (Yoh et al. 2001). Ultimately this indicates that whilst Nrf2 is not 
essential for the growth and development of mice, it is vital for survival 
following insult. 
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Protein Function Reference(s) 
ATP-binding 
cassette 
transporters (ABC) 
Drug transporters Malhotra et al. (2010) 
Hirotsu et al. (2012) 
Maher et al. (2007) 
Aldo-keto 
reductases (AKR) 
Reduces aldehydes and 
ketones to primary and 
secondary alcohols 
Lou et al. (2006) 
Nishinaka and Yabe-
Nishimura (2005) 
Cytochrome p450 
enzymes (CYP) 
Phase I drug metabolism Malhotra et al. (2010) 
Yates et al. (2009) 
Glutamate cysteine 
ligase, catalytic 
subunit (GCLC) 
Catalyses the conjugation 
of cysteine with L-
glutamate yielding γ-
glutamylcysteine (γ-GC) 
Chan and Kwong (2000) 
Jeyapaul and Jaiswal 
(2000) 
Glutamate cysteine 
ligase, modifier 
subunit (GCLM) 
Increases kinetic efficiency 
of GCLC-mediated 
reaction 
Chan and Kwong (2000) 
Moinova and Mulcahy 
(1999) 
Glutathione 
peroxidases (GPX) 
Catalyse reduction of 
peroxides (e.g. H2O2), 
uses GSH as a substrate 
Banning et al. (2005), 
Singh et al. (2006) 
Glutathione 
Reductase (GSR) 
Catalyses reduction of 
oxidised glutathione 
(GSSG) to GSH 
Thimmulappa et al. 
(2002) 
Glutathione 
Synthetase (GS) 
Catalyses conjugation of 
glycine with γ-GC to give 
GSH 
T. D. Lee et al. (2005) 
Glutathione-S-
transferase (GST) 
Catalyses conjugation of 
GSH to electrophiles 
Chanas et al. (2002) 
Hayes et al. (2000), 
McMahon et al. (2001) 
Heme-oxygenase 1 
(HO-1) 
Catabolises heme 
degradation 
Alam et al. (1999) 
Ishii et al. (2000) 
NAD(P)H:quinone 
oxidoreductases 
(NQO) 
Catalyses reduction and 
detoxification of quinones 
Venugopal and Jaiswal 
(1996) 
Wang and Jaiswal 
(2006) 
Peroxiredoxin 1 
(PRX1) 
Reduces peroxides Y. J. Kim et al. (2007) 
Superoxide 
Dismutase (SOD) 
Converts superoxide 
radicals into H2O2 and 
oxygen (O2) 
Park and Rho (2002) 
Sulfiredoxin 
(SRXN1) 
Catalyses reduction of 
PRX 
Abbas et al. (2011), 
Jeong et al. (2012) 
Thioredoxins (TRX) Catalyses reduction of 
disulphides to sulphydryl 
groups 
Kim et al. (2001) 
Kim et al. (2003) 
Table 1.2 Cell defence proteins encoded by Nrf2-regulated genes. 
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1.4.2 Glutathione (GSH) 
 
Upon activation of Nrf2, the synthesis of the abundant non-protein antioxidant 
GSH is up-regulated. GSH is a tripeptide comprised of glycine, cysteine and 
glutamic acid expressed in virtually all mammalian cells (Yu 1994), with roles 
in many aspects of homeostasis (Pompella et al. 2003). GSH can act as both 
a nucleophile and a reductant, and can detoxify oxidising agents and 
electrophiles via its reactive thiol group (Pompella et al. 2003). GSH is 
synthesised in two ATP dependent steps; 1) the rate limiting conjugation of 
cysteine with L-glutamate via γ-glutamate cysteine ligase (GLC) resulting in 
γ-glutamylcysteine and; 2) the addition of glycine to the C-terminal of γ-
glutamylcysteine via glutathione synthetase (GS) yielding γ-
glutamylcysteinylglycine (GSH) (Fig. 1.4A) (Kaplowitz et al. 1985).  
 
During GSH-mediated detoxification of peroxides, reduced GSH donates a 
reducing equivalent via glutathione peroxidase forming the oxidised form 
GSSG, a glutathione disulphide. This is recycled back to GSH in a 
nicotinamide adenine dinucleotide phosphate (NADPH)–dependent manner 
via glutathione reductase (Fig 1.4B). In a healthy cell, the ratio of GSH:GSSG 
is upwards of 9:1, with an increase in GSSG:GSH ratio indicative of oxidative 
stress (DeLeve and Kaplowitz 1991). If GSSG accumulates, it can be actively 
transported out of the cell to protect from a shift in the redox equilibrium 
(DeLeve and Kaplowitz 1991). The ability of GSH to conjugate with 
electrophiles is facilitated by its nucleophilic cysteine residue and can occur 
spontaneously or enzymatically, forming thioether conjugates (DeLeve and 
Kaplowitz 1991). The GSH conjugates are cleaved to remove the γ-glutamyl, 
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and dissociate the cysteinyl-glycine conjugate leaving a simple cysteinyl 
conjugate which is acetylated to form mercapturic acid (DeLeve and 
Kaplowitz 1991). The breakdown products are normally excreted or recycled.  
 
 
Figure 1.4. Chemical structure of GSH (A) and the recycling of oxidised 
glutathione (GSSG) to reduced glutathione (GSH) (B). 
 
 
 
1.4.3 Detoxification enzymes 
 
Other mechanisms of detoxification activated by Nrf2 include those facilitated 
by enzymatic reactions. The superoxide dismutase (SOD) family catalyse the 
dismutation of two superoxide anion radicals (O2
-) to H2O2 and O2(Nordberg 
and Arner 2001). H2O2 can be further reduced to H2O and O2 by catalase, 
glutathione peroxidases (GRX) or peroxiredoxins (PRX) (Nordberg and Arner 
2001). Catalase is a heme-containing enzyme which catalyses the 
conversion of H2O2 to H2Oand molecular oxygen, as well as detoxifying 
phenols and alcohols (Nordberg and Arner 2001). Peroxiredoxins (PRX) are 
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involved in the reduction of peroxides via a conserved cysteine residue (the 
peroxidatic cysteine), which can be oxidised to a sulphenic acid (Wood et al. 
2003). Typical PRXs form homodimers and the resolving cysteine in one 
PRX facilitates the recycling of the peroxidatic cysteine in another, forming a 
stable intermolecular disulphide bond (Wood et al. 2003). The atypical PRXs 
contain both cysteine residues in one peptide forming an intra-molecular 
disulphide bond upon reduction (Wood et al. 2003). These dipeptides can be 
reduced by thioredoxins (TRX) to re-establish PRX function(Wood et al. 
2003). In turn, the oxidised TRX is reduced by TRX reductase (TRXR) at the 
expense of NADPH (Collet and Messens 2010) (Fig 1.5). 
 
Figure 1.5.The recycling of oxidised peroxiredoxin via thioredoxin. 
Peroxiredoxin (PRX) is oxidised by hydrogen peroxide (H2O2) to a sulphenic 
acid intermediate. Further oxidation results in disulphide bond formation 
which can be reduced by thioredoxin (TRX) to re-establish PRX function. 
TRX is reduced by thioredoxin reductase (TRXR) at the expense of NADPH. 
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1.4.4 Kelch-like ECH Associated Protein 1 (Keap1) 
 
The activation of Nrf2 must be tightly regulated to prevent its constitutive 
activation, and this is facilitated by its repressor protein Keap1. Initial 
observations showed that in the absence of cellular stress, Nrf2 is 
sequestered in the cytosol by an inhibitor protein which it binds via the Neh2 
domain (Itoh et al. 1999). Keap1 was identified as this inhibitor following the 
observation that the deletion of the Neh2 domain of Nrf2 results in a 
significant increase in basal Nrf2 activity in erythroblasts (Itoh et al. 1999). 
Keap1 is regarded as the regulator of Nrf2 as when transfected into cells, 
recombinant Nrf2 accumulates in the nucleus however, when co-transfected 
with Keap1 the two co-localise in the cytoplasm (Itoh et al. 1999). In the 
presence of electrophiles such as diethyl maleate, this co-localisation is lost 
and Nrf2 localises in the nucleus (Itoh et al. 1999). Additionally, the over-
expression of Keap1 in cells reduces the activation of ARE-regulated genes 
(Dhakshinamoorthy and Jaiswal 2001, Itoh et al. 1999), whilst siRNA 
mediated knockdown of Keap1 results in increased Nrf2 levels in the cell 
(Williamson et al. 2012).Keap1 was named due to sequence similarities to 
the Drosophila cytoskeleton-binding protein Kelch (Xue et al 1993) (Figure 
1.6, Table 1.3). Keap1 is primarily located in the cytosol of the cell and 
interacts with the actin cytoskeleton and the mitochondria (Kang et al. 2004, 
Lo and Hannink 2008). Two Keap1 molecules are responsible for binding and 
sequestering one Nrf2 molecule (Tong et al. 2006).A more detailed 
explanation of how Keap1 regulates Nrf2 localisation and activity is provided 
in Section 1.5. 
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Figure 1.6.The functional domains of Keap1.Schematic of the three main 
functional domains of Keap1. BTB- bric-a-brac/tram-track/broad complex; 
IVR- intervening linker region; DGR- double glycine repeats. The positions of 
the cysteine residues in human Keap1 are indicated. See table 1.3 for details 
of the functions of each domain 
 
 
 
Domain Residues Function Reference(s) 
BTB 59-178 Facilitates 
homodimerisation and 
interaction with Cul3 / 
ubiquitination machinery 
 
Zipper and Mulcahy 
(2002) 
IVR 178-321 Contains many reactive 
cysteine residues 
 
Bryan et al. (2013) 
DGR 321-609 Kelch repeats 
Facilitates interaction with 
Nrf2 and other binding 
partners such as actin 
cytoskeleton 
Dhakshinamoorthy 
and Jaiswal (2001) 
Itoh et al. (1999) 
McMahon et al. 
(2006) 
Kang et al. (2004) 
Table 1.3.The functional domains of Keap1. 
 
Keap1-deficient mice (Keap1-/-) do not survive longer than 3 weeks post 
natally, and suffer from severe malnutrition due to hyperkeratosis of the 
digestive system, leading to ulcers in the oesophagus and stomach 
(Wakabayashi et al. 2003). This phenotype is rescued by synchronous 
knockout of Nrf2 and Keap1 (Keap1-/-::Nrf2-/-) indicating that this phenotype is 
due to Nrf2 accumulation, and that Nrf2 is likely to be the only down-stream 
BTB IVR DGR
Dimerisation/
Cul3 binding
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Nrf2 binding
N C
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effector of Keap1 (Wakabayashi et al. 2003). This made studying the role of 
Keap1 in the in vivo regulation of Nrf2 difficult, until the development of a 
hepatocyte-specific Keap1 knockout using a Cre-LoxP system (Okawa et al. 
2006). These mice show resistance to APAP doses which would be toxic to 
WT mice. Ultimately, this indicates that Keap1 is the main regulator of Nrf2.  
 
1.4.5 The hinge and latch hypothesis 
 
In the absence of cellular stress, the half-life of Nrf2 protein is approximately 
10-30 minutes (Itoh et al. 2003, Alam et al. 2003). This observation cannot be 
explained purely by the ability of Keap1 to tether Nrf2 in the cytosol. The 
inhibition of the proteasome results in the accumulation of Nrf2 protein in the 
cell, in particular in the nucleus, and an increase in the activation of ARE-
dependent gene expression (Sekhar et al. 2000, McMahon et al. 2003, 
Yamamoto et al. 2007). Under these conditions, ubiquitinated Nrf2 has been 
detected, suggesting that Keap1 is not simply a cytosolic anchor, but it also 
directs the poly-ubiquitination of Nrf2, leading to its proteasomal degradation 
(Cullinan et al. 2004, McMahon et al. 2003). This ubiquitination is facilitated 
by a Cullin-dependent E3 ubiquitin ligase complex which interacts directly 
with Keap1and is crucial for Nrf2 proteasomal degradation (Kobayashi et al. 
2004, Cullinan et al. 2004). The mutation of seven lysine residues within the 
Neh2 domain of Nrf2 inhibits the Keap1-mediated ubiquitination of Nrf2, thus 
preventing its proteasomal degradation and increasing its half-life (Zhang et 
al. 2004). Nrf2 must be appropriately positioned in order for the Keap1/Cul3 
complex to ubiquitinate the lysine residues, and this has led to the 
development of the “hinge and latch” hypothesis of Nrf2 regulation by Keap1. 
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In the absence of cellular stress, Nrf2 is sequestered in the cytosol, with a 
Keap1 homodimer acting as a substrate adaptor for the ubiquitination of Nrf2, 
in a Cul3 dependent manner (Kobayashi et al. 2004). Nrf2 binds to the DGR 
site of each Keap1 subunit in the homodimer via two motifs within the Neh2 
domain, one high affinity, 79ETGE82, and one low affinity, 29DLG31 (Tong et al. 
2006). The “hinge and latch” hypothesis proposes that the ETGE binding site 
acts as a hinge, permitting Nrf2 to bind to Keap1 but able to move freely. On 
the other hand, the DLG site acts as a latch hindering the movement of Nrf2. 
When bound via both binding sites, target lysine residues within the Neh2 
region of Nrf2 are positioned to undergo poly-ubiquitination via the Cul3 E3 
ligase, and Nrf2 is consequently degraded by the 26S proteasome (Fig 1.7A).  
 
Under conditions of chemical or oxidative stress, a conformational change in 
Keap1renders it unable to bind to Nrf2 via the DLG site, disrupting the 
transfer of ubiquitin molecules to Nrf2.As Nrf2 is no longer degraded, Keap1 
molecules become saturated with Nrf2 and newly synthesised Nrf2 
accumulates in the cytosol. This free Nrf2 is able to translocate to the 
nucleus and bind the ARE (Fig 1.7B). In this situation, the half-life of Nrf2 
increases, however the time varies between cell types due to differences in 
detectable basal levels of the Nrf2 (Kwak et al. 2001b, Nguyen et al. 2003a, 
Kwak et al. 2002). There is conflicting evidence on whether Nrf2 becomes 
free in the cell in the presence of stress, with evidence supporting the full or 
partial dissociation of the Keap1-Nrf2 complex (Levonen et al. 2004, Niture et 
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al. 2009)or the dissociation of Cul3 and Keap1 (Eggler et al. 2009, Gao et al. 
2007, Rachakonda et al. 2008), thus impeding the ubiquitination of Nrf2. 
 
 
 
Figure 1.7.Schematic of the hinge and latch hypothesis of Nrf2 
regulation.(A) Under basal conditions, a Keap1 homodimer binds a single 
Nrf2 molecule via two motifs- ETGE and DLG. This positions Nrf2 for lysine 
ubiquitination, targeting it for proteasomal degradation. (B) Under conditions 
of chemical or oxidative stress, binding via the low affinity DLG ‘latch’ is 
hindered due to a conformational change in Keap1, likely due to modification 
of one or more of Keap1’s cysteine residues. The ETGE domain remains 
bound to Keap1 acting as the “hinge”. Nrf2 is no longer located ideally for 
ubiquitination and Keap1 becomes saturated with Nrf2 molecules. Newly 
synthesised Nrf2 is free to accumulate in the cytosol and nucleus and thus 
activate the transcription of cytoprotective genes. Adapted from Bryan et al. 
(2013), based on work byTong et al. (2006), McMahon et al. (2006). 
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1.5 KEAP1-DEPENDENT REGULATION OF NRF2 
 
1.5.1 Keap1 as a sensor of stress 
 
Keap1 is a cysteine rich protein with 4.3% of all its residues being cysteines 
(27 of 624residues in human Keap1), approximately double the number of 
cysteine residues in the average protein (Miseta and Csutora 2000). Cysteine 
residues are commonly located within the functional domains of proteins and 
their thiol side chains (-SH) are nucleophilic and redox-sensitive, thus 
responsive to the local environment (Fig 1.5) (Marino and Gladyshev 2012). 
It is these reactive cysteine residues that are purported to afford Keap1 the 
ability to sense electrophilic or oxidative stress (Holland and Fishbein 2010). 
A number of Keap1 cysteine residues are considered to be highly reactive as 
they are flanked by basic amino acids, lowering the predicted pKa value of 
the residue, thus increasing its reactivity with electrophiles (Fig. 1.8)(Snyder 
et al. 1981). Both Cys-273 and –297 are immediately preceded and followed 
by basic residues, whilst Cys-151, -257, -434 and -613 have two or more 
basic residues in their proximity, in the primary structure of the protein. Thus, 
these residues are predicted to be highly reactive towards electrophiles. A 
vast number of Nrf2-inducing compounds are electrophilic and capable of 
reacting with cysteine thiol groups, forming direct covalent adducts. The 
ability of Nrf2-inducing compounds to form adducts with cysteine residues in 
Keap1 is considered to be the underlying mechanism of Nrf2-induction by 
electrophiles, and there is a considerable amount of literature supporting 
this(Chia et al. 2010, Copple et al. 2008a, Yamamoto et al. 2008, Dinkova-
Kostova et al. 2002).Other Nrf2-inducing compounds are oxidants which can 
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cause the addition of molecular oxygen to the SH group of cysteines. 
However, there is no concrete evidence demonstrating that Keap1 cysteine 
residues are sensitive to oxidation in vivo. Even so, Keap1 is considered a 
sensor of both chemical and oxidative stress within the cell, and it is 
postulated that the modification of specific cysteine residues disrupts the 
ability of Keap1 torepressNrf2 (Eggler et al. 2005).  
 
Figure 1.8.Cysteine residues in mouse Keap1 with low predicted pKa 
values. Full length sequence of Keap1 with cysteine residues highlighted in 
pink and labelled with their residue number. Basic amino acids (arginine (R), 
lysine (K), histidine (H)) flanking cysteine residues are highlighted in blue.  
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1.5.2 Evidence for chemical modification of Keap1 
 
The first proposal that Keap1 cysteine modification may play a role in Nrf2 
regulation was made by Dinkova-Kostova et al. (2002), who showed that a 
number of structurally dissimilar Nrf2 inducers were all reactive with Keap1 
cysteine residues at rates that correlated with their potency towards Nrf2. 
These Nrf2 inducers were capable of dissociating Keap1 from the Neh2 
region of Nrf2 in vitro (Dinkova-Kostova et al. 2002), implying that the thiol 
sensing mechanism is afforded by Keap1, as the Nrf2 Neh2 region contains 
no cysteine residues. Cysteine residues that lie in the IVR domain of Keap1; 
Cys-257, -273, -288 and -297 were shown to be particularly reactive 
(Dinkova-Kostova et al. 2002). Following this, it was shown in cells that Cys-
273 and -288are required for the basal repression of Nrf2 (Zhang and 
Hannink 2003). The expression of serine mutants of these Keap1 cysteines 
in cells results in constitutively increased Nrf2 levels, and no further increase 
in Nrf2–mediated gene expression following treatment of the cells with known 
Nrf2 inducers(Zhang and Hannink 2003). This study also identified a residue 
within the BTB region of Keap1 (Cys-151), required for Nrf2 regulation 
(Zhang and Hannink 2003). This cysteine is required for the stabilisation of 
Nrf2 following treatment with sulforaphane and tBHQ, and following its 
mutation to alanine (Keap1C151A), no Nrf2 induction is observed (Zhang and 
Hannink 2003). Zhang and Hannink (2003) also identified a stably-modified 
form of Keap1 which accumulates only following treatment with Nrf2-inducing 
compounds. This was the first evidence for electrophilic Nrf2-inducers 
modifying Keap1 and resulting in Nrf2 accumulation in cells. 
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There has been a vast quantity of literature published regarding the 
modification of Keap1 cysteine residues by Nrf2-inducing compounds. There 
does not appear to be a single cysteine or selection of cysteines that are 
reactive to all electrophilic Nrf2 inducers. Rather, some cysteine residues, 
spanning the Keap1 sequence, are more reactive than others(Holland et al. 
2008). The formation of direct adducts between a subset of cysteine residues 
in Keap1 and Nrf2-inducing electrophiles with similar structures, supports the 
hypothesis of a “cysteine code” and underlies the ability of Nrf2 to respond to 
such a diverse array of compounds (Kobayashi et al. 2009) (see Table 1.4 for 
the classes of Nrf2-inducing compounds). In support of the work performed 
by Zhang and Hannink (2003), the three cysteine residues which are most 
commonly adducted by Nrf2-inducing compounds are Cys-151, -273 and -
288. Work carried out in vivo shows that the expression of mutant Keap1 
(Keap1C273A/Keap1C288A) in Keap1-/- mice does not rescue Keap1’s ability to 
repress Nrf2, and results in constitutive activation of Nrf2, as seen in Keap1-
null cells(Yamamoto et al. 2008). On the other hand, mutant Keap1C151S 
retains the ability to suppress Nrf2, although it confers decreased expression 
of Nrf2-regulated genes both in the absence and presence of electrophilic 
insult (Yamamoto et al. 2008). Interestingly, the mutation of Cys-151 results 
in reduced Nrf2 activation in cells exposed to some inducers (tBHQ, DEM, 
sulforaphane) but not to others (CDDO-Im, mitro-oleic acid, cadmium 
chloride), compared to wild type cells (Takaya et al. 2012). These 
observations support the concept that Cys-273 and Cys-288 are required for 
basal Nrf2 repression, whilst Cys-151 is required for Nrf2 up-regulation in 
response to some Nrf2 inducers.  
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Class Example(s) Reference(s) 
Alkenes 
4-Hydroxynonenal 
 
Chen et al. (2005) 
Ishii et al. (2004) 
Zhang et al. (2006) 
 
Arsenicals 
Arsenite, Arsenate 
 
Prestera et al. (1993) 
Aono et al. (2003) 
Pi et al. (2003) 
Dithiolethiones 
Oltipraz, Anetholedithione 
 
Kensler et al. (2000) 
Ramos-Gomez et al. 
(2001) 
Petzer et al. (2003) 
Enones 
Chalcone, Acrolein 
 
Kumar et al. (2011) 
Tirumalai et al. (2002) 
 
Isothiocyanites 
Sulforaphane
 
Prestera et al. (1993), 
Thimmulappa et al. 
(2002) 
Jakubikova et al. 
(2006) 
Mercaptans / 
disulphides 
2-Mercaptoethanol 
 
Prestera et al. (1993) 
Chen et al. (2004) 
Fisher et al. (2007) 
Michael 
acceptors 
Diethylmaleate,CDDO-Me 
 
Prestera et al. (1993) 
Copple et al. (2014) 
Diphenols / 
quinones 
Hydroquinone, tBHQ 
 
Prestera et al. (1993) 
Lee et al. (2001) 
Li et al. (2005) 
Reactive oxygen / 
nitrogen species 
Hydrogen peroxide 
 
Prestera et al. (1993) 
Buckley et al. (2003) 
Ding et al. (2008) 
 
Table 1.4.Common classes of Nrf2-inducing compounds. Where more 
than one example is given, the structure shown is that of the example in bold 
type. 
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McMahon et al. (2010) propose that Keap1 can respond to endogenous 
stress by monitoring levels of cellular messengers NO, Zn+ and alkenals 
(which imply the presence of stress), using three unique cysteine sensors to 
confer an Nrf2 response. They further propose that whilst the Keap1 Cys-
151-dependent Nrf2-inducing nitric oxide (NO) –donor, acetoxymethylated 
diethylamine-NONOate (DEA-NO/AM) does not form direct adducts with Cys-
151, this cysteine may undergo S-nitrosylation facilitated by its flanking 
residues (His-129, Lys-131, Arg-135, Lys-150 and His-154) (McMahon et al. 
2010). The concept of the S-nitrosylation of Keap1 by NO is supported by 
others (Fujii et al. 2010, Um et al. 2011). This study also identified the 
sensors of Zn2+ as His-225, Cys-226 and Cys-613 of Keap1, and of alkenals 
as Cys-288 (McMahon et al. 2010). Keap1 cysteine residues can also be 
glutathionylated by GSSG, which can cause the formation of disulphide 
bridges within Keap1 (Holland et al. 2008). This is important as under 
conditions of oxidative stress, the balance between oxidised and reduced 
glutathione (GSSG:GSH) can become altered. It is possible that increased 
GSSG or GSH depletion can enhance Nrf2 activation, as seen following the 
exposure of cells to buthionine sulfoximine (BSO), an inhibitor of the rate-
limiting enzyme in the synthetic pathway of GSH, which provokes GSH 
depletion and the activation of Nrf2 in cells (Chia et al. 2010, Copple et al. 
2008a).  
 
These studies support the hypothesis of a “multiple sensor mechanism” 
within Keap1, and it is likely that the modification of a combination of cysteine 
residues is responsible for Nrf2 induction by discrete stimuli, as opposed to 
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direct adduct formation with one individual residue. See Figure 1.9 for an 
overview of the cysteine residues in human and/or mouse Keap1, which have 
been shown to be directly adducted by Nrf2-inducing electrophiles. One must 
bear in mind that whilst the mutation of one or many cysteine residues in 
Keap1 may prevent the activation of Nrf2 response by a known inducer, it is 
not necessarily correct that this cysteine residue is directly responsible for 
eliciting the Nrf2 response. Many other factors are likely to be involved, for 
example electrophilic compounds are likely to react with other cellular 
nucleophiles, which may, in turn, affect cellular homeostasis. Furthermore, 
there is no consensus on the precise impact that Keap1 modification has on 
the Keap1/Nrf2 interaction, and how this results in the activation of Nrf2 
signalling. There is no direct evidence that the formation of Keap1 adducts 
specifically attenuates the Keap1/Nrf2 interaction, however indirect evidence 
supports this notion. The incubation of recombinant Keap1 protein with Nrf2 
activators induces a conformational change in the secondary structure of 
Keap1, resulting in the dissociation of Cul3 in a Cys-151 dependent manner 
(Rachakonda et al. 2008), however its physiological relevance is currently 
unclear (Baird and Dinkova-Kostova 2013).  
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Figure 1.9 Schematic overview of Keap1 cysteine residues and their 
modification by electrophiles. Electrophile modification of human Keap1 
cysteine residues (black box) and mouse Keap1 cysteine residues (white 
box). The red box outlines the three critical cysteines of Keap1 (Cys-151, 
Cys-273 and Cys-88). Keap1 domains are outlined at the bottom of the figure 
and cysteine numbers are annotated at the top and bottom. Abbreviations of 
the electrophiles are as follows: BMCC; 1-biotinamido-4-4(4’-
[maleimidiethylcyclohexane]-carboxamido)butane (Hong et al. 2005b, Luo et 
al. 2007), IAB; N-iodoacetyl-N-biotinylhexylenediamine (Eggler et al. 2007, 
Hong et al. 2005b), SULF; sulforaphane (Hong et al. 2005a), DEX-MES; 
dexamethasone-21-mesylate (Liebler et al. 2006), ISO; isoliquiritigenin, SHO; 
10-Shogaol, XAN; xanthohumol (Luo et al. 2007), LIQ; liqustilide (Dietz et al. 
2008), P-SS-P; protein disulphide, P-SG; s-glutathionlyation (Holland et al. 
2008), NAPQI; N-acetyl-p-benzoquinoneimine, IA; iodoacetamide, DNCB; 
dinitrochlorobenzene (Copple et al. 2008a), DEX-MES (Copple et al. 2008a, 
Dinkova-Kostova et al. 2002), 15d-PGJ2; 15-deoxy-∆12,14-prostaglandin J2 
(Copple et al. 2008a, Kobayashi et al. 2009), PGA2; prostaglandin A2, DEM; 
diethylmaleate (Kobayashi et al. 2009). Adapted from Holland et al. (2008), 
Bryan et al. (2013). 
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1.5.3 Binding partners of Keap1 
 
Whilst Nrf2 is considered to be the only substrate for Keap1-mediated 
ubiquitination, a number of proteins have been shown to interact with Keap1. 
Some interactions with Keap1 have a functional impact on Nrf2 regulation, 
some tether Keap1 in a particular location within the cell to facilitate its 
function, whilst others have no obvious functional benefit. Nrf2 binds Keap1 
via two conserved motifs (ETGE and DLG), acting as the hinge and latch. 
ETGE-like motifs have been noted in a number of other proteins, which have 
been identified as Keap1 binding partners (Fig 1.10). Recently it was shown 
that this motif is required for the protein to interact with Keap1. (Hast et al. 
2013). Some known Keap1 binding partners which will be discussed in this 
Section are sequestosome1 (p62), phosphoglycerate mutase family member 
5 (PGAM5), prothymosin α and IKKβ. 
 
 
Figure 1.10. Table showing the conservation of the Keap1 binding 
ETGE-like domain across a number of known Keap1 binding partners 
 
p62acts as a scaffold protein in various signalling pathways via multiple 
protein-protein interactions, and binds to poly-ubiquitinated proteins and the 
autophagic machinery, targeting proteins for degradation (Kim et al. 2008, 
Pankiv et al. 2007). Recently, a physical and functional relationship between 
Keap1 and p62 has been elucidated (Lau et al. 2010, Fan et al. 2010, Copple 
et al. 2010, Jain et al. 2010, Komatsu et al. 2010). Evidence suggests that 
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p62 has a role in mediating Keap1 degradation via autophagy resulting in the 
up-regulation of Nrf2 (Taguchi et al. 2012, Komatsu et al. 2010). The ectopic 
expression of p62 in cells results in reduced levels of Keap1 protein, whilst 
siRNA-mediated knockdown of p62 results in an increase in Keap1 half-life, 
and decreased Nrf2 protein (without changes in mRNA levels), concurrent 
with reduced levels of a number of Nrf2-regulated genes (Copple et al. 2010). 
Liver-specific autophagy-deficient mice (Atg-/-) show p62 accumulation and 
the formation of p62/Keap1 aggregates as well as the development of 
hepatocellular carcinoma; moreover, this p62 accumulation leads to the 
consistent activation of Nrf2 which promotes the development of human 
hepatocellular carcinoma (Inami et al. 2011). p62 contains an STGE motif 
and it is proposed that under conditions of stress, Keap1 releases Nrf2 from 
the DLG binding site and p62 binds this site in Keap1 via this STGE motif 
(Komatsu et al. 2010). Additionally, p62 binds to LC3 which is associated 
with the autophagosome membrane, providing a link between the Keap1-
Nrf2 complex and autophagic degradation, supporting the notion that 
autophagy is capable of degrading specific, targeted proteins (I. Kim et al. 
2007, Sakai et al. 2006, Deretic 2006, Kaniuk et al. 2007). 
 
PGAM5 is a member of the phosphoglycerate mutate family with a role in 
programmed necrosis by accumulating in the cytosol and sensitising cells to 
death signals (Zhuang et al. 2013). This protein has been shown to be 
ubiquitinated and targeted for proteasomal degradation via a Keap1-
dependent E3 ubiquitin ligase complex, and this degradation is inhibited in 
the presence of oxidative stress and sulforaphane, indicating PGAM5 as a 
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novel substrate for Keap1 degradation(Lo and Hannink 2006). PGAM5 
contains an ETGE-like motif at its N-terminus, facilitating the interaction with 
Keap1. Interestingly, the half-life of PGAM5 is approximately 6 hr when co-
expressed with Keap1, considerably longer than the half-life of Nrf2, 
suggesting the affinity for PGAM5 may be lower than for Nrf2 (Lo and 
Hannink 2006). A follow up study showed that PGAM5 is primarily located on 
the outer membrane of the mitochondria via an N-terminal mitochondrial 
localisation sequence (Lo and Hannink 2008). As the mitochondria are a 
major source of ROS, it is possible that PGAM5 tethers the Keap1/Nrf2 
complex in this location to facilitate the sensing of oxidative stress (Lo and 
Hannink 2008). This interaction provides an interesting link between oxidative 
stress and cell death, especially as the knockdown of Keap1 or PGAM5 
activates the expression of Nrf2-dependent genes (Lo and Hannink 2008).  
 
Prothymosin α is a ubiquitously and abundantly expressed small nuclear 
protein with roles in proliferation and protection against apoptosis(Manrow et 
al. 1991, Gomez-Marquez et al. 1989, Jiang et al. 2003). There is growing 
evidence for this proteins role in transcriptional regulation (Karetsou et al. 
2002, Martini et al. 2000, Vareli et al. 2000). An association between 
prothymosin α and Keap1 was identified in a yeast two-hybrid screen, and 
confirmed using co-localisation studies (Karapetian et al. 2005). Furthermore, 
the interaction is via an ETGE-like motif within prothymosin α and the same 
region of Keap1 that binds Nrf2 (Karapetian et al. 2005). Additionally, the 
over-expression of prothymosin α in cells increases the level of HO-1 mRNA 
in both stressed and non-stressed cells, and vice-versa in cells transfected 
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with siRNA targeting prothymosin α (Karapetian et al. 2005).It has been 
suggested that the interaction with prothymosin α facilitates the localisation of 
the Nrf2/Keap1/Cul3/Rbx1 complex in the nucleus, which is promoted upon 
oxidative stress (Niture and Jaiswal 2009). It is also possible that the limited 
release of Nrf2 from Keap1 triggered by prothymosin α is sufficient to provide 
basal ARE-mediated transcription (Karapetian et al. 2005) 
 
IκB kinase β (IKKβ) is a subunit of the IKK complex which phosphorylates the 
inhibitor protein of NF-κB, IκBα (Gilmore 1999). This phosphorylation results 
in the dissociation of IκBα from NF-κB, allowing the latter to translocate to the 
nucleus (Gilmore 1999). Once in the nucleus, NF-κB up-regulates the 
expression of genes involved in immunity, inflammation, angiogenesis, cell 
proliferation and cell survival (Hoesel and Schmid 2013, Lee et al. 2009). An 
association between Keap1 and IKKβ was first identified by Lee et al. (2009) 
who demonstrated that Keap1 acts as an IKKβ E3 ubiquitin ligase and that 
the depletion of Keap1 leads to the stabilisation and accumulation of IKKβ in 
cells, and the up-regulation of NF-κB. Further studies have shown that the 
Kelch domain of Keap1 interacts directly with the kinase domain of IKKβ 
through an ETGE-like motif (Kim et al. 2010). Additionally, it was found that 
the ectopic expression of Keap1 in cells reduces tumour necrosis factor α 
(TNFα)-mediated stimulation of NF-κB, whilst the depletion of Keap1 up-
regulates NF-κB and the expression of its downstream genes (Kim et al. 
2010). This study further clarified that the degradation of IKKβ many not be 
due to proteasomal degradation, but rather via autophagy (Kim et al. 2010). 
Thus far, it is not known what effect this interaction has on the Nrf2 pathway. 
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1.6 KEAP1-INDEPENDENT REGULATION OF NRF2 
 
Whilst the regulation of Nrf2 by Keap1 is a commonly investigated 
mechanism, there are a number of mechanisms which result in changes in 
Nrf2 activity and function independently of Keap1. A recent publication by 
Papp et al. (2012) highlighted that whilst Nrf2 is associated with a variety of 
cellular processes and functions, there are few (10-20) known Nrf2-
interacting proteins in the major protein-protein interaction databases. A 
selection of Keap1-independent mechanisms which regulate Nrf2 activity 
discussed in this Section. 
 
1.6.1 Phosphorylation of Nrf2 
 
Protein kinase C (PKC) is a family of serine/threonine kinases, subdivided 
into classes (classical, novel and atypical), each requiring different co-factors 
for activation, with roles in cell growth, differentiation, apoptosis and 
survival(Numazawa et al. 2003). The atypical form can phosphorylate Nrf2 at 
Ser40 within the Neh2 domain, thus disturbing the association between Nrf2 
and Keap1 (Huang et al. 2002, Bloom and Jaiswal 2003). Mutation of this 
residue to an alanine (Nrf2S40A) results in reduced translocation of Nrf2 to the 
nucleus in comparison to WT Nrf2. Moreover, PKC enzymes are activated 
under similar conditions to those which induce Nrf2, such as oxidative stress 
(Numazawa et al. 2003).  
 
Casein kinase 2 (CK2) is a protein targeting a number of substrates with 
functions ranging from gene transcription to cell replication and survival, and 
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the Nrf2 protein sequence contains approximately 13 potential CK2 
phosphorylation sites (Pi et al. 2007). The Nrf2transactivation domains (Neh4 
and Neh5)can be phosphorylated by CK2 in vitro, and this post-translational 
modification correlates with the translocation of Nrf2 to the nucleus, and is 
reduced in the presence of a CK2 inhibitor (Apopa et al. 2008). Furthermore, 
the tyrosine kinase Fyn can phosphorylate Tyr-568 in Nrf2, and this 
correlates with the translocation of Nrf2 out of the nucleus, and its 
degradation following the activation of ARE-regulated gene expression 
(Kaspar and Jaiswal 2011). Upon mutation of Tyr-568 to alanine, Nrf2 
accumulates in the nucleus, due to a loss of phosphorylation and reduced 
interaction with the exportin protein Crm1 (Jain and Jaiswal 2006). Glycogen 
synthase kinase 3β (GSK3β) acts upstream of Fyn, phosphorylating it and in 
turn, triggering its nuclear accumulation, where it is suitably positioned to 
phosphorylate Nrf2 (Jain and Jaiswal 2007). 
 
A number of serine/threonine residues in Nrf2 have been shown to be 
phosphorylated by a panel of mitogen-activated protein kinases (MAPKs). 
MAP kinases respond to a variety of stimuli, including osmotic stress and 
heat shock to up-regulate differentiation, mitosis, cell survival and 
apoptosis(Cargnello and Roux 2011). Keum et al. (2006)showed that the 
classical MAPK, p38, phosphorylates Nrf2, promoting its association with 
Keap1, an effect reversed by the Nrf2-inducing compound sulforaphane. JNK 
(c-jun N-terminal kinase 1/2) and ERK (extracellular signal-regulated kinase) 
have also been implicated in the activation of Nrf2 as butylated 
hydroxyanisole (BHA) increases the phosphorylation of both ERK1/2 and 
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JNK1/2 and leads to Nrf2 release from Keap1 (Yuan et al. 2006). PERK 
kinase has also been shown to phosphorylate Nrf2, however the site of 
phosphorylation is yet to be identified (Cullinan et al. 2003). 
 
Glycogen synthase kinase 3 β (GSK3β) is a key regulator of Nrf2 protein 
stability, and has provided insight into the activation of Nrf2 by 
phosphorylation, whilst correspondingly acting as a common downstream 
effector for a number of Nrf2 inducers (Rojo et al. 2012). GSK3β is involved 
in the regulation of processes including glycogen metabolism and apoptosis 
(Salazar et al. 2006). GSK3β stabilises Nrf2 by phosphorylation of the Neh6 
region which, in turn, facilitates its ubiquitination by the adaptor protein β-
TrCP which forms a complex with Cullin-1 forming a complete E3 ligase 
(Rada et al. 2011). GSK3β is a downstream target of multiple kinase 
cascades (Akt, MAPK), the activation of which inhibits GSK3β through 
phosphorylation at multiple sites(Thornton et al. 2008, Moore et al. 2013). 
Furthermore, the inhibition of GSK3β promotes Nrf2 stabilization in Keap1-
deficient cells (Rojo et al. 2012), in Keap1-/- mice and in the presence of a 
mutant Nrf2 lacking the ETGE motif (Rada et al. 2011), suggesting that 
GSK3β degrades Nrf2 independently of Keap1.  
 
1.6.2 Alternative post-translational modification of Nrf2 
 
The transcriptional co-activators p300/CBP acetylate histones to facilitate 
chromatin decondensation and recruit RNA polymerase machinery (Ogryzko 
et al. 1996, Roth et al. 2001), and have been shown to associate with Nrf2 
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(Sun et al. 2009, Katoh et al. 2001). p300/CBP binds to Nrf2 in response to 
stress induced by arsenite and acetylates lysine residues within the Neh1 
DNA binding region of Nrf2(Sun et al. 2009). The mutation of these lysine 
residues does not affect Nrf2 protein abundance but compromises the ability 
of Nrf2 to bind to DNA (Sun et al. 2009), thus it is probable that this 
mechanism enhances the ability of Nrf2 to bind to DNA. 
 
The modification of cysteine residues in Nrf2 is another possible mechanism 
controlling its regulation. Li et al. (2006) characterised a nuclear export 
sequence (NES) in the Neh5 domain of Nrf2 which contains a reactive 
cysteine residue (Cys-183). The mutation of this residue to an alanine 
resulted in reduced nuclear translocation of Nrf2 (compared to WT) following 
the activation of Nrf2 by tBHQ and H2O2, with no effect on Keap1. Under 
conditions of stress or in the presence of electrophiles, it is possible that 
modification at Cys-183 prevents the exportin Crm1 binding to Neh5 of Nrf2, 
resulting in its nuclear accumulation. Thus far, mass spectrometry has not 
been used to detect the formation of adducts on this residue, and there is no 
further evidence to support the chemical modification of Nrf2 protein itself. 
 
More recently, caveolin-1 has been identified as an Nrf2-binding partner. 
Caveolin-1 is a scaffold protein component of caveolar membranes, involved 
in signal transduction and the uptake of lipophilic compounds (W. Li et al. 
2012). Caveolin-1 interacts with a number of proteins including: Toll-like 
receptor 4 and LC3B, a constituent of the autophagy machinery, and 
regulates biological functions including cholesterol homeostasis and 
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apoptosis (W. Li et al. 2012, Zheng et al. 2012). siRNA mediated knock-down 
of Caveolin-1 results in the dissociation of Nrf2 and Keap1(W. Li et al. 2012), 
which confirmed previous hypotheses of an association between this protein 
and the Nrf2 pathway (Zheng et al. 2012). On the other hand, the ectopic 
expression of Caveolin-1 does not result in changes in the Keap1/Nrf2 
association but impedes the transcriptional activity of Nrf2 (W. Li et al. 2012). 
Nrf2 binds Caveolin-1 via a caveolin-1 binding motif in the Neh5 domain, and 
mutagenesis of this motif reduces the association between Caveolin-1 and 
Nrf2 whilst enhancing the association between Keap1 and Nrf2, indicating 
that Caveolin-1 competes with Keap1 to bindNrf2 (W. Li et al. 2012).  
 
Ectoderm-neural cortex protein 1 (ENC1) has a similar sequence and domain 
organisation to Keap1 and plays an important role in neuronal differentiation. 
Its ectopic expression in cells has been linked to brain tumourigenesis by 
augmenting cell proliferation and inhibiting apoptosis (Wang and Zhang 
2009). ENC1 can form a complex with Cul3–Rbx1, as Keap1 does, and 
facilitates its own ubiquitination. Whilst no ubiquitination of Nrf2 has been 
observed with this complex, it can reduce Nrf2 protein levels and the 
transcription of Nrf2-dependent genes (Wang and Zhang 2009). ECN1 has 
no effect on Nrf2 mRNA, therefore it is proposed that it down-regulates the 
rate of Nrf2 protein synthesis (Wang and Zhang 2009), the mechanism of 
which remains to be understood. 
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1.6.3 MicroRNAs 
 
MicroRNAs (miRs) are short, single-stranded non-coding RNAs, which play a 
role in fine-tuning the regulation of a number of proteins(Yang et al. 2011). A 
number of miRs have been associated with the Nrf2 pathway, including miR-
144 (Sangokoya et al. 2010), miR-28 (Yang et al. 2011), miR-200 (Eades et 
al. 2011) and miR-34 (Li et al. 2011). Sangokoya et al. (2010) showed that an 
increase in miR-144 expression reduces Nrf2 protein levels, and GSH 
regeneration, thus altering the antioxidant capacity in erythroid cells. The 
abnormal expression of miR-144 has been associated with sickle cell 
disease, implicating a role for Nrf2 in the disease pathology (Sangokoya et al. 
2010). A similar relationship has been seen between Nrf2 and miR-28 in 
breast epithelial cells (Yang et al. 2011). miR-28 causes the depletion of both 
Nrf2 mRNA and protein whilst having no effect on Keap1 or the Keap1/Nrf2 
interaction (Yang et al. 2011). Other miRs which regulate Nrf2 include miR-
200, which targets Keap1 mRNA (Eades et al. 2011) and miR-34, which 
targets Nrf2 mRNA and the mRNA of downstream genes involved in the 
oxidative stress response (Mgst1)(Li et al. 2011). The mechanism by which 
micro-RNAs regulate Nrf2 and other proteins requires further elucidation but 
some hypotheses are reviewed by Filipowicz et al. (2008) and more recently 
by Ling et al. (2013) 
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1.7 NRF2/KEAP1 IN HEALTH AND DISEASE 
 
Due to the importance of the Nrf2 pathway for maintaining cellular 
homeostasis, and its role in defending the cell against numerous cell 
stresses, it is not surprising that it has been associated with toxicity and a 
number of diseases. The dysregulation of this pathway confers the cell with 
increased susceptibility to various pathological states, many of which are a 
consequence of increased oxidative stress, or are linked to changes in the 
cell’s ability to respond to stress. Additionally, the process of drug 
metabolism generating reactive metabolites which are able to interact with 
the pathway can also lead to unfavourable outcomes. Understanding how the 
Nrf2 pathway can affect the onset or progression of disease, or how certain 
compounds which cause toxicity activate this pathway, will be vital in 
informing the design of safe therapeutic agents. 
 
1.7.1 Nrf2 and cancer 
 
Nrf2 activation has tumour suppressor functions, and is considered “the good 
side of Nrf2”in cancer(Jaramillo and Zhang 2013). Many of the genes Nrf2up-
regulates are able to inhibit chemical carcinogenesis. For example, Nqo1 
catalyses the reduction of both highly reactive quinones, and lipid-soluble 
antioxidants maintaining them in an active state, as well as affecting cell 
survival decisions via a role in p53stabilisation following DNA damage (Nioi 
and Hayes 2004). For this reason, many Nrf2-inducing compounds are 
considered to be chemo-preventative agents, including butylated 
  Chapter 1 
- 44 - 
 
hydroxyasnisole, circumin and dithiolethiones (Hayes and McMahon 2009, 
Kwak et al. 2001a). Studies on Nrf2-/- mice show that Nrf2 can protect against 
chemical carcinogen-induced tumour formation in the stomach(Ramos-
Gomez et al. 2001), bladder(Fahey et al. 2002) and skin(Xu et al. 2006), and 
this is likely to be due to Nrf2’s ability to protect against oxidative stress and 
DNA damage. Moreover, individuals with a single-nucleotide polymorphism 
(SNP) in the promoter region of the Nrf2 gene have low Nrf2 mRNA levels 
and an increased risk of developing non-small-cell lung cancer (NSCLC), 
particularly in those who have smoked (Suzuki et al. 2013).  
 
Conversely, high Nrf2 levels can be associated with poor prognosis in 
cancer(Sporn and Liby 2012), and this is considered “the dark side of Nrf2”in 
cancer(Jaramillo and Zhang 2013). In malignant cells, the constitutive 
activation of Nrf2 can confer cells with a growth advantage and chemo/radio-
resistance in lung(Singh et al. 2010), breast(Wang et al. 2008), 
ovarian(Konstantinopoulos et al. 2011) and pancreatic (Lister et al. 2011) 
cancer. This constitutive activation increases the expression of drug 
metabolising enzymes and drug transport proteins, increasing the turn-over 
and efflux of chemotherapeutic drugs, reducing their pharmacological 
activity(Hayes and McMahon 2009). The ectopic expression of Nrf2 in cancer 
cells lines with endogenously low Nrf2 levels renders them more resistant to 
anti-cancer agents, whilst siRNA-mediated knock-down of Nrf2 in cancer 
cells with high Nrf2 activity can reduce drug resistance (Lister et al. 2011, 
Homma et al. 2009). Moreover, constitutive activation of Nrf2 enhances cell 
proliferation via metabolic reprogramming, by promoting the synthesis of 
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purine nucleotides, the building blocks of DNA and RNA (Mitsuishi et al. 
2012). The constitutive activation of Nrf2 which affords cancer cells with 
these characteristics can be conferred by a variety of mechanisms, including: 
a) mutations within Keap1/Nrf2 which disrupt their ability to interact; b) 
epigenetic silencing (by methylation) of Keap1 expression resulting in a loss 
of Nrf2 repression; c) accumulation of proteins which can disrupt the 
Nrf2/Keap1 interaction; d) transcriptional activation of Nrf2 by oncogenes (K-
Ras, c-Myc); and e) post-translational modification of Keap1 cysteines by 
metabolic intermediates (for more details regarding these mechanisms, 
seeJaramillo and Zhang (2013)). 
 
Whilst Nrf2 activation is protective in pre-malignant cells(i.e. where the 
Keap1/Nrf2 interaction is maintained), when this interaction is disrupted (i.e. 
in cancer cells) the cells favour survival, thus Nrf2 acts as a double-edged 
sword in this context (Hayes and McMahon 2006). 
 
1.7.2 Nrf2 and diseases associated with oxidative stress 
 
Oxidative stress has been associated with a wide variety of diseases, from 
neurological disorders such as Alzheimer’s and Parkinson’s, to 
cardiovascular disease, asthma and chronic obstructive pulmonary disease 
(COPD), as well as aging. This is not surprising, as oxidative stress is tied to 
mitochondrial dysfunction and thus a reduction in energy generation (Cui et 
al. 2012), and has the ability to disrupt many metabolic pathways (Hybertson 
et al. 2011).As cells age, there is emerging evidence that they express 
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decreased cellular levels of Nrf2 protein, which reduces the cell’s ability to 
protect itself from oxidative stress (Ungvari et al. 2011, Tomobe et al. 2012). 
Why this might be is not yet clear. 
 
Neurodegenerative diseases encompass conditions whereby nerve cells of 
the brain and spinal cord are lost, due to a functional (ataxia) or sensory 
(dementia) dysfunction (Uttara et al. 2009). Neurodegeneration is thought to 
arise due to an interplay between environmental and genetic predispositions, 
however ROS have also been shown to play a role (Emerit et al. 2004). The 
biochemical composition of neuronal cells is particularly sensitive to ROS due 
to a pool of unsaturated lipids which are liable to peroxidation and oxidative 
modification, starting a chain reaction of damage to neighbouring fatty acids 
(Butterfield et al. 2002). Not only are neurons more sensitive to ROS, these 
cells also have lower antioxidant capabilities than other cells of the body, that 
is approximately 10 % of the livers antioxidant capabilities(Uttara et al. 2009). 
It is the oxidative stress and mitochondrial dysfunction which contributes to 
neuronal cell death (Calkins et al. 2009). The induction of Nrf2 has been 
shown to protect against neurotoxicity in a number of models, whilst 
depletion of Nrf2 increases sensitivity (Calkins et al. 2009). Thus, the 
activation of Nrf2 signalling is considered a promising therapeutic strategy in 
this context. 
 
Whilst dysfunction of the Nrf2 pathway can be associated with many 
diseases, there are likely to be other factors at play. The accumulation of 
oxidative stress could be a symptom of Nrf2 dysfunction and/or other 
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simultaneous pathologies in the tissue. Therefore, reduced Nrf2 may be 
contributing to the onset and progression of these diseases, however it may 
not necessarily be causative.  
 
1.7.3 Adverse drug reactions and drug-induced liver injury 
 
Adverse drug reactions (ADRs) are briefly defined as an “undesirable effect 
of a drug beyond its anticipated therapeutic effect occurring during clinical 
use” (Pirmohamed et al. 1998). They constitute a major public health problem 
due to their contributions to patient morbidity and mortality (Park et al. 2005) 
and are often responsible for drug attrition (Jefferys et al. 1998).ADRs often 
occur due to the metabolic biotransformation of xenobiotics into potentially 
hazardous chemically reactive intermediates, which contribute to the onset of 
oxidative stress, or alter vital cellular factors via post-translational 
modifications (Park 1986). Drug metabolism is divided into three main 
phases. Phase I is a functionalisation step (via oxidation, reduction or 
hydrolysis), performed by cytochrome P450 enzymes (CYPs). Phase II 
facilitates the conjugation of the metabolite to charged species, such as 
glutathione (GSH) making them more hydrophilic, thus more readily 
excreted(Dansette 2008).Conjugation with GSH is especially important in the 
detoxification of electrophilic compounds (Caldwell et al. 1995), as 
conjugated metabolites are, for the most part, less toxic than the parent 
compounds and Phase I metabolites (Dansette 2008). Phase III is 
responsible for the excretion of the resultant metabolite from the cell and 
eventually, the body. 
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As the primary drug metabolising organ of the body, the liver is often 
exposed to reactive metabolites, and thus prone to drug-induced liver injury 
(DILI). In severe cases, DILI can become life-threatening and require an 
organ transplant, if enough of the tissue is damaged irreparably (Russo et al. 
2004). DILI is often caused by the accumulation of a toxic drug or metabolite 
causing changes in the biochemistry of the cell (commonly the hepatocyte), 
or mediating an immune response resulting in cell death (Wang 2014). 
 
Paracetamol (Acetaminophen/APAP) is widely used in in vitro and in vivo 
models of DILI due to its clinical relevance and dose-dependent 
toxicity(Newsome et al. 2000), and it has been shown in vivo that APAP 
activates the Nrf2 pathway in mouse liver (Goldring et al. 2004). Studies have 
shown thatNrf2-/- mice are more sensitive to APAP-induced liver injury, 
exhibiting increased liver necrosis and decreased survival rates, due to 
reduced detoxification enzymes and low cellular thiol levels(Chan et al. 2001, 
Enomoto et al. 2001). Moreover, liver-specific Keap1-null mice are resistant 
to APAP doses which are lethal in WT mice, demonstrating that Keap1-
mediated regulation of Nrf2 is required for protection against APAP(Okawa et 
al. 2006). The toxicity caused by APAP overdose is conferred by its reactive 
metabolite, N-acetyl-p-benzoquinone imine (NAPQI)(Dahlin et al. 1984). 
NAPQI is conjugated with GSH however, when that latter becomes depleted, 
NAPQI accumulates and can bind covalently to other cellular thiols, resulting 
in hepatocyte necrosis (James et al. 2003). NAPQI has been shown to 
activate Nrf2 via the direct covalent modification of Keap1 cysteine residues 
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(Copple et al. 2008a), thereby directly linking the Nrf2 pathway and the onset 
of DILI.DILI mimics many other diseases of the liver such as viral hepatitis, 
acute fatty liver and cirrhosis (Park et al. 2005), therefore furthering our 
knowledge of the pathogenesis of this disorder will improve both drug safety 
and the development of treatments for other liver disorders.  
 
1.7.4 Potential therapeutic strategies related to Nrf2 
 
Due to the association of many diseases with oxidative stress, there have 
been attempts to create therapeutic agents from superoxide dismutase 
(SOD), which can scavenge reactive oxygen (Greenwald 1990). Proteins and 
enzymes commonly make poor drugs due to immunogenicity, poor 
pharmacokinetic dynamics and non-availability by oral administration, and 
such issues were encountered with the SODs (Hybertson et al. 2011). A 
genetically engineered SOD was synthesised with high efficacy at low doses 
and slowed renal clearance (Gao et al. 2003). However, the problems 
outlined above remained, as well as issues of production costs, purification 
and stability (Hybertson et al. 2011). The direct activation of Nrf2 is a more 
promising approach, due to its ability to regulate the expression of a variety 
of cellular antioxidants (Hybertson et al. 2011). 
 
The majority of known Nrf2 inducers are purported to be inhibitors of the 
Keap1/Nrf2 interaction, facilitated by the modification of Keap1 cysteine 
residues by covalent adduction (or oxidation) (Magesh et al. 2012). 
Electrophiles can be divided into two groups, hard or soft. Soft electrophiles 
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will react predominantly with soft nucleophiles, such as the sulphydryl group 
of a cysteine, whereas hard electrophiles react with amino and hydroxyl 
groups on nucleic acids, which can result in carcinogenicity, thus are best to 
avoid with regards to developing therapeutic agent targeting Nrf2 (Magesh et 
al. 2012). The most potent inducers of Nrf2 signalling are triterpenoids (TPs), 
such as CDDO-Me (methyl 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate), 
which exhibit anti-tumour and anti-inflammatory properties, among other 
health benefits (Liby and Sporn 2012). The mechanism of action of these 
compounds with regards to Nrf2 activation will be discussed further in 
Chapter 3. There are a number of U.S. Food and Drug Administration (FDA)-
approved Nrf2-inducing compounds, including dimethyl fumarate (DMF) 
(Tecfidera, Biogen Idec) for the treatment of adults with multiple sclerosis. 
Protandim (LifeVantage Corporation) is a patented dietary supplement which 
has not been evaluated by the FDA, therefore not intended for prevention, 
treatment or cure of any disease. The components of Protandim are known 
Nrf2 inducers including turmeric and green tea, and it is advertised as an 
“Nrf2 activator”. It been tested both in vivo and in vitro (Nelson et al. 2006, 
Velmurugan et al. 2009, Qureshi et al. 2010) and there is interest in it as a 
potential therapeutic agent(Hybertson et al. 2011). As previously alluded to, 
the use of Nrf2 inducers for therapeutic purposes is controversial due to its 
association with cancer, therefore the conditions under which Nrf2 activators 
are used must be tightly monitored. 
 
The reversible disruption of the Keap1/Nrf2 complex by small peptides has 
recently become an avenue of investigation. Proteins that contain an ETGE-
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like motif have been shown to compete with Nrf2 to bind to Keap1, and result 
in the up-regulation of ARE-driven gene expression (Camp et al. 2012, Ma et 
al. 2012). The synthesis of peptides containing ETGE-like motifs has be 
optimised to increase protein binding and cellular activity (Hancock et al. 
2013), and a high throughput screening assay has been developed to 
discover novel small-molecule inhibitors of the Keap1/Nrf2 interaction 
(Inoyama et al. 2012). This method of manipulating Nrf2 activity will increase 
specificity for the pathway, and avoid the use of potentially toxic 
electrophiles, and is therefore a promising therapeutic strategy. 
 
The pharmacological inhibition of Nrf2 is considered a promising therapeutic 
approach in cancers which show elevated levels of Nrf2. Brusatol, a plant 
extract from the Brucea javanica seed, is able to reduce Nrf2 protein levels in 
cells at nanomolar (nM) concentrations, reducing the expression of Nrf2 
target genes and enhancing the cytotoxic effect of the chemotherapeutic 
agent cisplatin both in vitro and in vivo(Ren et al. 2011). The mechanism by 
which brusatol inhibits Nrf2, and its specificity for the pathway, is currently 
under investigation; however it appears to reduce Nrf2 protein levels 
independently of Keap1 and the proteasome (data presented in thesis of 
Adedamola Olayanju). The basal and inducible activity of Nrf2 can be 
suppressed by small molecules such as ascorbic acid (vitamin C) and 
luteolin(Magesh et al. 2012). Vitamin C inhibits formation of the Nrf2/DNA 
complex at the ARE of the GCL gene promoter and reduces peroxide 
levels(Tarumoto et al. 2004). Furthermore, the treatment of an imatinib-
resistant cell line with ascorbic acid enhances sensitivity to imatinib 
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(Tarumoto et al. 2004). Luteolin inhibits ARE-dependent gene expression in a 
redox-independent manner, and reduces both Nrf2 protein and mRNA 
levels(Tang et al. 2011). However, as a flavonoid, it has also been shown to 
have Nrf2-activating properties, and can induce HO-1 expression and 
increase Nrf2 ARE-binding (Lin et al. 2010). A further inhibitor of the Nrf2 
pathway is the chemo-preventative and chemotherapeutic agent all-trans 
retinoic acid (ATRA), which reduces the tBHQ-mediated induction of ARE-
driven genes in cells(Wang et al. 2007). Additionally, ATRA can repress the 
basal expression of ARE-driven genes in cells, by reducing the binding of 
Nrf2 to the ARE region, through formation of a complex with retinoic acid 
receptor α (RARα) (Wang et al. 2007). Retinoids are known to activate or 
repress gene expression by forming heterodimers with RARs and interacting 
with other transcription factors, such as AP-1 and NF-κB (Shaulian and Karin 
2002).A recent surge in interest in Nrf2 inhibitors will further the development 
of therapeutic possibilities in this area. 
 
1.8 THESIS AIMS 
 
In light of the critical role of the Nrf2 pathway in cell defence and its 
association with toxicity and many disease pathologies, furthering our 
understanding of the regulation of this pathway is vital to determine how 
these toxicities or diseases arise and develop. This thesis aims to investigate 
the molecular interactions with Keap1 which may play a role in the activation 
and/or repression of Nrf2 signalling by addressing the following questions:  
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1) Do molecules that are known to activate Nrf2 do so via the covalent or 
oxidative modification of cysteine residues in Keap1?  
2) Can the most potent known inducers of Nrf2 (triterpenoids; TPs) form 
covalent adducts with Keap1?  
3) Are there unidentified proteins that interact with Keap1 and which can 
modulate the activity of Nrf2 interaction? 
 
By furthering our knowledge of how Nrf2-inducing compounds are able to 
activate the pathway via interactions with Keap1, we can aim to develop 
predictive toxicity screens based on the ability of a compound to modify 
Keap1 covalently. As the manipulation of this pathway is considered a viable 
therapeutic target, with regards to the prevention and/or treatment of 
diseases such as cancer and other pathologies associated with oxidative 
stress, understanding the mechanism of action of pharmacological agents 
towards Nrf2 should allow the synthesis of chemically-tuned compounds with 
increased potency and specificity towards this pathway, thus reducing the 
risk of off-target effects. Therefore, this thesis aims to gain further insight into 
the regulation of this cytoprotective pathway via molecular interactions 
between Keap1 and pharmacological agents or other proteins. 
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CHAPTER 2 
 
COVALENT AND OXIDATIVE MODIFICATION OF KEAP1 
CYSTEINE RESIDUES AS A MECHANISM OF NRF2 
ACTIVATION 
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2.1. INTRODUCTION 
 
The Nrf2 cell defence pathway regulates the basal and inducible expression 
of an array of genes which combat chemical and oxidative stress(Bryan et al. 
2013). The most widely-accepted model of Nrf2 regulation describes the 
cysteine-rich protein Keap1 as an active repressor of Nrf2 activity, as 
discussed in Section 1.5. A number of studies provide compelling evidence 
for the direct covalent modification of cysteine residues in recombinant 
Keap1 by Nrf2-inducing molecules in vitro (Fig. 1.9)(Eggler et al. 2005, Hong 
et al. 2005a, Hong et al. 2005b, Luo et al. 2007, Dinkova-Kostova et al. 2002, 
He and Ma 2010). Furthermore, recent work by our group and others has 
shown that Keap1 can be selectively modified by reactive chemical species 
in a cell based model (Hong et al. 2005b, Rachakonda et al. 2008, Copple et 
al. 2008a). Moreover, it has also been shown that under conditions of 
substantial depletion of cellular GSH, an Nrf2 response can be elicited in the 
absence of Keap1 covalent modification (Chia et al. 2010, Copple et al. 
2008a). 
 
The mechanism whereby GSH depletion may induce Nrf2 activation is 
currently unclear, however one proposal is that when GSH levels are 
depleted, naturally produced ROS can no longer be scavenged and thus 
accumulate in the cell. This accumulation may give rise to oxidative stress 
and changes in the redox state of the cell, resulting in the oxidation of Keap1 
cysteines, and subsequent Nrf2 activation. Currently, there is no concrete 
evidence to suggest that Keap1 cysteine residues are susceptible to 
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oxidation in vivo and the techniques used to confidently identify thiol 
oxidation states are still in their infancy (Burgoyne and Eaton 2011). Under 
certain experimental conditions, evidence supports the presence of 
modifications on recombinant or ectopically expressed Keap1, including the 
formation of inter- and intra-disulphide bonds, glutathionlyation and 
nitrosylation (Wakabayashi et al. 2004, Holland et al. 2008, Fourquet et al. 
2010, Zhang et al. 2010, Um et al. 2011). Unfortunately, modification is often 
substoichiometric with only a small proportion of the protein being modified, 
obstructing analysis of protein modification and function simultaneously, and 
this is only made more challenging by the low abundance of Keap1 in cells 
(approximately 10 parts per million) (McMahon et al. 2006). 
 
As the oxidation of cysteine residues is both selective and, for the most part, 
reversible (Burgoyne and Eaton 2011), it can enable the function of a protein 
to be rapidly regulated in response to changes in cellular redox state. The 
thiol group of cysteine residues can form various reversible oxidative states 
such as sulphenic acid (S-OH) as well as the irreversible oxidative states of 
sulphinic (S-O2H) and sulphonic acid (S-O3H) (Lee et al. 2013) (Fig. 2.1). We 
have recently observed that all Keap1 cysteine residues are in a reduced 
state, thus are available for adduction by a common alkylating agent, and do 
not appear to participate in disulphide bonds under basal conditions 
(unpublished data). From this we conclude that, basally, all cysteine residues 
are available for modification following exposure to an Nrf2 inducer. 
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Figure 2.1.Schematic diagram of protein cysteine oxidation. Sulphydryl 
groups can be reversibly oxidised to sulphenic acid, which can be further 
irreversibly oxidised to sulphinic and sulphonic acids. Sulphydryl groups can 
also react with other sulphydryl groups to form disulphide linkages or be s-
glutathionylated. 
 
In order to investigate the oxidation of Keap1 cysteine residues in response 
to Nrf2-inducing compounds, a mass spectrometry based method (LC-ESI-
MS/MS) has been developed in our lab using the alkylating agents N-
ethylmaleimide (NEM) and iodoacetamide (IAA). These agents were used to 
investigate the susceptibility of cysteine residues in ectopically expressed 
Keap1-V5 in HEK293T cells to modification, following treatment with Nrf2-
inducing compounds. The compounds used for this investigation were 
chosen based on their purported mechanism of Nrf2 induction. 2,4-
Dinitrochlorobenzene (DNCB) depletes cellular GSH and has previously 
been shown to covalently modify Keap1 (Chia et al. 2010, Copple et al. 
2008a) whilst Dexamethasone 21-mesylate (dex-mes) has been shown to 
covalently modify Keap1 (Dinkova-Kostova et al. 2002, Hong et al. 2005b, 
Copple et al. 2008a) whilst having no effect on GSH levels in the cell. 
Buthionine (S,R)-sulphoximine (BSO) is a GCL inhibitor which provokes the 
specific depletion of intracellular GSH without causing protein covalent 
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modification (Copple et al. 2008a). Hydrogen peroxide (H2O2) causes 
significant oxidative stress in cells and is a strong oxidiser of thiol groups, 
which does not form stable covalent adducts with cysteine residues, nor 
attenuate cellular GSH (Fourquet et al. 2010). The semi-synthetic 
triterpenoids (TPs), such as CDDO-Me, are extremely potent Nrf2-inducing 
compounds (Yates et al. 2007) with a mechanism of action that is yet to be 
fully resolved however these compounds do not appear to provoke oxidative 
stress or alter GSH in cells. See Fig 2.2 for chemical structures of the 
compounds used in this study. These compounds will be used to test the 
hypothesis that small molecules, which activate Nrf2 in the absence of 
direct covalent adduction of Keap1, provoke changes in the oxidation 
state of Keap1 cysteine residues, which may alter the susceptibility of 
these residues to further modification. 
Figure 2.2 Chemical structures of the Nrf2 inducing compounds under 
investigation in this chapter. 
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2.2  MATERIALS AND METHODS 
2.2.1 Materials and reagents 
 
The human embryonic kidney cell line (HEK293T) was obtained from 
American Type Culture Collection (Masassas, VA, USA). The Wilovert D6330 
light microscope was from Will-Wetzler (Wetzlar, Germany). Nunclon Δ cell 
culture flasks, dishes and multi-well plates were from Nalge-Nunc 
International (c/o VWR International, Lutterworth, UK). The mouse Keap1-V5 
encoding plasmid was generated at the MRC Centre for Drug Safety 
Science, University of Liverpool, UK by Dr Ian Copple. The XL10-Gold ultra-
competent E.coli were purchased from Agilent Technologies (Stockport, UK). 
Sequencing grade modified trypsin was purchased from Promega 
(Southampton, UK) and the QIAfilter Plasmid Maxi Kit from QIAgen (Crawley, 
UK). Protein assay dye reagent, Precision Plus protein Kaleidoscope 
standards, non-fat dry milk, Mini Trans-Blot Cell and GS-800 calibrated 
image densitometer were from Bio-Rad (Hemel Hempsted, UK). FBS, 
NuPAGE Novex 4-12% Bis-Tris gels, NuPage LDS sample buffer, NuPAGE 
reducing agent and antioxidant, XCell Surelock mini-cell and Lipofectamine 
2000 were from Invitrogen (Paisley, UK). The goat-anti-Keap1 antibody was 
obtained from Santa Cruz Biotechnology (Heidelberg, Germany) whilst the 
mouse-anti-beta actin and rabbit–anti-Nrf2 antibodies were from Abcam 
(Cambridge, UK). The anti-goat HRP-conjugated antibody was from Dako UK 
(Ely, UK) and, anti-mouse HRP-conjugated antibody was from Abcam 
(Cambridge, UK). The MRX microplate reader was from Dynatech 
Laboratories (Billingshurst, UK) and TotalLab 100 software was from Non-
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linear Dynamics (Newcastle, UK). Western Lighting Enhanced 
Chemiluminescence (ECL) reagents were from Perkin-Elmer (Seer Green, 
UK). Hybond nitrocellulose membranes and Hyperfilm ECL were from GE 
Healthcare Life Sciences (Little Chalfont, UK). The Series 200 HPLC was 
from Perkin Elmer (Massachusets, USA), the C18 Uptisphere column from 
Interchim, Cheshire Sciences Ltd (Chester, UK). The MALDI target plate, 
Voyager-DE PRO-MALDI-TOF Biospectrometry Workstation, APSciex 
API3000 triple-quadrapole mass spectrometer, API QSTAR Pulsa 1 MS/MS 
spectrometer, Analyst QS and ProteinPilot software packages were from 
Applied Biosystems (Warrington, UK). The NanoDrop 1000 UV-
spectrophotometer was from Labtech International (East Sussex, UK). The 
concentrator 5301 and C18 ZipTips were from Eppendorf (Cambridge, UK). 
The DMEM, Penicillin-streptomycin solution, Trypsin, Trypan Blue solution, 
DNCB, DMSO, BSO, BSA, H2O2, MOPS, GSH, NADPH, GSH reductase, 
Kodak developer and fixer solution, Ponceau S solution, Tween-20, PBS 
tablets, sulphosalicylic acid (SSA), the goat-anti rabbit HRP-conjugated 
secondary antibody and anti-V5 agarose beads were from Sigma-Aldrich 
(Poole, UK) All other reagents were of analytical or molecular grade and from 
Sigma-Aldrich. 
 
2.2.2 Cell culture 
 
HEK293T cells were maintained at 37°C in 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 584 mg/L L-glutamine, 10% 
heat inactivated fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/ 
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mL streptomycin. Cells were grown in 75cm2 Nunclon Δ culture flasks and 
passaged routinely every 3-4 days at approximately 80% confluence. 
Following a wash with 5 mL unsupplemented DMEM, cells were returned to 
the incubator with 5 mL trypsin for up to 5 min to allow detachment of cells 
from the flask surface. Cells were resuspended in 5 mL supplemented 
DMEM and centrifuged at 1500 rcf for 5 min. Cells were then resuspended in 
5 mL supplemented DMEM and dissociated five times using a 21-gauge 
needle with a 5 mL syringe. For continuation, cells were re-seeded at a 
cells:growth medium radio of 1:10. 
 
To ensure that an accurate number of cells were seeded, cells were counted 
using Trypan Blue solution (0.4% w/v) and a haemocytometer. Briefly, cells 
were detached from the surface of a culture flask as described above and 40 
μL was combined with 10 μL of Trypan Blue solution. 10 μL of this was 
transferred to the haemocytometer. Cells were visualised using the 20X 
objective of a Wilovert D6330 light microscope. Viable cells (those that did 
not take up the Trypan Blue dye) within the central 5 x 5 square were 
counted and the original cell density was calculated as follows: 
Number of cells counted x 1.25 (to correct for dilution with Trypan Blue 
solution) = cells per 0.1 mm3 x 10,000 = cells per 1 cm3 = cells per 1mL 
 
2.2.3 Mouse Keap1-V5 plasmid purification 
 
The mouse Keap1-V5-encoding plasmid (Keap1-V5) was generated by Dr. 
Ian Copple (Copple et al. 2008a). Briefly, the full mouse Keap1 coding 
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sequence lacking a stop codon in the TOPO cloning site of pcDNA3.1/V5-
His-TOPO was transformed into XL10-Gold ultracompetent E.coli. A 15% 
(v/v) glycerol stock of pcDNA3.1/Keap1-V5 XL10-Gold E.Coli was cultured in 
1 L LB broth supplemented with 100 µg/mL ampicillin and incubated for 16 hr 
at 37°C, 250 rpm. The pc.DNA3.1/Keap1-V5 plasmid was purified using a 
QIAfilter Plasmid Midi Kit and eluted into 1XTE buffer (10 mM Tris base, 1 
mM EDTA, pH 7.5). The concentration and purity of the plasmid DNA was 
determined using a Nano Drop. The purity of the DNA was determined by 
reference to the 260 nm:280 nm ratio. Only samples with a ratio of above 1.8 
were used for future experiments. Mouse Keap1-V5 was used instead of 
human Keap1 due to the high sequence identity between the two (94%) and 
to facilitate the translation of these data to in vivo and transgenic studies 
which have previously been performed in mice. 
 
2.2.4 Transfection of cells with Keap1-V5 
 
For mass spectrometry experiments, HEK293T cells were seeded onto 9cm 
Nunclon Δ cell culture dishes at 5x106 cells/dish in 10 mL growth media (3 
dishes per condition) and returned to the humidified incubator. The following 
day, cells were transfected with pcDNA3.1/Keap1-V5-His plasmid using 
Lipofectamine 2000 according to the manufacturer’s instructions. For each 
dish of cells, 3 mL OptiMEM was combined with 60 µL Lipofectamine 2000 
and 20 µg of Keap1-V5 plasmid. The contents were mixed and incubated at 
room temperature for 20 min. The mixture was then added dropwise to the 
dish. Cells were then returned to the humidified incubator, at 37°C in a 5% 
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CO2 atmosphere for 24 hr. All preparations were done under sterile 
conditions. 
 
2.2.5 Cell treatment 
 
For mass spectrometry experiments, following the transfection of HEK293T 
cells with Keap1-V5-His for 24 hr, cells were treated with various compounds. 
DNCB, CDDO-Me, and Dex-Mes were dissolved, at 200x the required final 
concentration, in dimethyl sulphoxide (DMSO). BSO was dissolved in distilled 
water (dH2O) at 200x the final concentration. H2O2 was dissolved in cell 
culture media at 200x the final concentration. To the appropriate dish of cells, 
the vehicle control or Nrf2 inducer was added (a 1:200 dilution) giving the 
required final concentration. The final volume of solvent in the cell culture 
medium was 0.5% (volume/volume; v/v). The cells were placed back into the 
humidified incubator (37°C in a 5% CO2) for the indicated period of time (1 hr 
or 24 hr). Following this incubation, 2mM NEM dissolved in DMSO was 
added as above, for 5 min. 
 
2.2.6 Immunopurification of Keap1-V5 
 
Following exposure to Nrf2 inducers, followed by NEM, cells were 
resuspended in their own media. Cells were pelleted by centrifugation for 5 
min at 800rcf and washed once with 1 mL 1x PBS. The cells were then 
resuspended in 1 mL radioimmunoprecipitation assay (RIPA) buffer (0.15 M 
NaCl, 1% (v/v) NP-40, 0.5% (v/v) sodium deoxycholate, 0.1% (v/v) SDS, 25 
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mM Tris-Cl,). 1 mL of lysate was incubated with 50 µL anti-V5 agarose beads 
on a mechanical roller for 4 hr at 4˚C to facilitate immunopurification of 
Keap1-V5. The beads were collected by centrifugation at 14,000g for 1 min 
and washed 3 times in 0.5 mL 1x PBS.20 µL samples were taken before and 
after immunopurification to be analysed by immunoblotting. 
 
2.2.7 Measurement of protein content 
 
For western blotting and quantification of glutathione levels, the total protein 
content of whole cell lysates was determined using Protein Assay Dye 
Reagent based of the method of Bradford (1976). This assay relies on the 
binding of Coomassie Brilliant Blue G-250 dye to basic and aromatic amino 
acids. This results in a change in the colour of the dye from red to blue, and a 
consequential change in absorbance maximum from 465 to 595nm. The 
increase in absorbance at 570 nm, measured using an MRX microplate 
reader, is proportional to the amount of protein present. A standard curve, 
ranging from 0.0125-0.25 µg bovine serum albumin (BSA) was used to 
calculate the protein content in the cell lysates. 
 
2.2.8 Quantification of glutathione levels 
 
Total glutathione (GSH) content was quantified using the 5,5’-dithiobis(2-
nitrobenzoic acid) (DTNB)-GSH reductase recycling method, as previously 
described by Vandeputte et al. (1994). DTNB oxidises GSH to yield GSSG 
and the 5-thio-2-nitrobenzoic acid (TNB) chromophore, with an absorbance 
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maximum of 412 nm. The rate of formation of TNB, followed at 405 nm, is 
proportional to the sum of GSH and GSSG in each sample. 
 
1) 2GSH + DTNB → GSSG + TNB 
2) GSSG + NADPH + H+→ 2GSH + NADP+ (catalysed by GSH 
reductase) 
 
Briefly, 293T cells were seeded into 24-well plates at 3 x 105 cells/well before 
being treated with the appropriate Nrf2 inducer or vehicle control, as 
described in Section 2.2.5. Cells were resuspended in their own media and 
pelleted by centrifugation at 800 rcf for 5 min. Cells were then resuspended 
in 0.125 mL of 10 mM HCl. Aliquots were taken to enable the determination 
of total protein content as described in Section 2.2.7. Sulphosalicylic acid 
(SSA) was added to the remaining samples to a final concentration of 1.3 % 
(w/v), and samples incubated on ice for 10 min to facilitate protein 
precipitation. Protein was pelleted by centrifugation at 18,000 rcf for 5 min. 
The supernatant was removed and placed into a fresh eppendorf and a 
proportion of the supernatant was diluted 1:5 in assay buffer (0.143 M 
NaH2PO4, 6.3 mM EDTA, pH 7.4). 20 μL of the diluted supernatant and the 
neat supernatant were transferred to a clear 96-well plate. Samples were 
incubated at room temperature with 0.2 mL assay reagent (1.0 mM DTNB, 
0.34 mM NADPH, in 0.143 M NaH2PO
4, 6.3 mM EDTA, pH 7.4) for 5 min. 
The enzymatic reaction was initiated by the addition of 0.35 U GSH 
reductase and followed kinetically at 405 nm for 5 min on a MRX microplate 
reader. The rate of TNB formation was calculated as the change in 
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absorbance min-1. Sample GSH concentrations were calculated via reference 
to a standard curve (1-50 nmol/mL GSH). The GSH concentration for each 
sample was normalised to total protein content and expressed as mean ± 
standard deviation of the mean (SD). 
 
2.2.9 Western Immunoblotting- whole cell lysates 
 
Cells were seeded into 12-well Nunclon Δ cell culture plates at 3x105 cells/ 
well and returned to the humidified incubator overnight. Cells were treated 
with Nrf2 inducers as described in Section 2.2.5. After treatment for the 
indicated period of time, cells were resuspended in their own media, pelleted 
by centrifugation for 5 min at 800 rcf and washed twice in 1 mL PBS. Cells 
were resuspended in 60 µL RIPA buffer and incubated on ice for 5 min 
before storing at -80˚C. Clarification by centrifugation at 18,000 rcf for 5 min 
before analysis was necessary, as freeze-thaw cycles may promote the 
formation of protein aggregates. 
 
Whole cell lysates (20 μg), or samples taken before and after Keap1-V5 
immunopurification were denatured via the addition of 5 μL loading buffer (70 
% (v/v) NuPAGE sample loading buffer, 30 % (v/v) NuPAGE reducing agent) 
and heated to 80 °C for 5 min. Samples were loaded onto pre-cast 4-12 % 
NuPAGE Novex bis-tris polyacrylamide gels, alongside PrecisionPlus protein 
Kaleidoscope standards. Samples were resolved by electrophoresis in an 
XCell Surelock Mini-cell, using 3-(N-morpholino)propanesulphonic acid 
(MOPS) running buffer (50 mM MOPS, 50 mM Tris base, 3.5 mM sodium 
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dodecyl sulphate, 1 mM EDTA, 0.25 % (v/v) NuPAGE antioxidant), at 90 V 
for 10 min, followed by 170 V for 60 min. Separated proteins were transferred 
to nitrocellulose membranes using the Bio-Rad Mini Trans-Blot cell, in 
accordance with the manufacturer’s instructions. To ensure the transfer 
process was successful, membranes were stained for 10 sec with Ponceau S 
solution. Membranes were blocked for 30 min or overnight, on an orbital 
shaker, in tris-buffered saline (TBS; 0.15 M NaCl, 25 mM Tris base, 3 mM 
KCl, pH 7.0) containing 0.1 % (v/v) Tween 20 and 10 % (weight/volume; w/v) 
non-fat dry milk. Blocked membranes were probed for 3 hr with a rabbit anti-
human Nrf2 (1:400 in TBS-Tween containing 2 % (w/v) non-fat dry milk), or a 
goat anti-Keap1 (1:2000 in TBS-Tween containing 2 % (w/v) non-fat dry milk) 
primary antibody. Following several washes in TBS-Tween, membranes were 
probed for 1 h with goat anti-rabbit (1:10,000 in TBS-Tween containing 2 % 
(w/v) non-fat dry milk) or rabbit anti-goat (1:2000 in TBS-Tween containing 2 
% (w/v) non-fat dry milk) horseradish peroxidise (HRP) -conjugated 
secondary antibodies. Immunoblots were visualised with Western Lightening 
chemiluminescence reagents and exposed to Hyperfilm ECL under darkroom 
conditions. Blots were developed using Kodak developer and fixer solutions. 
To ensure equal loading across gels, membranes were probed with rabbit 
anti-actin primary (1:20,000 in TBS-Tween containing 2 % (w/v) non-fat dry 
milk) and goat anti-rabbit HRP-conjugated secondary antibodies. Films were 
scanned using a GS-710 calibrated imaging densitometer, immune-reactive 
band volumes were quantified using TotalLab 100 software, and normalised 
to actin. 
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2.2.10 Western Immunoblotting- immunopurified Keap1-V5 
 
To assess the immunopurification of Keap1-V5, proteins were eluted from 
anti-V5 agarose beads by resuspending in an equal volume of NuPAGE 
loading buffer. The slurry was heated at 80 °C for 10 min, the beads were 
pelleted by centrifugation at 5000 g for 5 min, and the supernatant loaded 
onto a pre-cast 4-12 % NuPAGE Novex bis-tris polyacrylamide gel as 
described in Section 2.2.9. 
 
2.2.11 Preparation of Keap1-V5 for LC-ESI-MS/MS 
 
After incubation and washing, PBS was removed from the Keap1-V5-bound 
anti-V5 agarose beads after centrifugation. The resulting beads (50 µL dry 
volume) were reduced by resuspending in 1 mL 0.1mM dithiothreitol (DTT). 
The mixture was incubated on a mechanical roller for 15 min at 4˚C. The 
beads were washed three times with 0.5 mL PBS to remove residual DTT. 
Any unmodified cysteines were alkylated by resuspending beads in 1 mL 
55mM iodoacetamide (IAA) and incubated on a mechanical roller for 15 min 
at 4˚C. The beads were washed twice in 0.5 mL PBS to remove residual IAA. 
Prior to trypsin digestion, beads were washed twice with 0.5 mL 25mM 
ammonium bicarbonate and resuspended in 90 µL ammonium bicarbonate. 
A 400 µg/mL stock solution of sequence-grade modified trypsin was diluted 
1:10 with 25mM ammonium bicarbonate and 10 µL (40ng) was added to the 
bead slurry. Trypsin digestion of the sample was performed overnight at 
37˚C.  
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2.2.12 MALDI-TOF mass spectrometry 
 
Following overnight trypsin digestion and C18 ZipTipping according to the 
manufacturer’s instructions, peptide mixtures (0.5 μL) were combined with an 
equal volume of α-cyano-4-hydroxy-cinnamic acid (αCHCA) matrix (5 mg/mL 
αCHCA in 50 % (v/v) acetonitrile (ACN), 0.1 % (v/v) trifluoroacetic acid 
(TFA)) and spotted onto a matrix-assisted laser desorption ionization mass 
spectrometry (MALDI-MS) target plate alongside ProteoMass MALDI-MS 
standards (angiotensin II, adrenocorticotropic hormone fragment 18-39, 
oxidised insulin chain B, 0.5 pmol each), using the dried-droplet method. 
Peptide mass fingerprints were obtained on a Voyager DE Pro MALDI time-
of-flight (TOF) Biospectrometry Workstation, in positive ion reflector mode, 
and used in a MASCOT protein database search 
(http://www.matrixscience.com) to identify proteins present within the sample. 
 
2.2.13 LC-ESI-MS/MS methods 
 
Samples were delivered into a Triple TOF 5600 mass spectrometer (AB 
Sciex) by automated in-line reversed phase liquid chromatography (LC) using 
an Eksigent NanoUltra cHiPLC System mounted with microfluidic trap and 
analytical column (15cm x 75µm) packed with ChromXP C18-CL 3µM. A 
NanoSpray III source was fitted with a 10 μm inner diameter PicoTip emitter 
(New Objective). Samples were loaded in 0.1% formic acid onto the trap 
which was then washed with 2% ACN/0.1% FA for 10 min at 2 µL/min before 
switching in-line with the analytical column. A gradient of 2-50 % (v/v) ACN, 
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0.1 % (v/v) FA over 90 min was applied to the column at a flow rate of 300 
nL/min. Spectra were acquired automatically in positive ion mode using 
information-dependent acquisition powered by Analyst TF 1.5.1. software, 
using mass ranges of 400-1600 atomic mass units (amu) in MS and 1000-
1400 amu in MS/MS. Up to 25 MS/MS spectra were acquired per cycle 
(approx. 10Hz) using a threshold of 100 counts per sec, with dynamic 
exclusion for 12sec and rolling collision energy. The instrument was 
automatically calibrated after every fifth sample using a beta-galactosidase 
digest. Amino acid modifications were detected with ProteinPilot software 
v4.0 using the ParagonTM algorithm (Shilov et al. 2007) and the most recent 
version of the SwissProt database. Carboxyamidomethyl (IAA) (+57.0 amu) 
or NEM (+125.0 amu) were selected as variable modifications. Adducts were 
confirmed by visual inspection of MS/MS spectra. Changes in the 
susceptibility of a cysteine to modification by NEM or IAA were deemed 
relevant if observed ≥2 out of 6 biological repeats. 
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2.3  RESULTS 
 
2.3.1 Optimisation of Keap1-V5 transfection in HEK293T cells 
 
To obtain adequate Keap1-V5 expression in HEK293T cells to give sequence 
coverage sufficient (>70%) to detect cysteine modification, the protocol for 
cell transfection was optimised. A number of batches of 293T cells were 
transfected with Keap1-V5 or mock transfected. Batch 3, which showed the 
highest level of Keap1-V5 expression (Fig. 2.3A) was used in subsequent 
experiments. The conditions for Keap1-V5 immunopurification (IP) were 
optimised by varying the volume of V5-agarose beads and incubation time. 
An incubation time of 4 hr yielded the highest amount of Keap1-V5 following 
IP, whilst altering the volume of V5-agarose beads had minimal effect (Fig. 
2.3B). The loss of Keap1-V5 in some samples indicates a loss of V5 agarose 
beads during washing steps. For subsequent experiments, 
immunopurification was carried out for 4 hr with 50 µl V5-agarose beads.  
 
2.3.2 MALDI validation of Keap1-V5 
 
Following transfection of HEK293T cells using optimised conditions, MALDI-
TOF analysis was performed to confirm expression, IP and tryptic digestion 
of Keap1-V5. These data show that the most highly represented proteins in 
the sample were mouse and rat Keap1 (Fig. 2.4A) which share 98% 
sequence homology. A Mascot search showed 75% sequence coverage of 
mouse Keap1 (Fig. 2.4B). 
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Figure 2.3.Optimisation of Keap1-V5 transfection in HEK293T cells.(A) 
Different batches of HEK293T cells (1,2,3) were transfected with 1xTE buffer 
(-) or Keap1-V5 plasmid (+) for 24 hr. (B) Cells transfected as in A were 
lysed, and clarified lysates incubated with differing volumes of anti-V5 
agarose beads (25, 50, 100 µl) for increasing time periods (2, 4, 16 hr). The 
proteins eluted from the beads were resolved by SDS-PAGE. Expression 
levels of Keap1-V5 were assessed by western blotting using an anti-Keap1 
antibody. The volume of anti-V5 agarose beads is indicated in the lower 
panel by a Ponceau S stain and highlights the immunoglobulin fraction of the 
monoclonal anti-V5 (Ig). 
 
2.3.3 LC-ESI-MS/MS validation of Keap1-V5 
The successful detection of Keap1 using MALDI-TOF mass spectrometry 
afforded confidence to use LC-ESI-MS/MS to detect Keap1 peptides in 
trypsin digests. Samples were prepared as in 2.3.2 and analysed using an 
AB SCIEX TripleTOF 5600 LC-ESI-MS/MS setup. A ProteinPilot search 
showed that mouse Keap1 was significantly represented (92.6% sequence 
coverage) and 188 mouseKeap1 peptides confidently detected (Fig. 2.4C). 
High sequence coverage is considered necessary for the reliable detection of 
covalent modifications of Keap1, as determined by previous users of this 
technique within the lab. 
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Figure 2.4. Validation of Keap1-V5 Immunopurification. Following cell 
transfection with Keap1-V5 and immunopurification using anti-V5 beads, 
trypsin digestion preceded the sample analysis by mass spectrometry. (A) 
MALDI-TOF analysis protein summary report showed mouse Keap1 and rat 
Keap1 as highly represented in the immunopurified fraction. (B)A Mascot 
search shows 75% sequence coverage of mouse Keap1 (C) LC-ESI-MS/MS 
analysis confirmed the presence of mouse Keap1 with high sequence 
coverage. 
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2.3.4 Effect of chosen compounds on Nrf2 and GSH in cells 
 
It was important to confirm that the compounds chosen for this investigation 
were capable of inducing Nrf2, and whether they induce changes in GSH. 
HEK293T cells were treated with the relevant vehicle control (DMSO, dH2O 
or growth media) orNrf2-inducing compound at the following concentrations: 
DNCB 100 µM, Dex Mes 30 µM, CDDO-Me 100 nM, BSO 300 µM and H2O2 
200 µM. The treatment conditions used in this study had previously been 
optimised in the lab as treatment duration is critical when investigating Nrf2 
activation. Western blot analysis was performed on whole cell lysates. Nrf2 
induction was seen with all compounds (Fig. 2.5A). Quantification of GSH 
was performed on samples prepared under the same conditions with these 
data showing a significant depletion of GSH by DNCB (98%) and BSO (72%) 
(p ≤ 0.01 and p ≤ 0.05, respectively)but not for other compounds (Fig. 2.5B). 
 
 
 
Figure 2.5. Nrf2 induction and GSH quantification by Nrf2-inducing 
compounds.HEK293T cells were treated with the indicated compounds.(A) 
Western blot analysis shows Nrf2 induction (representative blot from 3 
biological repeats) (B) Levels of GSH in cell lysates following treatment. ** p 
≤0.01 ** p ≤0.05.Average GSH levels of 3 biological repeats. 
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2.3.5 Determining susceptibility of cysteine residues to modification 
 
The LC-MS/MS method employed allows for the detection of differential 
capping of cysteine residues in proteins. Following treatment with Nrf2-
inducing compounds, cells were treated with NEM which can covalently 
modify all reduced cysteine residues, i.e. those not involved in direct adducts 
with the Nrf2-inducing compound, or oxidised (Fig. 2.6). Following cell lysis 
and Keap1 immunopurification, DTT treatment reduces all reversibly oxidised 
cysteine residues (Fig. 2.6). The subsequent addition of IAA caps all newly 
reduced cysteine residues, whilst not affecting those previously adducted by 
the Nrf2-inducing compound, or NEM (Fig. 2.6). Cysteine residues less prone 
to forming an adduct with IAA indicate the presence of a reversible 
modification, such as oxidation, whilst residues more prone to IAA adduct 
formation indicate the presence of irreversible modifications. It has previously 
been determined in our lab that NEM and IAA can form adducts with all 
Keap1 cysteine residues, except Cys-622 and -624, which reside close to the 
V5 tag and are often not cleaved during trypsin digestion (data not shown). 
 
Figure 2.6.Schematic overview of the experimental protocol. Cells were 
treated with vehicle control or Nrf2 inducers followed by NEM. Cells were 
then lysed, Keap1-V5 was immunopurified and reduced with DTT prior to re-
alkylation with IAA after which samples were prepared for LC-MS/MS.  
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2.3.6 Modification of cysteines in Keap1-V5 by DNCB 
 
Cells expressing Keap1-V5 were treated with DNCB, which induces Nrf2 and 
depletes GSH (Fig. 2.5). LC-MS/MS analysis of immunopurified Keap1-V5 
provided evidence for the covalent modification of cysteine residues, one of 
which has previously been shown to be targeted by DNCB (Cys-257) (Chia et 
al. 2010, Copple et al. 2008a), as well as a number not previously reported 
(Fig. 2.7). DNCB formed covalent adducts (detected as dinitrophenol (DNP) 
adducts) with the following cysteine residues: Cys-77, -226, -257, -319, -434, 
-489 and -622. Notably, Cys-23, -38, -151, -241, -249, -257, -297 and -319 of 
Keap1-V5 were found to be less prone to NEM capping following DNCB 
treatment compared to vehicle control (Fig. 2.7), suggesting DNCB induces 
modifications of these cysteines preventing NEM binding. Under the same 
conditions, Cys-23, -38, -241, -249, -297 and -434 of Keap1-V5 were found 
to be more prone to post-DTT capping by IAA following DNCB exposure. 
Given that amongst this subset of cysteines, only Cys-434 was covalently 
modified by DNCB, this datum implies that exposure to DNCB promotes 
reversible (potentially oxidative) modifications on specific cysteine residues in 
Keap1. These modifications may be responsible for the inability of NEM to 
bind to this group of cysteines. In addition, we noted that Cys-395 and -406 
of Keap1-V5 showed decreased post-DTT capping by IAA following DNCB 
exposure(Fig. 2.7), suggesting an irreversible modification on these residues. 
These data show evidence of direct adducts between Keap1-V5 and DNCB, 
as well as reversible/irreversible modification of thiol groups, potentially 
caused by oxidation subsequent to GSH depletion.
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Figure 2.7.Labelling of Keap1-V5 cysteine residues by NEM and IAA following exposure of HEK293T cells to DNCB. 
HEK293T cells expressing Keap1-V5 were treated with DMSO or 100µM DNCB for 1hr, followed by 2mM NEM for 5 min. Keap1-V5 
was immunopurified, incubated with DTT, and newly reduced cysteines capped with IAA. Trypsin digestion was performed and 
digests were analysed by LC-MS/MS for direct covalent modifications or NEM/IAA modifications. Numbers in circles represent 
number of independent experiments in which a modification was observed (n=6). Average protein coverage 84.7%.
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2.3.7 Modification of cysteines in Keap1-V5 by Dex-mes 
 
In cells expressing Keap1-V5 and treated with dex-mes, which induces Nrf2 in 
the absence of GSH depletion (Fig. 2.5), LC-MS/MS analysis revealed 
evidence for the direct covalent modification of a number of cysteine residues 
in Keap1-V5 by dex-mes (Cys-226, -257, -288, -434, -489 and -613) (Fig. 2.8). 
Whilst some of these cysteines have previously been shown to be targeted by 
dex-mes (Dinkova-Kostova et al. 2002) some of these modifications (Cys-266, 
-434, -489 and -613) have not previously been reported. Interestingly, one 
cysteine residue of Keap1-V5 (Cys-273) was found to be less prone to NEM 
capping following dex-mes treatment compared to vehicle control, indicating 
the presence of an irreversible modification (Fig. 2.8). This cysteine has 
previously been shown to be directly modified by dex-mes (Dinkova-Kostova 
et al. 2002) and would explain this observation. Additionally, there was an 
increase in the ability of IAA to cap Cys-226 and Cys-368 in Keap1-V5 
following dex-mes and DTT treatment, indicating a reversible modification (Fig. 
2.8). Furthermore, Cys-288 was shown to be less prone to post-DTT capping 
by IAA following dex-mes and DTT treatment, indicative of the irreversible 
modification of this residue- most likely the adduct formed between dex-mes 
and the thiol that we, and others (Dinkova-Kostova et al. 2002) have observed. 
These data highlight the covalent modification of cysteine residues in Keap1-
V5 by dex-mes following the treatment of cells with the compound, as well as 
a limited number of reversible/irreversible modifications of thiol groups.
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Figure 2.8.Labelling of Keap1-V5 cysteine residues by NEM and IAA following exposure of HEK293T cells to Dex Mes. 
HEK293T cells transiently expressing Keap1-V5 were treated with (DMSO or 30µM Dex Mes for 1hr, followed by 2mM NEM for 5 
min. Keap1-V5 was immunopurified, incubated with DTT, and newly reduced cysteines capped with IAA. Trypsin digestion was 
performed and digests were analysed by LC-MS/MS for direct covalent modifications or NEM/ IAA modifications. Numbers in circles 
represent number of independent experiments in which a modification was observed (n=6). Average protein coverage 85.3%.
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2.3.8 Modification of cysteines in Keap1-V5 by H2O2 
 
Following treatment of Keap1-V5 expressing cells with H2O2, which induces 
Nrf2 in the absence of GSH depletion, there was no evidence for the covalent 
modification of cysteine residues in Keap1-V5 (Fig. 2.9). Whilst H2O2 does 
bind covalently to thiol groups, this would be rapidly degraded to form a 
sulphonic acid (S-O3H),and oxygen (O2) as a by-product. Interestingly, there 
were relatively few changes in the ability of NEM or IAA to modify cysteine 
residues in Keap1 (Fig. 2.9), indicating that the induction of Nrf2 by H2O2 is 
not associated with the substantial oxidative modification of Keap1-V5. Cys-
434 was rendered more prone to IAA modification following DTT-mediated 
reduction (Fig. 2.9), suggesting a reversible modification on this amino acid, 
potentially oxidation. Additionally, Cys-513 and -518 were shown to be less 
prone to IAA modification following DTT treatment indicating non-reversible 
modification of these residues (Fig. 2.9). The protein coverage in these 
samples (73% average) was lower than in other experiments detailed in this 
chapter (all were above 80% average) which may explain why a number of 
cysteine containing peptides were not found to be modified by either NEM or 
IAA. However, of the peptides that were consistently detected, only a few 
residues (Cys-434, -513, 518) showed an altered susceptibility to 
modification by NEM or IAA following treatment with H2O2 that would 
implicate the oxidative modification of Keap1 as a mechanism of action for 
H2O2 as an inducer of Nrf2. As no covalent modification of Keap1-V5 is 
expected, or indeed detected, this implicates a mechanism of Nrf2 induction 
independent of Keap1, or changes in cell redox state.
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Figure 2.9.Labelling of Keap1-V5 cysteine residues by NEM and IAA following exposure of HEK293T cells to H2O2.HEK293T 
cells transiently expressing Keap1-V5 were treated with cell growth media or 200µM H2O2 for 1hr, followed by 2mM NEM for 5 min. 
Keap1-V5 was immunopurified, incubated with DTT, and newly reduced cysteines capped with IAA. Trypsin digestion was 
performed and digests were analysed by LC-MS/MS for direct covalent modifications or NEM/IAA modifications. Numbers in circles 
represent number of independent experiments in which a modification was observed (n=6). Average protein coverage 73.0%.
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2.3.9 Modification of cysteines in Keap1-V5 by BSO 
 
Consistent with previous published data from our group (Chia et al. 2010, 
Copple et al. 2008a), LC-MS/MS analysis of Keap1-V5 peptides following the 
treatment of cells with BSO yielded no evidence for the covalent modification 
of cysteines in Keap1-V5 by this compound (Fig. 2.10), which induces Nrf2 in 
conjunction with GSH depletion (Fig. 2.10). Interestingly, no other 
modifications indicative of cysteine oxidation were detected in Keap1-V5 
purified from cells exposed to BSO (Fig. 2.10). This raises the possibility that 
the mechanism of Nrf2 induction by BSO is independent of Keap1.  
 
Unpublished data from our lab demonstrates that BSO pre-treatment can 
render Keap1-V5 Cys-257 less available for DNP modification (data not 
shown). DNP adduction of Cys-257 was only observed in two of five 
experiments when cells were pre-treated with BSO, and five out of five 
experiments when BSO was omitted. This may indicate a change in the 
redox state of this residue that is beyond the limit of detection of the method 
employed here. This observation indicates that BSO is able to alter the 
sensitivity of at least one Keap1 cysteine residue to modification by an Nrf2-
inducing electrophile. It is worth highlighting that, in this study, following 
treatment with vehicle control or BSO, Cys-257 is modified by IAA more 
frequently than following treatment with the other vehicle controls or Nrf2-
inducing compounds (Fig. 2.10). Further work is needed to define the 
chemical basis of this phenomenon. 
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Figure 2.10.Labelling of Keap1-V5 cysteine residues by NEM and IAA following exposure of HEK293T cells to BSO. 
HEK293T cells transiently expressing Keap1-V5 were treated with dH2O or 300µM BSO 1hr, followed by 2mM NEM for 5 min. 
Keap1-V5 was immunopurified, incubated with DTT, and newly reduced cysteines capped with IAA. Trypsin digestion was 
performed and digests were analysed by LC-MS/MS for direct covalent modifications or NEM/IAA modifications. Numbers in circles 
represent number of independent experiments in which a modification was observed (n=6). Average protein coverage 88.5%.
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2.3.10 Modification of cysteines in Keap1-V5 by CDDO-Me 
 
In cells expressing Keap1-V5 and treated with the potent Nrf2 inducer 
CDDO-Me, LC-MS/MS analysis provided no evidence for the direct covalent 
modifications of any cysteine residues in Keap1-V5 by the compound (Fig. 
2.11). Additionally, there was no detectable change in the ability of NEM to 
modify any of the cysteine residues in immunopurified Keap1-V5 (Fig. 2.11). 
Interestingly, a subset of cysteine residues (Cys-151, -226 -369) were found 
to be more prone to IAA modification following reduction with DTT, indicating 
the presence of reversible modification of these residues (Fig. 2.11). 
Additionally, Cys-434 was rendered less prone to IAA modification following 
DTT treatment (Fig. 2.11), implying the presence of an irreversible 
modification on this residue. Cys-151 of Keap1 has been implicated in the 
activation of Nrf2 by TPs(Eggler et al. 2009, Cleasby et al. 2014), however, 
the importance of this residue in the mechanism of TP-mediated Nrf2 
induction is the subject of controversy (Takaya et al. 2012). Our data 
suggests that Cys-151 may be reversibly modified by this compound, thus 
potentially playing a role its chemico-biological mechanism of action. These 
data are also in agreement with the purported reversibility of this compound 
when binding thiol groups (Ahmad et al. 2006) and may explain the difficulty 
in detecting changes in modification by NEM and IAA following the treatment 
of cells with this compound. The chemical mechanism of action of this 
compound as an inducer of Nrf2 is further examined in Chapter 3.
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Figure 2.11. Labelling of Keap1-V5 cysteine residues by NEM and IAA following exposure of HEK293T cells to CDDO-Me. 
HEK293T cells transiently expressing Keap1-V5 were treated with DMSO or 100µM CDDO-Me 1hr, followed by 2mM NEM for 5 
min. Keap1-V5 was immunopurified, incubated with DTT, and newly reduced cysteines capped with IAA. Trypsin digestion was 
performed and digests were analysed by LC-MS/MS for direct covalent modifications or NEM/IAA modifications. Numbers in circles 
represent number of independent experiments in which a modification was observed (n=6). Average protein coverage 84.4% .
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2.4  DISCUSSION 
 
Keap1 cysteine residues are purported to serve as sensors of both chemical 
and oxidative stress. The selective modification of Keap1 cysteine residues 
by Nrf2-inducing compounds, and Nrf2 induction in the absence of adduct 
formation, has inspired the hypothesis that oxidative modifications caused by 
changes in the redox state of the cell, for example by the depletion of GSH, 
may contribute to the de-regulation of Nrf2 provoked by certain chemical 
entities, which do not form covalent adducts with proteins.  
 
The data presented here support the proposal that there are modifications of 
Keap1-V5 provoked by DNCB that may be attributed to oxidation. Previous 
data from our lab shows that the mutation of Cys-257 to a non-reactive amino 
acid does not attenuate the ability of this compound to induce Nrf2, 
suggesting that the direct covalent modification of Cys-257 is not involved in 
the mechanism by which DNCB induces Nrf2 in cells (data not shown). The 
importance of direct covalent modification of other cysteines identified here 
(Cys-77, -226, -434, -489 and -622) requires further investigation. It has been 
demonstrated previously that Cys-23/-38; Cys-241/-249; and Cys-257/-297 of 
Keap1 form disulphide bonds upon incubation of the protein with an excess 
of glutathione (Holland et al. 2008). It is plausible that exposure of cells to 
DNCB results in the formation of disulphide bonds within/between this subset 
of residues, which our data supports, although more extensive analysis 
would be required to confirm this. The accumulation of reversibly oxidised 
peroxiredoxin and thioredoxin proteins induced by DNCB has been reported, 
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indicating the inhibition of thioredoxin reductase (TRX-R) (Baty et al. 2005). 
As thioredoxin reductase inhibition has been shown to induce Nrf2-mediated 
transcription, it is possible that this is an alternative mechanism of Nrf2-
activation by DNCB. It is also possible that the oxidation/covalent 
modification of Keap1 by DNCB may be sufficient for perturbation of the 
Nrf2/Keap1 interaction, leading to Nrf2 activation. 
 
Dex-mes forms covalent adducts with Cys-288 and Cys-273. These residues 
are known to be required for the basal regulation of Nrf2 by Keap1 
(Kobayashi et al. 2004), and their mutation to a less reactive residue renders 
Keap1 unable to suppress Nrf2 (Yamamoto et al. 2008). Notably, we have 
shown here that dex-mes provokes changes in Keap1 cysteine redox state, 
indicative of oxidative modification. Therefore, whilst direct modification of 
Keap1 cysteine residues by dex-mes may result in Nrf2 induction, the 
importance of the oxidative modification of cysteine residues by this 
compound requires further investigation. There is little experimental evidence 
for the ability of dex-mes to oxidise thiol groups directly, therefore it is likely 
that the oxidation seen in this study is due to changes in the redox state of 
the cell, however not dependent on GSH depletion.  
 
Hydrogen peroxide is a strong oxidising agent which forms highly unstable 
adducts with thiol groups, thus it is improbable that LC-MS/MS techniques 
will be able to detect them directly(Luo et al. 2005). H2O2 was found to alter 
the susceptibility to modification of only a few cysteine residues, including 
Cys-434 which lies within the Nrf2 binding region of Keap1. It has been 
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shown that under situations of oxidative stress, glutathionlylation of Keap1 
Cys-434 may be sufficient for the activation of Nrf2 (Holland and Fishbein 
2010). The formation of disulphide bonds between two Keap1 molecules at 
Cys-151 in response to H2O2 has previously been demonstrated (Fourquet et 
al. 2010), and it is possible that the analytical method used here was not 
sensitive enough to detect such a modification. Moreover, they observed that 
changes in oxidation state were transient (Fourquet et al. 2010), thus there is 
the potential that the disulphide bond was degraded during our 1 hr exposure 
of cells. As direct adducts are formed then rapidly degraded, they may play a 
part in Nrf2 induction, however, due to the absence of alternative modification 
of Keap1 observed here, our hypothesis regarding the oxidative modification 
by H2O2does not seem to be a viable mechanisms of Nrf2 induction. This is 
surprising as H2O2is known to oxidise proteins thiols and alter their function, 
as is the case with the oxidation of peroxiredoxins (Pillay et al. 2009).  
 
The depletion of GSH by BSO did not alter the susceptibility of cysteine 
residues to modification by NEM/IAA, within the limits of detection of our 
assay. This implies that the activation of Nrf2 by BSO may be independent of 
Keap1. Interestingly, the GSH-depleting action of BSO can increase cellular 
levels of nitro-cGMP, a signalling molecule that can adduct Keap1 (Fujii et al. 
2010). However it is not clear which residue this occurs on or whether it 
results in Nrf2 activation, and we do not see evidence for this modification in 
this study. Whilst there is evidence for the oxidation of proteins following BSO 
treatment of cells (Go et al. 2013), we do not show the oxidation of Keap1 by 
BSO treatment in our study.  
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CDDO-Me is a potent Nrf2-inducer showing promise as a therapeutic agent 
due to antioxidant, anti-inflammatory and pro-apoptotic properties (Wang et 
al. 2014). Whilst we saw that CDDO-Me rendered a subset of residues more 
(Cys-151, -226, -368), or less (Cys-434), susceptible to further modification, 
the inability to detect direct interactions between triterpenoids and Keap1 is 
not unique to our lab, due to their ability to selectively and reversibly bind 
thiol groups (Couch et al. 2005). The mechanism of action of CDDO-Me with 
respect of Nrf2 induction is largely unknown, and its inclusion in this 
investigation was to gain insight into the potential for it to modify Keap1. 
Published data implicates the involvement of Cys-273 and -288 (Dinkova-
Kostova et al. 2005, Ahn et al. 2010) with dispute over Cys-151 (Takaya et 
al. 2012, Eggler et al. 2009) and the data presented here further indicates a 
role for the latter residue. There is evidence for the oxidation of unidentified 
mitochondrial proteins by the TP CDDO which is potentially a mechanism of 
inducing apoptosis via attenuating the permeability transition pore (Brookes 
et al. 2007). Moreover, the ability to TPs to inhibit the inflammatory response 
mediated by NF-κB has been shown to be facilitated by TP-mediated 
inhibition of IκBα kinaseβ (IKKβ) via a reversible modification of Cys-
179(Ahmad et al. 2006), which could be oxidation or reversible adduct 
formation. Therefore, the oxidation of Keap1 by CDDO-Me is worth 
investigating as a mechanism of Nrf2 induction. A more in-depth review of 
published data regarding CDDO-Me modification of Keap1, and further 
experimental investigation, is presented in Chapter 3. 
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Previous attempts to detect the native redox state of Keap1 cysteine residues 
by LC-MS/MS have not been successful as Keap1 requires alkylation of 
cysteine residues for efficient MS detection and analysis. If this step is 
emitted, a loss of protein coverage is observed (data not shown). The 
reversible and dynamic nature of oxidation makes detection extremely 
challenging. A MS method for detecting sulphinic (S-O2H) and sulphonic acid 
(S-O3H) in vivo and in vitro has recently been published (Lee et al. 2013). 
The method is a label-free, quantification method with high sensitivity (Lee et 
al. 2013), however attempts to replicate this method proved unsuccessful 
with our MS set-up and would require substantial method optimisation. 
Furthermore, methods utilising dimedone-based chemical probes to label 
sulphenic acid (S-OH) are common (Klomsiri et al. 2010) however, this 
method only identifies reversible oxidative states and not irreversible 
oxidative states of cysteines. Multiple reaction monitoring (MRM), an MS 
method used to detect modification involving isotope labelling and differential 
alkylation of residues, has been adapted to detect oxidative modifications in 
some enriched proteins (Held et al. 2010). The use of such an approach here 
would require the development of a method to detect each cysteine-
containing peptide of Keap1, of which there are 19. Antibodies targeted 
towards oxidised peptides have been used successfully to detect oxidation of 
recombinant protein and components of cell lysates (Woo et al. 2003), 
however, the use of such an approach in this context would require the 
synthesis of antibodies targeted to all cysteine-containing peptides in Keap1. 
Non-reducing SDS-PAGE can detect oxidised Keap1 following the treatment 
of cells to H2O2(Fourquet et al. 2010), however such an approach is unable 
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to identify specific target residues unless a mutagenesis approach is taken. 
As a result, there is considerable scope for the improvement of methods 
available for distinguishing the oxidation states of cysteine residues in 
proteins. Such advances would better enable the occurrence and importance 
of Keap1 oxidation to be determined. 
 
The data presented here provides evidence that Keap1 cysteine residues 
may undergo oxidation in response to GSH depletion, and under conditions 
of Nrf2 induction, or that GSH-depleting compounds may alter the 
susceptibility of Keap1 cysteines to modification. This may represent an 
alternative mechanism of Nrf2 activation, as direct covalent modification of 
cysteines is not necessarily a pre-requisite for Nrf2 activation. To test the 
functional importance of the oxidative modification of Keap1 for the induction 
of Nrf2, it would be necessary to perform mutagenesis experiments. It is 
worth investigating in our cell model, whether the oxidation of one or more 
cysteines can lead to the formation of intra- and inter-molecular disulphide 
bond formation, which could render Keap1 unable to repress Nrf2 
(Wakabayashi et al. 2004, Fourquet et al. 2010).In a physiological sense, the 
oxidation of Keap1 thiols would be preferable to their irreversible covalent 
modification, as the former would allow for the regeneration of fully-functional 
Keap1, possibility facilitated by the Nrf2-mediated induction of antioxidant 
proteins (e.g. TRX, TRX-R, GSH) which serve to maintain the redox state of 
important thiol-containing proteins. On the other hand, the irreversible 
inactivation of Keap1 by the formation of stable covalent adducts would 
require de novo synthesis of Keap1 to regain protein function.
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CHARACTERISING THE COVALENT MODIFICATION OF 
KEAP1 BY TRITERPENOIDS, POTENT INDUCERS OF NRF2 
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3.1 INTRODUCTION 
 
The Nrf2 pathway plays a vital role in defining the susceptibility of cells to 
chemical and oxidative insults. This, in combination with links between Nrf2 
and the pathology of many diseases, has resulted in considerable interest in 
the manipulation of this pathway for therapeutic benefit (Copple 2012). Such 
manipulation may involve the pharmacological activation or inhibition of Nrf2. 
The activation of Nrf2 may reduce the onset of pathologies associated with 
oxidative stress, such as cancer, inflammation and degenerative disease 
(Hybertson et al. 2011). Alternatively, the inhibition of Nrf2 has been shown 
to sensitise cancer cells to treatment with chemotherapeutic agents and 
reduce tumour size (Ren et al. 2011).Whilst there are a number of known 
Nrf2 inducers, none are as potent as those synthesisedfrom TPs, which are 
naturally produced in many plants (Phillips et al. 2006). 
 
TPs exhibit anti-inflammatory and anti-tumorigenic properties in vivo (Nishino 
et al. 1988, Huang et al. 1994, Singh et al. 1992). In order to improve the 
potency of naturally occurring TPs (such as oleanolic acid), medicinal 
chemists have made modifications to the basic TP structure (Dzubak et al. 
2006, Connolly and Hill 2005) giving rise to compounds such as CDDO, 
CDDO-Im and CDDO-Me. These are, to our knowledge, the most potent anti-
inflammatory and anti-carcinogenic TPs described to date (Liby et al. 2007). 
The increase in potency is concurrent with additional health benefits including 
anti-viral, anti-microbial and antioxidant properties (Jung et al. 2004). The 
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diverse biological effects of TPs have been attributed to their ability to react 
with nucleophiles within the cell, such as the thiol group of cysteine residues 
(Liby et al. 2007, Couch et al. 2005). Moreover, the antioxidant and anti-
inflammatory effects of these compounds is purported to be due to their 
ability to induce Nrf2 (Liby and Sporn 2012). CDDO-Me activates Nrf2 
signalling at concentrations approximately 1000-fold lower than many other 
inducers (Copple et al. 2014). However, the chemico-biological mechanism 
that underlies the ability of TPs to induce Nrf2 remains largely unknown.  
 
Due to the established role of Keap1 as a sensor of stress, and the ability of 
TPs to react selectively and reversibly with nucleophiles (Couch et al. 2005), 
we hypothesised that CDDO-Me induces Nrf2 via the reversible covalent 
modification of one or more cysteine residues in Keap1. To date, there have 
been no reports describing the formation of direct adducts between CDDO-
Me (or other TPs), and specific cysteine residues in the full length Keap1 
protein (or other proteins).We postulate that the selective and reversible 
nucleophilic addition between TPs and non-protein thiols (Couch et al. 2005) 
underlies the difficulty in detecting adducts between CDDO-Me and Keap1 
(i.e. using standard LC-MS/MS techniques). We further hypothesised that the 
reversibility accounts for the potent nature of CDDO-Me as an inducer of 
Nrf2. For example, whilst electrophiles which irreversibly bind thiol groups will 
be removed by detoxification mechanisms, i.e.by conjugation with GSH, 
CDDO-Me can evade this, enabling each molecule of the compound to bind 
multiple Keap1 molecules. 
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To examine the above hypothesis, and through a collaboration with the 
Department of Chemistry at the University of Liverpool, we have synthesised 
novel TPs which can be used as biochemical tools to characterise the 
covalent modification of thiols by CDDO-Me. Indeed, through the chemical 
tuning of CDDO-Me, we have generated a TP capable of irreversible adduct 
formation with the model thiol β-mercaptoethanol (confirmed by NMR and 
MS; data presented in thesis of Michael Wong). The cyano (CN) group on the 
A ring of CDDO-Me acts as an electron withdrawing group and the double 
bond is rich in electrons, attracting electrons from nucleophiles and enabling 
soft nucleophiles to react. However, the electron withdrawing group affords 
the compound with a reversible nucleophilic binding property. An epoxide 
group is a highly strained group, making it more reactive than other ethers, 
and has been used as affinity probes for protein labelling (Chen et al. 2003). 
When an epoxide group is added to the A ring of CDDO-Me (yielding CDDO-
Epoxide, Table 3.1), nucleophilic attack opens the epoxide ring, forming a 
stable, irreversible adduct. 
 
Due to the complexity of the Keap1 protein structure, the vast number of 
cysteine residues, and the lack of evidence for CDDO-Me binding to protein 
thiols, we used recombinant glutathione-S-transferase pi (GSTP1) as a 
model protein to determine whether the TPs are capable of forming adducts 
with protein thiols. Of the four cysteine residues present in GSTP1, one of 
these (Cys-47) is highly reactive, and has previously been used to 
characterise site-specific protein modification by electrophilic compounds, 
including the reactive metabolite of paracetamol (NAPQI) (Jenkins et al. 
  Chapter 3 
- 98 - 
 
2008), DNCB (Caccuri et al. 1992), and NEM (Tamai et al. 1990), using LC-
MS/MS. We investigated the ability of TPs to bind to purified recombinant 
GSTP1 and Keap1 using LC-MS-MS techniques. This was further 
investigated by transfecting HEK293T cells with Keap1-V5 and treating with 
the TPs. Moreover, we use an in silico approach using homology modelling 
and the crystal structure of the Keap1 BTB domain recently published by 
Cleasby et al. (2014), to model the point of interaction between Keap1 
cysteine residues and TPs. We use these data to correlate their covalent and 
non-covalent interactions with Keap1 thiol groups with their potency towards 
the Nrf2 pathway. In this chapter we use chemically tuned TPs to test the 
hypothesis that CDDO-Me induces Nrf2 via the covalent modification of 
one or more cysteine residues in Keap1. 
Triterpenoid Mwt 
(Da) 
Thiol binding 
properties 
Chemical structure 
CDDO-Me 
C32H43NO4 
505.7 
 
 
 
Reversible 
 
 
 
 
 
 
 
 
 
CDDO-Epoxide 
C32H43NO5 
521.3 
 
 
 
Irreversible 
 
 
 
 
 
 
 
 
 
 
Table 3.1 Chemical structure and properties of the semi-synthetic TPs 
used in this study. 
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3.2  MATERIALS AND METHODS 
 
3.2.1. Materials and reagents 
 
Both pET-21a(+)/Keap1-transformed BL21 (DE3) and pET-15b(+)/GSTP1-
transformed BL21 (DE3) E.coli stocks were generated at the CDSS, 
University of Liverpool. All TPs were synthesised at the Department of 
Chemistry, University of Liverpoo,l by Michael Wong. H4IIE cells stably 
expressing the ARE8L-reporter transgene (originally generated by Dr. 
Joanne Walsh, CDSS, University of Liverpool) were provided by Prof. Alex 
Odermatt (Department of Pharmaceutical Sciences, University of Basel, 
Switzerland). All antibodies used were from Abcam (Cambridge, UK). GS-
800 calibrated imaging densitometer was from Bio-Rad (Hemel Hempsted, 
UK) and TotalLab 100 software was from Nonlinear Dynamics (Newcastle, 
UK). Power Broth was from Molecular Dimensions (Suffolk, UK).Bright-Glo 
luciferase assay system and Glo lysis buffer were from Promega 
(Southampton, UK). Sonication was performed in a Soni-prep 150 from MSE 
(London, UK). All other reagents were either described in Section 2.2.1, or of 
analytical or molecular grade and from Sigma-Aldrige (Poole, UK). 
 
3.2.2. Cell culture 
 
HEK293T cells were maintained as described in Section 2.2.2. Rat hepatoma 
H4IIE ARE-reporter cells were maintained in the same way but in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 584 mg/L L-glutamine, 
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10% heat inactivated fetal bovine serum (FBS), 5mL sterile filtered 100xnon-
essential amino acid solution and 1mM sterile filtered HEPES solution. The 
culture medium was antibiotic free. Cells were counted as in Section 2.2.2. 
 
3.2.3. H4IIE ARE-reporter cell luciferase assay 
 
To determine the ability of the TPs to activate the expression of ARE driven 
genes which are commonly activated by Nrf2, we obtained a cell line which 
contains an ARE-driven luciferase reporter gene. Luciferases are a class of 
oxidative enzymes found in several species that enable the host to 
bioluminesce in the presence of luciferin. The emission can be read using a 
luminometer and is directly correlated to the level of ARE activation (Fig 3.1). 
 
 
Figure 3.1.Schematic of ARE-reporter luciferase assay. Upon 
translocation to the nucleus, Nrf2 binds to the ARE in the promoter region of 
Nrf2 regulated genes. In this cell line, luciferase is under the control of an 
ARE promoter therefore luciferase protein is synthesised following Nrf2 
activation. On addition of luciferin, in the presence of oxygen (O2) and 
adenosine triphosphate (ATP), luciferase catalyses the formation of 
oxyluciferin, carbon dioxide (CO2), adenoside monophosphate (AMP), 
inorganic pyrophosphate (PPi) and light which can be quantified using a 
luminometer. 
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Cells were plated at 2.0x104 cells per well in 0.2 mL media onto a sterile 
Nunclon Δ flat bottom 96 well plate, and returned to the incubator overnight. 
The cells were then treated with the compound of interest at the stated 
concentrations, diluted in DMSO to a final volume of 0.5% (v/v). The cells 
were returned to the humidified incubator for 24 hours, before adding 0.1 mL 
1x Glo Lysis buffer to each well. The plate was shaken at 700 rpm for 5 min 
to provoke cell lysis. A proportion (80 µL) of lysate was transferred to a flat-
bottomed white 96-well microplate and 20 µL of Bright-Glo luciferase reagent 
was added. The plate was shaken at 700 rpm for 15 sec prior to 
quantification of luminescence on a Varioskan Flash Spectra Luminometer. 
 
3.2.4. Western blotting- whole cell lysates 
 
For the measurement of Nrf2 activation, H4IIE ARE-reporter cells were 
seeded into 12-well Nunclon Δ cell culture plates at 3.0 x105 cells/well and 
returned to the humidified incubator overnight. Cells were treated with 
increasing doses of the TPs dissolved in DMSO(final volume of 0.5 % (v/v)) 
for 1 or 24 hrs. Cells were washed twice with 1 mL PBS before lysis in 60 µL 
RIPA buffer. Protein content was measured as described in Section 2.2.7 
and western blotting for Nrf2 and Nqo1 was carried out as in Section 2.2.9. 
 
3.2.5. Quantification of glutathione levels 
 
H4IIE cells were treated with increasing concentrations of the compounds for 
up to 24hr before glutathione levels were quantified as in Section 2.2.8. 
  Chapter 3 
- 102 - 
 
3.2.6. Expression and purification of recombinant proteins 
 
LB broth or Power Broth (0.02 L), supplemented with 100 μg/mL ampicillin, 
was inoculated with 50 µL pET-21a(+)/GSTP1-transformed BL21 (DE3) or 
pET-21a(+)/Keap1-transformed BL21 (DE3) glycerol stock respectively and 
incubated at 37 °C, 220 rpm, overnight. The cultures were diluted to 1 L with 
the relevant broth containing 100 μg/mL ampicillin, and incubated at 37 °C, 
220 rpm. At 30 minute intervals, the optical density at 600 nm (OD600) was 
measured using a spectrophotometer, to ensure that the cultures were at the 
early-log phase of growth (OD600 ~0.4). Upon reaching this point in the 
growth phase, His-tagged protein expression was induced over 24 hr, at 
room temperature, 150 rpm, with 1 mM isopropyl-β-Dthiogalactopyranoside 
(IPTG). For Keap1-His only, the pH of the culture was adjusted to 7.5 with 
1M Tris base. Bacteria were then pelleted at 5000 g, for 5 min, and re-
suspended in 10 mL His buffer (0.5 M NaCl, 20 mM imidazole, 20mM 
Na2HPO4, pH 8.0). This was divided into equal aliquots in 50 mL tubes and 
disrupted by sonication (60 sec, followed by 30 sec recovery, x 3 repeats). 
Disrupted bacteria were divided into 1.5 mL aliquots and cell debris was 
pelleted at 18,000 g for 10 min. The supernatants were then pooled.and 
frozen at -80°C before being thawed and re-centrifuged at 18,000g for 
10minutes, and re-pooled. The resulting supernatant was incubated at a ratio 
of 1:1 lysate (GSTP1) or 10:1 lysate (Keap1) to dry volume HIS-Select nickel 
(Ni2+) -charged agarose beads at room temperature for 15 min. Beads were 
pelleted by centrifuging at 18,000 g for 1 min and were washed 3x in His 
buffer. 
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3.2.7. Determination of on-bead protein content 
 
The on-bead content of Keap1-His orGSTP1-His was assessed with a 
bicinchoninic acid (BCA) Protein Assay Kit, with a slight modification of the 
method of Stich (Stich 1990). The BCA assay is based on the reduction of 
Cu2+ to Cu+ by protein in an alkaline environment (the biuret reaction). Each 
Cu+ formed reacts with two molecules of BCA to form a purple chromophore 
that has an absorbance maximum at 562 nm (Smith et al. 1985). For the 
determination of protein immobilised on agarose beads, the BCA assay is 
preferred to a standard Bradford protein assay, as the blue chromophore that 
forms when Coomassie Brilliant Blue G-250 reacts with immobilised protein 
remains associated with the agarose beads, which settle at the bottom of the 
plate/tube. Thus, constant stirring of the sample is required to enable 
spectrophotometric determination of protein content. The purple 
chromophore formed via the reaction of BCA with immobilised protein is 
water-soluble, and thus does not remain associated with the agarose beads, 
enabling spectrophotometric determination of protein content, without the 
need for constant stirring of the sample. Keap1-His or GSTP1-His coupled 
Ni2+-charged agarose beads (50 μL dry volume) were washed five times with 
0.5 mL PBS. A standard curve ranging from 0.01-1 mg/mL BSA was 
prepared in separate tubes (25 μL each). 5 µL dry beads resuspended in 20 
µL of dH2Oor standards were combined with 0.2 mL BCA assay reagent and 
incubated in a 37 °C incubator for 30 min. Tubes were vortexed every 10 min 
during this incubation period. Following the incubation, the beads were 
pelleted by centrifugation at 18,000 g for 1 min, and 0.2 mL supernatant, or 
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standards were transferred to a clear 96-well plate, and the absorbance at 
570 nm was read on a MRX microplate reader. A blank reading (dH2O and 
BCA reagent) was subtracted from all sample/standard readings. A bead 
blank reading (uncoupled Ni2+-charged agarose beads and BCA reagent) 
was subtracted from the sample readings. For the calculation of molar ratios, 
the concentration of Keap1-His orGSTP1-His (μg/μL) was converted to 
molarity using the following equation: 
 
Protein concentration (μg/μL) x [1/protein molecular weight (Da)] = 
concentration 
 
3.2.8. Treatment of recombinant protein 
 
Following quantification of protein levels on the agarose beads, beads were 
incubated with a specified molar ratio of the indicated compound for the 
specified time points. Compounds were dissolved in DMSO to make a stock 
solution of 20 mM and from this; dilutions to the final concentration were 
made in PBS. Following all treatments, cells were pelleted by centrifugation 
at 18,000 g for 1 min and washed in 0.5 mL PBS x 2. For competition assays, 
the beads were not pelleted or washed in between the compound treatments. 
All Keap1-His samples were treated with 55 mM IAA, and the beads were 
washed in 0.5mL PBS x 3. 
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3.2.9. Preparation of recombinant protein for LC-ESI-MS/MS 
 
In preparation for LC-ESI-MS/MS, beads washed in 0.5 mL PBS x 2 were 
then washed in 0.5mL 25 mM ammonium bicarbonate x 2 and resuspended 
in 90 µL ammonium bicarbonate. A 400 µg/mL stock solution of sequence-
grade modified trypsin was diluted 1:10 with 25 mM ammonium bicarbonate 
and 10 µl was added to the bead slurry. Trypsin digestion of the sample was 
performed overnight at 37˚C. 
 
3.2.10. LC-ESI-MS-MS methods 
 
Samples were delivered into a Triple TOF 5600 mass spectrometer (AB 
Sciex) as described in Section 2.2.13. All adducts were confirmed by visual 
inspection of the MS/MS spectra. The presence of adducts was determined 
by the addition of the molecular weight of the compound to the expected 
molecular weight of the cysteine containing peptide. For CDDO-Me, this was 
an addition of 505.7 amu, for CDDO-Epoxide 521.3 amu, for Iodoacetamide 
(IAA), 184.9 amu (See Appendix 1, 2 and 3 for details). Modified peptides 
were quantified using PeakView software to extract parent ions of the 
appropriate peptide plus compound m/z (extracted ion count, XIC). The area 
under the curve of each XIC peak was used to assess the relative 
quantification of individual modified peptides across samples. This was 
normalised to the total ion count (TIC) for the first datum point for each set of 
samples. 
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3.2.11. Mouse Keap1-V5 plasmid purification 
 
Mouse Keap1-V5 was purified as described in Section 2.2.3.  
 
3.2.12. Transfection of cells with Keap1-V5 
 
HEK293T cells were transfected as described in Section 2.2.4. 
 
3.2.13. Cell treatment 
 
For mass spectrometry, Keap1-V5-expressing HEK293T cells were prepared 
as in Section 2.2.4 and 2.2.5. Cells were treated with CDDO-Epoxide 
dissolved in DMSO at 100µM for 1 hr. The final volume of DMSO in the cell 
culture medium was 0.5% (v/v). The cells were then returned to the 
humidified incubator (37 °C in 5 % CO2) for the indicated period of time. 
 
3.2.14. Immunopurification of Keap1-V5 
 
After treatment for the indicated period of time, cells were lysed and Keap1-
V5 was immunopurified as described in Section 2.2.6. Samples (20µl) were 
taken before and after immunopurification for immunoblot analysis to ensure 
sufficient Keap1-V5 expression and purification. 
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3.2.15. Preparation of Keap1-V5 for LC-ESI-MS/MS 
 
After incubation and washing, the Keap1-V5-bound anti-V5 agarose beads 
were prepared as described in Section 2.2.11. 
 
3.2.16. In silico modelling 
All in silico modelling was performed by Jaclyn Bibby, Department of 
Chemistry, University of Liverpool. The mouse Keap1 protein sequence was 
aligned against that of KLHL11 (PDB: 4AP2) (Canning et al. 2013) using 
ClustalW and was used, alongside crystal structures of the BTB (PDB: 4CXI) 
(Cleasby et al. 2014) and DGR (PDB: 2DYH) (Lo et al. 2006) domains of 
Keap1, to generate models using Modeller 9.11 (Sali and Blundell 1993). 
GOLD 5.2 (CCDC Software; Jones et al. (1997)) was used to dock each TP 
ligand within the pocket surrounding a given cysteine, with the binding site 
defined as 10 Å around the cysteine Cα. A generic algorithm with ChemPLP 
(Korb et al. 2009) as the fitness function was used to generate 50 binding 
modes per ligand. Default settings were retained for the “ligand flexibility”, 
“fitness and search options” and “GA settings”, however the “allow early 
termination” setting in the “fitness and search option” was turned off to retain 
all ligand conformations. Protons were added, and crystallographic water 
molecules were removed. For covalent docking to cysteines, the 
corresponding side chain was removed from the protein and the ligand 
modified to contain the side chain to allow flexibility. The site of covalent 
attachment was at the cysteine Cα. The best score, and mean score + SD 
were calculated from the 50 poses generated. Quantitative structure activity 
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relationship data for the induction of Nqo1 by a series of TPs was taken from 
Dinkova-Kostova et al. (2005). Pearson correlation coefficients were 
determined using GraphPad Prism 6.01 (GraphPad Software, USA). 
 
3.2.17. Data analysis 
 
Where appropriate, experiments were performed at least in duplicate, all 
replicates performed on separate occasions. Data are expressed as mean ± 
standard deviation of the mean (SD). A two-sided P value of ≤0.05 was 
considered to be statistically significant.  
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3.3. RESULTS 
 
3.3.1. Effect of chemically tuned TPs on the Nrf2 pathway in cells 
 
We hypothesised that the ability of CDDO-Me to reversibly bind thiol groups 
underlies the potency of this compound as an inducer of Nrf2. To investigate 
this, we synthesised a TP with the ability to bind thiol groups irreversibly 
(Table 3.1) and tested both TPs to determine their potency towards Nrf2. To 
measure Nrf2 activation, we used the rat hepatoma H4IIE-ARE reporter cell 
line, which expresses luciferase under control of the ARE and is therefore 
responsive to Nrf2 induction. The concentration at which the TPs caused a 
200% increase in reporter activity (EC200) show that the TPs are of similar 
potencies (EC200= 0.6 nM and 2.1 nM respectively) (Fig 3.2A). We 
confirmed this observation by western blot analysis for Nrf2 and Nqo1, an 
Nrf2-regulated gene, following treatment of H4IIE-ARE cells with the TPs 
(Fig. 3.2 B-D). This data confirms that the TPs induce Nrf2 in cells and this 
translates to an induction of Nqo1 protein expression. We measured GSH 
levels within the cell, as GSH depletion would indicate irreversible binding of 
the TP to GSH molecules, reducing its potency towards Nrf2. Following 
exposure of H4IIE-ARE cells to the TPs for 1 hr, no substantial effect on GSH 
was seen (Fig 3.2E). We also show that dimethyl fumarate (DMF), an 
irreversible thiol modifier, and sulforaphane (Sul), a purported reversible thiol 
modifier cause GSH depletion, under the same conditions. The data 
presented suggests that the ability of these compounds to bind thiol groups 
reversibly does not have significant bearing on its ability to activate Nrf2. 
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Figure 3.2.Effect of TPs on Nrf2 cell defence pathway in cells.H4IIE-ARE 
reporter cells were treated with CDDO-Me or CDDO-Epox for 24 hr before 
being lysed and luminescence measured (A). Western blot analysis for Nrf2 
and Nqo1 was carried out after 1 hr or 24 hr treatment respectively (B) and 
band density quantified using TotalLab (C,D). Glutathione levels measured 
following 1 hr CDDO-Me, CDDO-Epoxide, dimethyl fumarate (DMF) or 
sulforaphane (SUL) exposure. All data representative of 3 biological repeats. 
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3.3.2 LC-ESI-MS/MS validation of recombinant protein 
 
In order to examine the ability for TPs to form covalent adducts with protein 
thiols, we exposed purified recombinant GSTP1 and Keap1 to novel TPs, 
before subjecting the protein to LC-MS/MS analysis. Sufficient (>70%) 
protein coverage is required in order to detect adducts between protein 
peptides and compounds. Following expression and purification, the 
recombinant protein was subjected to trypsin digestion and LC-MS/MS 
analysis. These data were subjected to a ProteinPilot search to identify all 
proteins in the sample. Sequence coverage was found to be sufficient for 
both proteins and would enable the detection of adducts (Table 3.2). 
 
 
 
 
 
Table 3.2. Sequence coverage of recombinant His tagged GSTP1 and 
Keap1 following LC-ESI-MS/MS, as determined by a ProteinPilot search. 
 
3.3.3 LC-ESI-MS/MS evidence for TP modification of GSTP1-His 
 
It was then investigated whether the TPs bind the highly reactive cysteine 
residue of the model protein GSTP1. The purified recombinant protein was 
incubated with 10 – 100- fold excess of CDDO-Me or CDDO-Epoxide for 1-
24 hr (see Figure 3.3A for an overview of the procedure undertaken). We 
observed that both TPs were able to covalently modify Cys-47 of GSTP1 (Fig 
3.4). To our knowledge, this is the first direct evidence that CDDO-Me can 
form a covalent adduct with a protein thiol. 
Protein Coverage (%) 
hGSTP1-His 98.4 
mKeap1-His 86.4 
  Chapter 3 
- 112 - 
 
 
 
 
Figure 3.3. Schematic of the procedure to identify covalently modified 
cysteine residues. (A) E.coli containing vectors coding for recombinant His-
tagged human GSTP1 or mouse Keap1 were cultured. Proteins were 
expressed using IPTG, and purified with Ni2+-charged agarose beads before 
treatment with the TPs at the specified molar excess for up to 24 hr. (B) 
HEK293T transfected with V5-tagged mouse Keap1 were treated with 100 
µM CDDO-Epoxide for 1 hr before Keap1-V5 was purified with anti-V5 
agarose beads. Proteins were then subjected to trypsin digestion and 
prepared for tandem mass spectrometry (LS-ESI-MS/MS). Peptides 
containing the addition of the molecular weight of the TP were identified. 
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Figure 3.4. Mass spectrometry spectra showing GSTP1 cysteine-47 
modified by (A) CDDO-Me and (B) CDDO-Epoxide. PurifiedGSTP1-His 
was exposed to 10 -100- fold molar excess of each compound, dissolved in 
DMSO and diluted in PBS (pH 8.4), at 37°C for 24 hr. LC-MS/MS was 
performed and mass spectra were analysed manually for cysteine containing 
peptides with an additional mass equivalent to the relevant compound. 
Representative spectra from three biological repeats. 
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3.3.4 LC-ESI-MS/MS evidence for TP modification of Keap1-His 
 
Having detected modification of GSTP1 by both TPs, the procedure was 
repeated with recombinant Keap1-His (see Fig 3.3A for an overview). After 
exposure to the TPs, the protein was treated with 55 mM IAA for 15 min to 
alkylate all remaining cysteines and improve their detection rate, including 
those not modified by the TP (Table 3.3). Following incubation with a 100:1 
molar excess of the TP, modification of Keap1-His cysteine residues by 
CDDO-Epoxide was observed on the following residues:  
Cys-257, -273, -288, -434, -489 and -613 (Fig 3.5). 
 
There was no evidence for modification of Keap1 by CDDO-Me. All cysteine 
residues were sensitive to adduction by IAA following CDDO-Epoxide, except 
Cys-257 and -273 (Table 3.3) which is likely to be due to the presence of a 
CDDO-Epoxide adduct on these residues, preventing IAA binding. No 
adducts between IAA and Cys-622 and -624 were seen (Table 3.3) which, as 
described in Section 2.3.5, are close to the V5 tag and often not cleaved 
during the trypsin digest, therefore not identified by LC-MS/MS. 
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Keap1-His Peptide 
Cys 
Residue 
IAA Mod 
CPEGAGDAVMYASTECK 23, 38 2 
LSQQLCDVTLQVK 77 4 
CVLHVMNGAVMYQIDSVVR 151 4 
ACSDFLVQQLDPSNAIGIANFAEQIGCTELHQR 171, 196 4 
QEEFFNLSHCQLATLISR 226 4 
CESEVFHACIDWVK 241, 249 1 
YDCPQR 257 0 
CHALTPR 273 0 
CEILQADAR 288 4 
CK 297 3 
DYLVQIFQELTLHKPTQAVPCR 319 4 
SGLAGCVVGGLLYAVGGR 368 4 
NNSPDGNTDSSALDCYNPMTNQWSPCASMSVPR 395, 406 4 
IGVGVIDGHIYAVGGSHGCIHHSSVER 434 4 
LNSAECYYPER 489 4 
SGAGVCVLHNCIYAAGGYDGQDQLNSVER 513, 518 4 
IYVLGGYDGHTFLDSVECYDPDSDTWSEVTR 583 4 
SGVGVAVTMEPCR 613 4 
QIDQQNCTC 622, 624 0 
 
Table 3.3.Recombinant Keap1-V5 cysteines modified by IAA in vitro. 
 Purified Keap1-His was exposed to 100:1 molar ratio of CDDO-Epoxide for 
24 hr at 37°C followed by 55 mM IAA for 15 min. LC-ESI-MS/MS analysis 
was performed following trypsin digestion, and ProteinPilot searches 
identified cysteine containing peptides with an additional mass equivalent to 
IAA over 4 biological repeats. Average sequence coverage= 94.6%. 
  Chapter 3 
- 116 - 
 
 
 
 
Figure 3.5.Mass spectra showing Keap1 cysteine residues modified by 
CDDO-Epoxide.(A Cys-257; B Cys-273; C Cys-288). Purified Keap1-His was 
exposed to 100:1 molar ratio of CDDO-Epoxide for 24 hrs at 37°C. LC-ESI-
MS/MS analysis was performed following trypsin digestion, and ProteinPilot 
searches identified cysteine containing peptides with an additional mass 
equivalent to the compound (521). Showing one representative spectra from 
four biological repeats. 
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Figure 3.5 continued. Mass spectra showing Keap1 cysteine residues 
modified by CDDO-Epoxide.(D Cys-434; E Cys-489; F Cys-613). Purified 
Keap1-His was exposed to 100:1 molar ratio of CDDO-Epoxide for 24 hrs at 
37°C. LC-ESI-MS/MS analysis was performed following trypsin digestion, 
and ProteinPilot searches identified cysteine containing peptides with an 
additional mass equivalent to the compound (521). Showing one 
representative spectra from four biological repeats. 
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Following the treatment of Keap1-His with increasing molar excesses of 
CDDO-Epoxide, Cys-257 was found to be most readily modified (Fig 3.6). 
However, this requires further investigation, as it may be a function of the 
relative ability of the Cys-257-containing peptide to be ionized, lending itself 
better to MS detection compared to other peptides. Of the cysteine-
containing peptides in Keap1 we observed to be modified by CDDO-Epoxide, 
all show a concentration-dependent increase in modification (Fig 3.6). At 
higher molar ratios of CDDO-Epoxide (200:1), the presence of non-tryptic 
peptides in the MS data suggests protein degradation is occurring, and may 
explain why modification levels were found to decrease.  
 
 
 
 
 
Figure 3.6. Concentration-dependent changes in Keap1-His cysteine 
modification by CDDO-Epoxide. Keap1-His was treated with increasing 
molar ratios of CDDO-Epoxide for 24 hrs, at pH 8.4, 37°C. Following trypsin 
digestion, LC-ESI-MS/MS analysis was performed, and the level of 
modification of each cysteine-containing peptide was compared. Showing the 
average level of cysteine modification of 3 biological repeats. 
 
C D D O -E p o x id e  M o la r  R a tio
C
D
D
O
-E
p
o
x
id
e
 M
o
d
if
ic
a
ti
o
n
(N
o
rm
a
li
s
e
d
 I
o
n
 C
o
u
n
t)
0
.0
1
0
.1 1 1
0
1
0
0
1
0
0
0
0
2 .01 0 5
4 .01 0 5
6 .01 0 5
8 .01 0 5
2 .01 0 6
4 .01 0 6
6 .01 0 6
8 .01 0 6
1 .01 0 7
2 8 8
4 8 9
6 1 3
4 3 4
2 5 7
2 7 3
  Chapter 3 
- 119 - 
 
3.3.5 Investigating the ability of CDDO-Me to compete with CDDO-
Epoxide to covalently modify protein thiols 
 
In light of our inability to detect modification of Keap1 cysteine residues by 
CDDO-Me, we examined the ability of CDDO-Me to competitively inhibit the 
modification of Keap1 by CDDO-Epoxide. A reduced ability of CDDO-
Epoxide to bind a cysteine residue following pre-treatment with CDDO-Me 
would indicate that both TPs are capable of forming adducts with the same 
cysteine residues in Keap1. We focussed analyses on the modification of 
Cys-257, as this is the residue most readily modified by CDDO-Epoxide, 
particularly at low molar ratios (1:1) of drug:protein. Keap1-His was pre-
treated with CDDO-Me at increasing molar ratios for 1 hr followed by the 
addition of CDDO-Epoxide, at a 1:1 molar ratio for a further 24 hrs. We 
observed significant variation of Cys-257 modification by CDDO-Epoxide 
between biological repeats (Fig. 3.7). This pattern of variable modification 
was also seen on the other cysteine residues modified by CDDO-Epoxide 
(data not shown). This inherent variability within the assay made it difficult to 
conclude whether CDDO-Me is able to compete with CDDO-Epoxide to bind 
to Keap1, from this data.  
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Figure 3.7.Variation in CDDO-Me competing with CDDO-Epoxide to bind 
to Keap1.Keap1-His was exposed to increasing molar ratios of CDDO-Me for 
1 hr, followed by a single molar ratio of CDDO-Epoxide (1:1) for a further 24 
hr, and LC-ESI-MS/MS analysis was performed following trypsin digestion. 
Showing the level of CDDO-Epoxide modification of Cys-257 following 
normalisation to the TIC, and shown relative to vehicle control (i.e. no CDDO-
Me followed by 1:1 CDDO-Epoxide) for 3 biological repeats. 
 
We further examined the variation by simultaneously preparing four Keap1-
His samples treated with a 1:1 molar ratio of CDDO-Epoxide. All recombinant 
protein was purified from the same bacterial lysate, and treated under 
identical conditions. We observed substantial variation between the levels of 
modification of the cysteine residues adducted by CDDO-Epoxide (Fig. 3.8 A-
D). This variation is unlikely to be due to discrepancies in the volume / 
amount of peptides loaded or the MS process as the TIC (total ion count; the 
sum of intensities of all MS peaks belonging to the same scan, including 
background noise) of each sample is consistent (Table 3.4). The source of 
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the variability is likely to be the multi-step process of sample preparation, 
whereby each step can introduce variability. 
 
Table 3.4. Total ion count (TIC) of four Keap1 samples treated with 
CDDO-Epoxide. Conditions: 1:1 molar ratio, 24 hr, followed by 55 mM Iodo 
for 15 min, made simultaneously and prepared for LC-MS/MS by trypsin 
digestion 
. 
. 
Figure 3.8.Variation in CDDO-Epoxide modification of 
Keap1.Recombinant Keap1-His was exposed to a 1:1 molar ratio of CDDO-
Epoxide for 24 hr followed by 55 mM IAA for 15 min, before trypsin digestion 
and LC-MS/MS analysis was performed on four biological repeats prepared 
simultaneously.  
Repeat 1 2 3 4 
TIC 1.22x1010 8.27x109 1.21x1010 1.16x1010 
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Due to the variation seen in the modification levels of Keap1 cysteine 
residues by CDDO-Epoxide, the experiment was repeated withGSTP1. We 
focussed on the reactive cysteine residue (Cys-47), on which we had 
previously detected modification by both CDDO-Me and CDDO-Epoxide. 
GSTP1 was pre-treated with CDDO-Me at increasing molar ratios for 1 hr, 
followed by treatment with CDDO-Epoxide at a single molar ratio (1:1) for 24 
hr. The data show that there is a loss of CDDO-Epoxide binding to GSTP1 
Cys-47 with increasing molar ratios of CDDO-Me (Fig 3.9), indicating that 
both compounds can bind to the same cysteine residue within a protein and 
can compete with each other to do so.  
 
 
 
 
 
 
 
 
 
 
Figure 3.9. CDDO-Me competes with CDDO-Epoxide to bind to GSTP1 
Cys-47. Purified recombinant GSTP1 was pre-treated with increasing molar 
ratios of CDDO-Me, followed by a single molar ratio of CDDO-Epoxide (1:1), 
prior to trypsin digestion and LC-MS/MS analysis. Showing CDDO-Epoxide 
modified cysteine normalised to TIC and as a percentage of vehicle control 
(i.e. no CDDO-Me, 1:1 CDDO-Epoxide). Average of 3 biological repeats.  
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3.3.6 CDDO-Epoxide forms covalent adducts with Keap1-V5 in cells 
 
Following the detection of adducts between CDDO-Epoxide and six cysteine 
residues in recombinant Keap1in vitro, we hypothesised that these adducts 
would also be formed in a cell based model. Using methods outlined in 
Section 2.2, HEK293T cells were transfected with Keap1-V5 before being 
treated with 100µM CDDO-Epoxide for 1 hr (see Figure 3.3B for an overview 
of the procedure undertaken). Following immunopurification of Keap1-V5 
using anti-V5 agarose beads, the protein was treated with 55 mM IAA for 15 
min to cap all remaining cysteines, and improve our ability to detect the 
cysteine containing peptides, including those not modified by the compound 
(Table 3.5). LC-ESI-MS/MS analysis revealed that CDDO-Epoxide modified 
the following cysteine residues in Keap1-V5: Cys-257, -273, -288 and -489 
(Fig 3.10, Table 3.6), in agreement with those detected in the experiments 
with recombinant protein (Fig 3.11). Only Cys-434 and Cys-613 were found 
to be modified by CDDO-Epoxide in recombinant Keap1 in vitro but not in the 
cell based model. Both of these residues were found to be modified by IAA 
(Table 3.4), therefore we conclude that they were successfully detected in 
the MS analysis, yet, at least in this cell based model, these residues were 
not modified by CDDO-Epoxide. 
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Keap1-V5 Peptide 
Cys 
Residue 
IAA Mod 
CPEGAGDAVMYASTECK 23, 38 4 
LSQQLCDVTLQVK 77 4 
CVLHVMNGAVMYQIDSVVR 151 4 
ACSDFLVQQLDPSNAIGIANFAEQIGCTELHQR 171, 196 4 
QEEFFNLSHCQLATLISR 226 4 
CESEVFHACIDWVK 241, 249 4 
YDCPQR 257 1 
CHALTPR 272 0 
CEILQADAR 288 4 
CK 297 4 
DYLVQIFQELTLHKPTQAVPCR 319 4 
SGLAGCVVGGLLYAVGGR 368 4 
NNSPDGNTDSSALDCYNPMTNQWSPCASMSVPR 395, 406 4 
IGVGVIDGHIYAVGGSHGCIHHSSVER 434 4 
LNSAECYYPER 489 4 
SGAGVCVLHNCIYAAGGYDGQDQLNSVER 513, 518 4 
IYVLGGYDGHTFLDSVECYDPDSDTWSEVTR 583 4 
SGVGVAVTMEPCR 613 4 
QIDQQNCTC 622, 624 0 
 
Table 3.5.Keap1-V5 cysteines modified by IAA in cells.HEK293T cells 
expressing Keap1-V5 were treated with 100 µM CDDO-Epoxide (1 hr), lysed 
and Keap1-V5 was immunopurified. Cysteines were capped with 55 mM IAA 
before trypsin digestion and LC-MS/MS analysis. ProteinPilot identified the 
indicated peptides as modified by IAA over four biological repeats. Average 
sequence coverage =93.5 % 
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Figure 3.10.Mass spectra showing Keap1-V5 cysteine containing 
peptides modified by CDDO-Epoxide in cells. (A Cys-256; B Cys-273; C 
Cys-288; D Cys-489) HEK293T cells transfected with Keap1-V5 were treated 
with 100 µM CDDO-Epoxide for 1 hr. Keap1-V5 was immunopurified, 
residues were capped with 55 mM IAA before undergoing trypsin digestion 
and LC-ESI-MS/MS analysis. 
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Table 3.6.Keap1-V5 cysteine residues modified by CDDO-Epoxide in 
cells. 
 
 
 
 
 
 
Figure. 3.11. Correlation between CDDO-Epoxide modification of 
recombinant Keap1 and Keap1-V5 expressed in cells. Recombinant 
Keap1 was exposed to 100:1 molar ratio of CDDO-Epoxide for 24 hr or 
HEK293T cells expressing Keap1-V5 were treated with 100 µM CDDO-
Epoxide for 1 hr before Keap1 immunopurification, trypsin digestion and LC-
MS/MS analysis. Number in circle represents the number of times this 
residues was identified as modified in 4 biological repeats. 
  
Keap1-V5 Peptide Cys Residue 
Number of times 
CDDO-Epox mod 
seen (4 repeats) 
YDCPQR 257 4 
CHALPTR 273 1 
CEILQADAR 288 2 
LNSAECYYPER 489 3 
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3.3.7 Molecular modelling of CDDO-Epoxide modification of Keap1 
 
To further examine the nature of the chemical interaction between CDDO-
Epoxide and Keap1, we used an in silico approach to model the points of 
interaction. Using previously reported crystal structures of Keap1 domains 
including the BTB (PDB: 4CXI) (Cleasby et al. 2014) and the DGR (PDB: 
2DYH) (Lo et al. 2006) domains, along with homology modelling based on 
the crystal structure of the BACK domain of KLHL11 (PDB: 4AP2) (Canning 
et al. 2013), a member of the Kelch family of proteins, we modelled the most 
likely docking pose or orientation in which CDDO-Epoxide would bind 
covalently to the Keap1 cysteine residues found to be modified by MS. Using 
GOLD 5.2, CDDO-Epoxide was docked within the pocket surrounding a 
given Keap1 cysteine residue. ChemPLP was used to generate 50 binding 
modes (poses) per ligand. The poses are grouped into those which are most 
similar, and we show the pose most representative of the largest group for 
the cysteine residues in Keap1 identified as modified by CDDO-Epoxide (Fig. 
3.12). Interestingly, Cys-257 and Cys-288 form a binding pocket in which 
CDDO-Epoxide can sit (Fig 3.12A,C) In this model we show, in accordance 
with previously published data (McMahon et al. 2010), these cysteine 
residues are located adjacent to basic amino acids (Fig 3.11), which are 
known to reduce the pKa of cysteine thiols, enhancing their reactivity towards 
electrophilic compounds (Snyder et al. 1981).
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Figure 3.12. Molecular modelling of CDDO-Epoxide bound to Keap1 
cysteine residues identified in this study. The depicted poses are 
representative of the largest group of poses from 50 pose simulations using 
ChemPLP. Cysteine residues and neighbouring basic amino acids are shown 
in bold type. The cysteine residue of interest in each panel is highlighted in 
magenta. CDDO-Epoxide is shown in light blue, Keap1 structure in green. 
Red moieties represent oxygen, blue nitrogen and yellow sulphur. 
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3.3.8 Correlation of TP potency towards Nqo1 activity and Keap1 
covalent binding score 
 
To investigate the importance of the ability of TPs to covalently bind to Keap1 
cysteine residues Keap1, we used data for the potency of TPs as inducers of 
Nqo1 activity published by Dinkova-Kostova et al. (2005). Modifications to the 
A or C ring are thought to alter the potency of the TP by affecting the ability to 
interact with thiol groups whilst modification of the side chain between the D 
and E ring are thought to affect cellular permeability. From the original 
published data set, we took 14 compounds (Appendix 4), removing those that 
contained large side chains at the D/E ring. These structures were covalently 
docked into the models detailed in Section 3.3.7, and ChemPLP was used to 
generate and score 50 binding modes per ligand. The scores are generated 
based on a number of factors including covalent, lipophilic, hydrogen bond, 
clash and torsion components. These scores were correlated with log10 of the 
CD value for each TP, where CD is the concentration required to double the 
activity of Nqo1. We show no correlation between the covalent binding of the 
TP via the A ring and the potency of these compounds towards Nqo1 activity 
(Fig 3.13). We show this for the six cysteine residues we have seen modified 
by CDDO-Epoxide in this study. We also show this for three Keap1 cysteine 
residues chosen at random, one from each functional domain of Keap1 (Cys-
77, -196 and -583), as well as Cys-151 which has previously been suggested 
to be the key molecular target of TPs such as CDDO-Me (Cleasby et al. 
2014, Eggler et al. 2009) (Fig 3.14). We also observed no correlation 
between the covalent binding of the TP via the C ring of the TPs and the 
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potency towards Nqo1 activity, for the same cysteine residues (data not 
shown). 
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Figure. 3.13. Correlation between TP in silico covalent binding score 
and potency as inducers of Nqo1 activity. Showing log10 scale of 
concentration at which Nqo1 activity is doubled (CD) by each TP. Average 
covalent binding score shown from 50 randomly generated poses for each 
TP, binding each cysteine residue identified as modified by CDDO-Epoxide in 
MS studies, via the A ring. Pearsons r and p values calculated using 
Pearsons coefficient. Negative Pearsons r value indicates positive 
correlation. 
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Figure. 3.14. Correlation between TP in silico covalent binding score 
and potency as inducers of Nqo1 activity. Showing log10 scale of 
concentration at which Nqo1 activity is doubled (CD) by each TP. Average 
covalent binding score shown from 50 randomly generated poses, for each 
TP binding 4 cysteine residues within Keap1 functional domains, via the A 
ring. Pearsons r and p values calculated using Pearsons coefficient. Negative 
Pearsons r value indicates positive correlation. 
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3.3.9 Correlation of TP potency towards Nqo1 activity and Keap1 non-
covalent binding score 
 
As no correlation was observed between the ability of these compounds to 
covalently modify Keap1 cysteine residues and their potency towards Nrf2, 
we hypothesised that the ability of these compounds to bind Keap1 non-
covalently within cysteine containing pockets may be important. We used the 
same approach as detailed in Section 3.3.8, and docked the structures 
outlined in Appendix 4 non-covalently into the models detailed in Section 
3.3.7. The score generated in this case differs from the covalent binding 
score, as the covalent binding component is removed, and in this docking 
mode, the ligand is allowed to bind anywhere within a docking sphere (i.e. 
the cysteine containing pocket), whilst the covalent dockings are limited by 
the restraint of covalently binding to a specific residue. We show a significant 
correlation between potency towards Nqo1 activity and the average non-
covalent docking score for Cys-273 (p < 0.05) and Cys-288 (p ≤ 0.001) (Fig 
3.15). There was no significant correlation observed with the additional 
Keap1 cysteine residues identified as modified by CDDO-Epoxide (Cys-257, 
-434, -489, -613) (Fig 3.15), nor with those chosen from Keap1 functional 
domains (Cys-77, -151, -196 and -583) (Fig 3.16). This in silico data support 
the hypothesis that TPs mechanism of action may be the modification 
(covalent or non-covalent) of the pockets containing Cys-273 and Cys-288 in 
Keap1, which have previously been shown to be essential for Keap1s ability 
to repress Nrf2 (Zhang and Hannink 2003, Yamamoto et al. 2008, McMahon 
et al. 2010).  
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Figure. 3.15. Correlation between TP in silico free binding score and 
potency as inducers of Nqo1 activity. Showing log10 scale of concentration 
at which Nqo1 activity is doubled (CD) by each TP. Average score shown 
from 50 randomly generated poses for each TP at each cysteine residue 
identified as modified by CDDO-Epoxide in MS studies. Pearsons r and p 
values calculated using Pearsons coefficient. Negative Pearsons r value 
indicates positive correlation (* P ≤ 0.05, *** P ≤ 0.005). 
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Figure. 3.16. Correlation between TP in silico free binding score and 
potency as inducers of Nqo1 activity. Showing log10 scale of concentration 
at which Nqo1 activity is doubled (CD) by each TP. Average score shown 
from 50 randomly generated poses, for each TP at 4 cysteines within Keap1 
functional domains. Pearsons r and p values calculated using Pearsons 
coefficient. Negative Pearsons r value indicates positive correlation (* P < 
0.05, *** P < 0.005). 
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3.4 DISCUSSION 
 
With a growing interest in Nrf2 as a potential therapeutic target, it is important 
to further our understanding of the molecular mechanism of action of the 
compounds which manipulate its activity, in order to predict or design out 
toxicity. TPs have potential as therapeutic agents due to their many health 
benefits (Dzubak et al. 2006) and large therapeutic index in vitro (Copple et 
al. 2014), however little is known about their mechanism of action with 
regards to Nrf2 activation. Clinical trials using CDDO-Me (Bardoxolone 
methyl; BM) for the treatment of solid tumours or lymphoid malignancies 
showed promising results. This led to further clinical trials (the BEAM trial), 
for the treatment of patients suffering from mid-stage chronic kidney disease 
(CKD) and type 2 diabetes (Pergola et al. 2011a, Pergola et al. 2011b). The 
subsequent Phase 3 trial in patients with end-stage CKD (the BEACON trial) 
was halted due to “severe adverse events and mortality”, namely 
cardiovascular events, in patients receiving the drug(de Zeeuw et al. 2013, 
Chin et al. 2014). There had been no prior indication of severe adverse 
events (Pergola et al. 2011b, Pergola et al. 2011a). The cardiovascular 
events are purported to be due to the pharmacological modulation of the 
endothelin pathway, promoting sodium and volume retention, thus increasing 
blood pressure in patients with late-stage CKD (Chin et al. 2014), who are 
known to be pre-disposed to cardiovascular disease (Locatelli et al. 2003). 
Whilst Nrf2 has been shown to protect against kidney pathologies in animal 
models (Shelton et al. 2013), a role for Nrf2 in the increased estimated 
glomerular filtration rate (eGFR) observed in CKD patients receiving BM is 
not known. It is for these reasons it is important to gain a greater 
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understanding of the chemico-biological triggers for Nrf2 activation by TPs, to 
determine whether these play a role in toxicity. 
 
To determine whether TP-mediated Nrf2 induction occurs due to the covalent 
modification of Keap1 cysteine residues, we synthesised a novel TP (CDDO-
Epoxide), capable of irreversible thiol modification, as a chemical tool to 
characterise protein modification using LC-MS/MS. We hypothesised that the 
ability of CDDO-Me to bind thiol groups reversibly contributes to its potency 
towards Nrf2. However, as CDDO-Epoxide is of similar potency as CDDO-
Me, we conclude that reversible thiol modification does not fully explain its 
potency. As neither TP causes GSH depletion, we conclude that the 
compounds are likely to be thiol selective. The Nrf2 inducing compounds, 
DEM, an irreversible thiol modifier (Kobayashi et al. 2009, Castillo et al. 
2002), and sulforaphane, a purported reversible thiol modifier (Dinkova-
Kostova et al. 2002) both deplete GSH and are less potent inducers of Nrf2 
than the TPs (Copple et al. 2014), further supporting that reversibility does 
not affect potency. We conclude that the TPs may be more potent towards 
Nrf2 than other inducers due to increased specificity for Keap1 thiol groups. 
 
We observed that both TPs form adducts with the reactive Cys-47, in 
recombinant GSTP1in vitro. Moreover, we detected the modification of a 
subset of cysteine residues by CDDO-Epoxide on recombinant Keap1 protein 
(Cys-257, -273, -288, -434, -489 and -613) and in cells (Cys-257, -273, -288 
and -489). This is the first direct observation of adducts formed between a 
TPand the full length Keap1 protein. In Section 2.3.10, we observed a 
reversible thiol modification on Cys-434 of Keap1-V5 following treatment of 
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cells with CDDO-Me, and show here that CDDO-Epoxide is able to form 
adducts with this residue, therefore it is possible that this adduct explains the 
data in Section 2.3.10. We hypothesise, based on the ability of CDDO-Me to 
compete with CDDO-Epoxide to bind GSTP1, that both TPs will bind to the 
same cysteine residues, or will fit in to the same cysteine containing pockets 
within Keap1. Performing competition assays between the TPs on Keap1 
proved unsuccessful due to variation in the quantification of CDDO-Epoxide 
adducts. This variation is likely to be an artefact of the multi-step process 
used to prepare samples for MS analysis. Often, modifications are at the 
lower limit of detection of the MS, thereby reducing our ability to quantify 
levels of modification with confidence. Furthermore, the presence of highly 
abundant peptides in the MS at the same time may overwhelm the less 
abundant proteins, affecting our ability to detect them. Multiple reaction 
monitoring (MRM) could reduce this issue and is discussed in Chapter 5. 
 
Our data are consistent with work carried out by Dinkova-Kostova et al. 
(2005)who shows that TPs compete with radiolabelled dex-mes to bind to 
Keap1 in vitro which, as seen in Section 2.3.7, covalently binds Keap1 at 
Cys-226, -257, -288, -434, -613 and potentially Cys-489. Additionally, Ahn et 
al. (2010)show that TPs compete with a click-tagged analogue of SF in cells, 
which binds to Keap1 at Cys-273, -288 and -613. This data, in conjunction 
with the findings reported here, indicate the importance of Cys-273 and -288. 
These residues are important for the ability of Keap1 to repress Nrf2 
(Kobayashi et al. 2004, Yamamoto et al. 2008). Whilst we show no 
modification of Cys-151 by TPs, there is evidence for a role of this residue in 
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the de-repression of Nrf2 by Keap1 (Yamamoto et al. 2008), and conflicting 
data regarding the role of this residue in relation to TP-mediated Nrf2 
induction. Eggler et al. (2009) show that the mutation of Cys-151 diminishes 
Nrf2 induction by the TP CDDO-Im in cells. On the other hand, experiments 
using embryonic fibroblasts derived from Cys-151 mutant mice have shown 
that the Nrf2 response to CDDO-Im is not diminished (Takaya et al. 2012). 
 
The MS data shown here are supported by our in silico molecular modelling 
approach. We show no correlation between potency towards Nqo1 activity 
and the ability of a panel of TPs to covalently bind Keap1 cysteine residues, 
in our model. Conversely, we show that the potency of the TPs towards Nqo1 
activity correlates with their ability to interact non-covalently with the pockets 
surrounding Cys-273 and -288. It is possible that whilst the other cysteine 
residues are covalently modified by TPs, they are not functionally relevant 
regarding Nrf2 induction, as Cys-273 and Cys-288 are. Indeed, there are no 
reports on the functional effect of mutating Cys-434, however neighbouring 
residues Ser-431 and Asn-414 form a hydrogen bond, stabilising Arg-415 
allowing it to interact with residues located within the ETGE and DLG motifs 
of the Neh2 domain of Nrf2 (Padmanabhan et al. 2006). Therefore, it is 
possible that the modification of this residue could provoke a conformational 
change which may disrupt the Keap1/Nrf2 interaction. 
 
The in silico data supports observations that Cys-151 of Keap1 is unlikely to 
be important in the TP mechanism of action. The recent publication which 
provided the crystal structure of the Keap1 BTB domain showed that CDDO 
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was able to bind to Cys-151 of human Keap1 (Cleasby et al. 2014). The 
protein domain used in this study contains Keap1 residues 48-180, with only 
3 cysteine residues. Thus one could argue that, due to the reactivity of Cys-
151 towards electrophiles, and its low pKa value, an interaction between 
CDDO and this residue is likely under the conditions used, however may not 
be reproducible with the full Keap1 protein. It is important to note that 
homology modelling was used, thus the location and organisation 
surrounding these residues in the homology model may not mirror that of the 
endogenous protein. Furthermore, in this study, the TP and Keap1 are 
modelled using rigid-docking which will not take into account whether there is 
a conformational change in the protein that may affect further interactions. 
 
The investigation of whether Cys-151 of Keap1 is important for the ability of 
TPs to activate Nrf2 could be tackled by using a competition assay similar to 
that used in Section 3.3.5. Efforts should be made to identify a compound 
which forms an adduct with Cys-151, to a sufficient level that the loss of 
modification could be confidently quantified using MS. Initial attempts in our 
lab using monomethyl fumarate (MMF) (Linker et al. 2011) and DEM 
(Kobayashi et al. 2009) have not been successful (data not shown). To 
confirm the involvement of the residues indicated in this study, mutagenesis 
studies would quantify the ability of TPs to induce Nrf2 in cells expressing 
Keap1 mutants. Unfortunately, the mutation of residues Cys-273 and -288 
causes a marked increase in Nrf2 levels under basal conditions (Yamamoto 
et al. 2008, McMahon et al. 2010, Zhang and Hannink 2003), thus detecting 
further activation of Nrf2 by TPs would be difficult.  
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Whilst the detection of adducts between Keap1 and TPs does not 
categorically confirm that the modification of Keap1 cysteines by these 
compounds is responsible for Nrf2 activation, there is sufficient evidence in 
the literature to suggest that this is a likely mechanism. The in silico model 
detailed here highlights that non-covalent modification of Keap1 by TPs may 
be important. Using the knowledge that increased TP potency towards Nrf2 
correlates with increased safety (Copple et al. 2014), by screening 
compounds using this model there is a potential for identifying novel 
inducers. which may be more efficacious and less toxic, and structurally 
dissimilar enough to CDDO-Me to circumvent the effects on the endothelin 
pathways, thought to be responsible for the cardiovascular events in the BM 
trial in patients with CKD (Chin et al. 2014). This is currently ongoing in our 
lab. The data shown here do not explain why BM was toxic in clinical trials, 
and investigating the effect of these compounds of other pathways will be 
important. The publication of the molecular structure of the BTB region of 
Keap1 (Cleasby et al. 2014) will help determine the importance of covalent 
and non-covalent modification of Keap1 as a mechanism of Nrf2 induction. 
Complementing the existing crystal structures of the BTB and Kelch domains 
of Keap1 with those of the IVR domain and/or full length Keap1, will facilitate 
virtual screening of compound libraries to identify novel Nrf2 inducers with 
potential as drug candidates.
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4.1 INTRODUCTION 
 
Keap1 directs the ubiquitination and subsequent proteasomal degradation of 
Nrf2, and is therefore a main regulator of Nrf2 activity (Bryan et al. 2013). 
The Keap1/Nrf2 complex has been shown to associate with proteins/protein 
complexes, in addition to the Cul3 ubiquitination system (Kobayashi et al. 
2004, Hast et al. 2013). Interactions between Nrf2 and other proteins affect 
the localisation of Nrf2 (Theodore et al. 2008), its DNA binding (Itoh et al. 
1997), and the transcription of Nrf2 target genes (Katoh et al. 2001). 
Additionally, Keap1 has been shown to associate with a number of other 
proteins (Zhang et al. 2004, Kang et al. 2004, Furukawa and Xiong 2005, 
Karapetian et al. 2005, Lo and Hannink 2006, Kim et al. 2010). Functionally, 
protein interactions with Keap1 may impact its ability to regulate the activity 
of Nrf2, by affecting the sub-cellular location and stabilisation of the protein. 
The localisation of Keap1 is vital for its ability to sense chemical/oxidative 
stress and to sequester Nrf2 outside of the nucleus, and some of its known 
protein-protein interactions reflect this. For example, by binding to the actin 
cytoskeleton, Keap1 is located in the cytosol, in proximity to reactive 
metabolite by-products of drug metabolism (Kang et al. 2004). By binding to 
PGAM5, Keap1 is located in proximity to the mitochondria, where 
considerable quantities of ROS are produced (Lo and Hannink 2008). 
Additionally, other cytoplasmic proteins which bind to Keap1 can compete 
with Nrf2, including prothymosin α (Karapetian et al. 2005) and fetal Alz-50 
clone 1 (FAC1) (Strachan et al. 2004), resulting in reduced Nrf2 degradation. 
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Due to the variety of diseases in which the dysregulation of Nrf2 activity has 
been shown, therapeutic strategies are evolving which aim to manipulate 
Nrf2 activity levels, by altering the association between Keap1 and Nrf2, or 
between Keap1 and the ubiquitination machinery. This can be achieved 
through the use of small molecular inhibitors, thus avoiding the requirement 
for pharmacological intervention with (potentially toxic) electrophiles (Zhuang 
et al. 2014, Magesh et al. 2012). Small peptides that competitively target the 
point of contact between Keap1 and Nrf2, or Keap1 and Cul3, have recently 
been shown to cause activation of Nrf2 signalling (Magesh et al. 2012). 
Based on these observations, the discovery of novel Keap1/Nrf2 binding 
partners, which play a role in the regulation of the Nrf2 pathway, may provide 
an alternative therapeutic route to exploit, as they can compete with Nrf2 to 
bind to Keap1. 
 
In 2010, a novel physical and functional interaction between Keap1 and 
sequestosome1 (p62) was identified in our lab (Copple et al. 2010), and by 
others (Jain et al. 2010, Fan et al. 2010, Komatsu et al. 2010). It was 
observed that p62 binds Keap1 via an ETGE-like motif (Komatsu et al. 2010). 
In our lab, the identification of novel Keap1 binding partners was facilitated by 
MS techniques employed to characterise the proteins co-purified with Keap1-
V5 ectopically expressed in HEK293T cells (Copple et al. 2010). Since our 
identification of p62 as a Keap1 binding partner, we have obtained a 
substantially more sensitive MS system, which may facilitate the identification 
of novel Keap1 binding partners that were below the limit of detection of our 
previous assay. In Chapter 2 of this thesis, HEK293T cells were transfected 
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with Keap1-V5 prior to treatment with Nrf2-inducing compounds (or vehicle 
controls), followed by exposure to NEM for 5 min to alkylate remaining 
cysteine residues, to facilitate MS analysis. The aim of this work was to 
examine chemical and oxidative modifications on the cysteines of 
immunopurified Keap1-V5, provoked by different Nrf2 inducers. Incidentally, 
the output from these analyses included a comprehensive list of proteins in 
the samples which were co-purified with Keap1. Here, this data has been 
analysed to identify proteins which are putative Keap1 binding partners, by 
comparison to a data set obtained following mock transfection of the cells. 
Additionally, the occurrence of changes in the Keap1 complex, following the 
treatment of cells with the Nrf2-inducing compounds used in Chapter 2, has 
been investigated. These analyses have been informed by the observation 
that many Keap1 binding partners have a conserved ETGE-like motif (Fig 
1.10), which has been shown to be essential for the ability of numerous 
Keap1 binding partners to interact with Keap1 (Hast et al. 2013). This 
allowed us to concentrate the analyses on proteins with ETGE-like motifs 
which are predicted to directly bind to Keap1. In order to validate Keap1 
interacting partners, yeast two-hybrid (Y2H) has been used (see Figure 4.1 
for an overview of the methods used in this study). Therefore, the aim of the 
work described in this chapter is to use our previously generated MS 
data sets to identify novel Keap1 binding partners which may play a 
role in the regulation of the Nrf2 cell defence pathway. These may, in 
turn, provide an alternative avenue to manipulate the activity of the Nrf2 
pathway for therapeutic benefit. 
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Figure 4.1. Flow diagram of the methods used in this study. HEK293T 
cells were transfected with Keap1-V5, or mock transfected. Using anti-V5 
agarose beads, Keap1-V5 was purified following lysis. Proteins were 
subjected to trypsin digestion and LC-ESI-MS/MS. A list of protein co-purified 
with Keap1-V5 was generated using ProteinPilot. Of those identified which 
contained ETGE-like motifs, network and pathways analysis was performed. 
Validation of protein interactions was performed using yeast two-hybrid.  
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4.2  MATERIALS AND METHODS 
 
4.2.1 Materials and reagents 
 
The KOD HotStart DNA Polymerase kit was obtained from Novagen, 
(Hertfordshire, UK). The Biotaq DNA Polymerase, agarose and HyperLadder 
1kb was obtained from Bioline (London, UK). All primers, SybrSafe were from 
Life Technologies (Paisley, UK). The 10x TBE buffer (Tris/borate/EDTA) and 
tryptone, were from Fisher Scientific (Loughborough, UK). The glucose, 
peptone and yeast extract were from ForMedium (Norfolk, UK), and the 
Bio/Agar was from Biogene (Cambridgeshire, UK). All antibodies were 
obtained from Abcam (unless stated otherwise in Section 2.2.1). All PCR was 
performed on a Tetrad PTC-225 Thermo Cycler system from MJ Research 
(Quebec, Canada), and agarose gels visualised on a Gene Genium Bio-
Imaging System from Syngene (Cambridge, UK). All plasmids used were a 
kind gift from Amy Ponsford, University of Liverpool. All other reagents were 
either described in Section 2.2.1, 3.2.1, or of analytical or molecular grade 
and from Sigma-Aldridge (Poole, UK). 
 
4.2.2 Cell culture 
 
Cells were cultured as described in Section 2.2.2.  
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4.2.3 Mouse Keap1-V5 plasmid purification 
 
The mouse Keap1-V5-encoding plasmid was cultured as in Section 2.2.3 
 
4.2.4 Transfection of cells with Keap1-V5 
 
Cells were transfected as described in Section 2.2.4. Control cells were 
transfected in the same manner, with equal volumes of 1x TE buffer 
replacing the Keap1-V5 plasmid. 
 
4.2.5 Immunopurification of Keap1-V5 
 
Keap1-V5 was immunopurified as described in Section 2.2.6. 
 
4.2.6 Preparation of Keap1-V5 for LC-ESI-MS/MS 
 
Keap1-V5 was prepared for LC-ESI-MS/MS as described in Section 2.2.11 
 
4.2.7 LC-ESI-MS/MS methods 
 
LC-ESI-MS/MS was performed as described in Section 2.2.13 
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4.2.8 Western immunoblotting of immunopurified Keap1-V5 
 
Proteins bound to immunopurified Keap1-V5 were identified by western 
immunoblotting as described in Section 2.2.10. 
 
4.2.9 Network analysis 
 
Network analysis was performed using QIAGEN Ingenuity Pathway Analysis 
(IPA, QIAGEN Redwood City, www.qiagen.com/ingenuity. A spreadsheet 
containing the UniProt details of all proteins outlined in appendix 5, as well as 
Keap1 and Nrf2, was uploaded to the program, and network and pathway 
analysis were performed. Network analysis was performed in the same 
manner for the comparison of the Keap1-V5 complex following the treatment 
of cells with various Nrf2 inducers.  
 
4.2.10 Amplification of PCR product from pDONR DNA plasmid 
 
Sequence verified cDNA clones in pDONR plasmids containing the protein 
encoding sequence of a selection of potential Keap1 binding partners were a 
kind gift from Jonathan Woodsmith, (Max-Planck Institute for Molecular 
Genetics, Berlin, Germany), and were used as templates for Hot-Start KOD 
Polymerase amplification. Primers were designed against the appropriate 
pDONR plasmid as follows:  
pDONR221 Forward:  
5’ GAATTCACAAGTTTGTACAAAAAAGCAGGCTCCACCATG 3’ 
pDONR221 Reverse: 
5’ GTCGACCACTTTGTACAAGAAAGCTGGG 3’ 
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pDONR223 Forward: 
5’ GAATTCACAAGTTTGTACAAAAAAGCTGGCATG 3’ 
pDONR223 Reverse: 
5’ GTCGACCACTTTGTACAAGAAAGCTGGG 3’. 
PCR reactions contained 10 ng of pDONR DNA plasmid, 0.5 µM forward and 
reverse primers, 2.5 µL of 10x KOD buffer, 0.2 mM dNTPs, 15 mM MgSO4, 
0.5 µL Hot-Start KOD enzyme and made up to a final volume of 25 µl with 
dH2O. Conditions for Hot-Start KOD PCR can be found in Table 4.1. 
Step Cycles Temperature/Time Process 
1 1 95°C for 2 min Pre-denaturing 
2 
29 
95 °C for 30 sec Denaturing 
3 60 °C for 60 sec Annealing 
4 70°C for 30 sec/kb Extension 
5 1 4°C to finish Hold 
Table 4.1. Steps and cycles for Hot-Start KOD Polymerase amplification 
of sequence verified cDNA clones 
4.2.11 DNA electrophoresis 
 
The PCR products were resolved on a 1% agarose gel dissolved in 0.5 x 
Tris/borate/EDTA (TBE) buffer, supplemented with a 1:20,000 dilution of 
SYBR Safe DNA Gel Stain, at 120 V for approximately 30 minutes. The PCR 
product (5 µl) was combined with 2 µl of 5 % Orange G (5 % sucrose, 0.005 
% Orange G) prior to loading onto the gel. PCR samples were resolved 
alongside a Hyperladder DNAmarker to enable estimation of DNA band 
sizes. Bands were visualised using a UV Transillumination system (Syngene 
Bioimaging system).  
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4.2.12 GAP repair of PCR product 
 
If a DNA band of the correct size was obtained (Fig 4.2A), the PCR product 
was used for Gap Repair reactions. The yeast transformation/gap repair was 
performed using the lithium acetate method as previously described by Ito et 
al. (1983). Briefly, 2 mL YPAD broth (10 g/L yeast extract, 100 µg/L adenine 
hemisulphate, 20 g/L peptone and 20 g/L D-glucose) was inoculated with 
PJ69-4A (MatA) yeast and incubated for 18 hr at 30 °C shaking at 220 rpm. 
Following this, a further 8 mL of YPAD broth was added and incubated for an 
additional 5 hr at 30 °C, 220 rpm. The culture was then centrifuged at 2,300 
rpm for 5 min at room temperature and the supernatant discarded. The pellet 
was resuspended in 5 mL 100 mM lithium acetate (LiOAC), 1.5 mL was 
transferred to 1.5 mL eppendorf tube and centrifuged at 2,300rpm for 5 min. 
The supernatant was discarded and to each pellet, the following was added: 
230 µL 50% (w/v) PEG 3350, 35 µL 1M LiOAC, 9 µL of 10.5 mg/mL heat 
denatured (5 min at 95°C) salmon testes DNA, 45 µL dH2O and 30 ng of 
BamHI linearised bait destination vector (pGBAE-B). Of this solution, 34 µL 
was transferred to individual 0.5 mL tubes and 4 µL of the PCR product 
obtained in Section 4.2.10 was added. The samples were heat shocked in 
the following steps: 30°C for 30 min, 42°C for 25 min, 30°C for 1 min. The 
yeast transformation reaction was then plated onto selective drop-out media 
(supplemented with low adenine (ADE) to enable identification of 
successfully transformed yeast) and incubated at 30°C for 3-5 days (Fig. 
4.2B). 
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Figure 4.2.Flow diagram of the experimental procedure undertaken for 
Yeast 2-Hybrid.Constructs in pDONR vectors were amplified using KOD 
PCR and confirmed by observing PCR bands on an agarose gel. PCR 
products were inserted into a pGBAE-B vector (A) and MatA yeast cells were 
transformed (B). Yeast were left to grow for 3-5 days before 3-6 red colonies 
were picked and clones were checked for the correct MW insert by yeast 
colony PCR (YCPCR) and confirmed by observing PCR bands on an 
agarose gel (C). Clones were checked for auto-activation status prior to the 
generation of glycerol stocks by growing on –WA media and –WH(AT) 
media. Growth on either of these plates indicated the auto-activation of the 
Ade2 or the His3 reporter genes, respectively (D). Auto-activating clones 
were not used in the subsequent yeast 2-hybrid screen. 
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Successful bait transformants can be identified by the growth of red colonies 
on this selective drop-out media. The pGBAE-B bait vector contains both the 
DNA binding domain (BD) and the activation domain (AD) of the Gal4 
transcription factor, separated by an in-frame linker sequence. This vector 
has been previously modified to introduce a stop codon at the 3’ end of gene 
inserts following gap repair, to prevent transcription of the activation domain, 
thus removing the need for stop codons at the 3’ end of the open reading 
frame (ORF) (Semple et al. 2005). Therefore, when the PCR product 
containing compatible gap repair flanking sequences is recombined in the 
correct reading frame into the pGBAE-B vector, the yeast cell itself cannot 
transcribe the Ade2 reporter gene, and grows red on media containing low 
adenine. Un-linearised vector will produce both the AD and BD in a single in-
frame fusion and will therefore be able to activate transcription of the Ade2 
gene to produce adenine, and will grow white on the same media. Colonies 
unable to transcribe the Ade2 reporter gene grow red due to the 
accumulation of P-ribosylamino imidazole (AIR) which is generated during 
the synthesis of adenine. In the presence of Ade2, the adenine biosynthetic 
pathway can continue, however in its absence, the next step of the pathway 
is inhibited. When AIR accumulates in yeast which grow aerobically, it is 
oxidised to a red pigment. 
 
4.2.13 Diagnostic yeast colony PCR (YCPCR) 
 
The aforementioned cloning method is directional; therefore inserts should 
always be introduced with the correct orientation and reading frame. 
However, to ensure the insert size is as expected, primers flanking the 
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recombination sites can be used to amplify the insert. The primers used are 
as follows: 
Forward:5’CCGGAATTCACAAGTTTGTAC3’ 
Reverse: 5’ CGTTAGAGGAGGCAATTGGTTG3’ 
A toothpick was used to take a sample from 3-6 red colonies from each plate 
into 3 µL 20mM sodium hydroxide (NaOH), and left to lyse for 20 min at room 
temperature. To each of the yeast NaOH suspensions, 12 µL of the following 
master mix for Taq DNA PCR was added (amounts indicated are sufficient 
for 10 reactions): 0.7 µM forward and reverse primers, 0.625 mM dNTPs, 15 
µL of 10x NH4 buffer, 7.5 µL of 2.25 mM MgCl2, 3 µL DMSO, 73.5 µM dH2O 
and 1.5 µL Taq polymerase. Conditions for Taq DNA PCR can be found in 
Table 4.2. PCR products were resolved on a 1% agarose gel, as described in 
Section 4.2.11 (Fig 4.3 C). 
Step Cycles Temperature/Time Process 
1 1 95°C for 5 min Pre-denaturing 
2 
39 
95°C for 1 min Denaturing 
3 55-68 for 1 min Annealing 
4 72°C for 3 min 30 secs Extension 
5 1 72°C for 5 min Final extension 
6 1 15°C to finish Hold 
Table 4.2. Steps and cycles for Taq DNA polymerase yeast colony PCR
  
4.2.14 Determination of auto-activating clones 
 
To avoid false positives, such as clones capable of activating reporter genes 
in haploid form (i.e. in the presence of only the BD of the Gal4 transcription 
factor), all clones were tested to assess their potential to self-activate either 
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higher (ADE) or lower (His + 3-AT) stringency Y2H reporter genes. Of the red 
colonies picked with the correct insert size (Fig 4.2C), the remainder of the 
colony on the plate was picked into 20 µL dH2O. Of this, 3 µL was pipetted 
onto selective drop-out media plates for bait (MatA) yeast as described in 
Table 4.3, and plates incubated at 30°C for 7-14 days (Fig. 4.2 D).If colonies 
grew on auto-activation plates (-WA, -WH(AT)), they were not continued. 
Causes of auto-activation may include: spontaneous host mutations allowing 
yeast to grow on selective media in the absence of bait/prey interactions; bait 
proteins with inherent transcriptional activity or that interact with other factors 
with transcriptional activity, or prey proteins that bind DNA may non-
specifically drive transcription of yeast reporter genes. 
 
Of colonies showing no auto-activation, colonies were selected from the –W 
plate using a toothpick and resuspended in 200 µL –W media, before the 
addition of 80 µL 80 % glycerol and storage at -80 °C. 3 µL of each was 
spotted onto –W plates to grow for 3-5 days at 30 °C.  
Plate Constituents Purpose 
-WA 
No tryptophan  
No adenine 
High stringency 
Yeast without Ade reporter gene 
activation should not grow 
-WH(AT) 
No tryptophan 
No histidine 
With 2.5mM 3-Amino-
1,2,4-triazole (3AT) 
Low stringency 
3-AT makes it more difficult for yeast 
to survive by competing to binding 
the His3 promoter 
Yeast without His reporter activation 
should not grow 
-W 
No tryptophan Positive control for the growth of the 
yeast. All yeast grow in the absence 
of tryptophan due to the Trp1 gene 
Table 4.3.Table describing media for determining auto-activation. 
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4.2.15 Yeast 2-Hybrid (Y2H) matrix style mating 
 
Matrix style Y2H assays test for binary interaction between a pre-defined set 
of proteins (bait or prey) in a high throughput manner. TheY2H system 
exploits the properties of the Gal4 transcription factor which activates the 
transcription of an array of reporter genes within the yeast genome (Fields 
and Song 1989). The protein is comprised of two domains- a DNA binding 
domain (BD) and a transcriptional activation domain (AD). The BD binds to 
Gal4 specific sequences within the yeast DNA promoter regions whilst the 
AD recruits and activates RNA polymerase which in turn, activates 
transcription. The system is used to look at protein-protein interactions by 
dividing the two domains of the protein and fusing them each to proteins of 
interest. Conventionally, the BD region is fused to the N-terminus of a protein 
of interest (bait) whilst the AD domain is fused to the N-terminus of a second 
protein (prey). If the two fused proteins interact, this will bring together the 
two domains of the Gal4 transcription factor which can, in turn activate 
transcription of the reporter gene (Figure 4.3). The reporter genes used in 
this study are ADE2 and HIS3, which are under the control of different Gal4-
induced promoters, Gal2p and Gal1p, respectively. The yeast used in this 
study will therefore only grow on low adenine or low histidine selective media 
if these reporter genes are activated, i.e. in the presence of a protein-protein 
interaction, bringing together the DB and the AD of Gal4. 
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Figure 4.3.Schematic of the classical Y2H system.(A) The two domains of 
the Gal4 transcription factor; the DNA binding domain (BD), and the 
transcriptional activation domain (AD). Gal4 activates the transcription of a 
reporter gene. (B) In the Y2H system, Gal4 is fragmented. The DB domain is 
fused to a protein of interest and the AD domain to a potential binding 
partner. If the two proteins interact, the DB and AD domains are brought 
together and drive transcription of a downstream reporter gene (prey 1). If 
they do not interact, no reporter activation is seen (prey 2) 
 
 
Using a toothpick, a small amount of prey colony was picked from an SD-L 
plate (Matα yeast) and resuspended in 6 µL of sterile water. Of this, 3 µL was 
spotted onto a YPAD plate and allowed to dry. The same method was used 
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to pick bait colonies from an SD-W plate (MatA yeast) and 3 µL spotted on 
top of the prey (Fig 4.4 A). They preys screened were a gift from Amy 
Ponsford (University of Liverpool, UK) and include Keap1, and the known 
Keap1 binding partners Nrf2 and p62, as the protein co-purified with Keap1-
V5 may not bind Keap1 directly, but via an interaction with other Keap1 
binding partners. Once dry, the plates were incubated at 30 °C for 24 hr. 
Once grown, a replication block was used with a sterile velvet overlay. The 
YPAD plate was inverted onto the velvet and gentle, even pressure was 
applied using the fingertips. The YPAD plate was removed and replaced with 
two diploid selection plates (SD-WL). Gentle pressure was applied to the 
plate to transfer the colonies from the velvet and the plate was then 
incubated at 30 °C for 2 days (Fig 4.4 B). Incubation on this media allows the 
bait and prey yeast to mate, and selects for only those that have mated (i.e. 
diploid). The process was then repeated, transferring the colonies from one 
SD-WL plate into an SD-WLA plate and an SD-WHL(AT) plate and these 
were incubated at 30 °C for up to 14 days. The growth of yeast colonies on 
the plates indicates the activation of the reporter genes ADE2 and HIS3 
respectively, which are under the control of the Gal4-induced promoters 
Gal2p and Gal1p respectively. Growth was recorded by photographing plates 
(Fig 4.4 C) 
 
4.2.16 β-Galactosidase enzymatic assay 
The β-galactosidase (β-gal) enzymatic assay was used as a third reporter 
gene assay to increase stringency. Briefly, X-Gal (5-bromo-4-chloro-3-indolyl-
beta-D-galactopyranoside) is an inert chromogenic substrate for β-
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galactosidase, an enzyme that promotes lactose utilisation. β-gal hydrolyses 
X-Gal into a colourless galactose and 4-chloro-3-brom-indigo, which forms an 
intense blue precipitate. Induction of the lacZ gene in yeast by the Gal4 
transcription factor (i.e. by a protein-protein interaction) leads to the 
production of the β-galactosidase enzyme, and thus hydrolysis of X-Gal and 
the development of blue colonies (Fig 4.4 C). 
 
X-gal was reconstituted in DMF to 100 mg/mL and stored away from direct 
light at 2 °C. The β-gal reagent was made from 6 mL sterile Z buffer (60 mM 
Na2HPO4, 40 mM NaH2PO4, 10mM KCl, 1mM MgSO4), 100 µL of 100 mg/mL 
X-gal, and 11 µL β-Mercaptoethanol. Filter paper was cut to cover the 
colonies, laid over yeast and rubbed until the yeast was transferred onto the 
paper. The paper was peeled off at an angle to leave maximum yeast 
attached. This filter paper was submerged in liquid nitrogen for 10 sec to lyse 
the cells, and then allowed to thaw for 30 sec. This was repeated. Two 
circular pieces of filter paper were covered with the β-Gal reagent ensuring 
no air bubbles are present beneath either the two filters, or the bottom filter 
and the plastic base of the plate. The thawed filter paper with the yeast on 
was placed face up onto the filter paper, and sealed. The plate was 
incubated at 37°C for 6 hr, checking frequently to record colour change, and 
then left at 4 °C overnight to allow further development of the blue pigment. 
Colour change was recorded by photographic filter paper (Fig 4.4 C). 
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Figure 4.4. Flow diagram of the experimental procedure used for 
determining binary protein interactions. The prey yeast (Matα) was 
pipetted on to the YPAD media and allowed to dry, before the bait yeast 
(MatA) was pipetted on top, and incubated at 30 °C for 24 hr. A replicate 
plate was created for diploid selection and grown for 48 hr at 30 °C. The 
yeast were then replicated for reporter gene assays onto Ade or His growth 
media (SD-WLA or SD-WLH)AT) respectively, and grown at 30 °C for 14 
days. Yeast were also transferred onto filter paper for the β-Gal assay and 
grown for 6 hr at 37 °C. 
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4.3  RESULTS 
4.3.1 Validation of LC-MS/MS assay 
To identify novel Keap1 binding partners, HEK293T cells were transfected 
with Keap1-V5, or mock transfected. As the end-point of the original 
experimental set up used in this study was to identify modifications of Keap1-
V5 provoked by Nrf2 inducing compounds (see Chapter 2), cells were treated 
with NEM (2 mM for 5 min) prior to lysis and LC-ESI/MS/MS analysis, to cap 
the cysteine residues in Keap1 and enhance their detection. Following lysis, 
Keap1-V5 was purified using anti-V5 agarose beads before trypsin digestion 
and LC-ESI/MS/MS analysis. A ProteinPilot search was used to identify 
proteins co-purified with Keap1-V5 from HEK293T cells, or co-purified 
following mock transfection of the cells. To validate these data, western 
blotting was performed for known Keap1-binding proteins, following their 
elution from the anti-V5 agarose beads. Of the known Keap1- interacting 
partners chosen for this analysis, none were purified from the mock 
transfected cells (Table 4.4).  
Protein Average number of peptides Reference(s) 
Keap1-V5 Mock 
Keap1 109.3 0  
p62 3.2 0 
Copple et al. 
(2010) 
Fan et al. (2010), 
Komatsu et al. 
(2010) 
IKKβ 2.6 0 
Kim et al. (2010), 
Lee et al. (2009) 
DPP3 4.2 0 Hast et al. (2013) 
Table 4.4.Proteins chosen for validation of MS data. The average number 
of peptides detected across six biological repeats is shown, and references 
confirming their interaction with Keap1. 
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In a validation of the experimental approach, both Keap1-V5 and its known 
binding partner p62 were enriched on anti-V5 agarose beads following 
immunopurification of Keap1-V5 from cell lysates (Fig 4.5A, B). Additionally, 
IKKβ has previously been shown to bind to Keap1 and therefore provides a 
link between the Nrf2 and NF-κB pathways (Kim et al. 2010, Lee et al. 2009). 
IKKβ was shown to be highly enriched on the anti-V5 agarose beads 
following Keap1-V5 transfection, compared to mock transfection (Fig.4.5C). 
DPP3 is a recently described Keap1 binding partner (Hast et al. 2013) that 
was also identified in our MS data set. Western blot analysis confirmed that 
this protein is considerably enriched following anti-V5 immunopurification 
from Keap1-V5 transfected cells, compared to mock transfected cells (Fig 
4.5D). Overall, the LC-MS/MS analysis identified a number of known Keap1 
binding partners which we have successfully validated by western blotting, 
confirming the robustness of our experimental approach. It is worth noting 
that following immunopurification of Keap1-V5 from cells, there is a 
considerable loss of Keap1 and p62 from the cell lysate (compare input (IN) 
with flow through (FT) following Keap1-V5 transfection, Fig 4.5A,B), due to 
their presence on the agarose beads. This is not the case for IKKβ and DPP3 
(Fig 4.5C,D), indicating that the interaction is not as substantial between 
these proteins and Keap1 as it is between Keap1 and p62. 
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Figure 4.5.Western blot validation of Keap1 binding proteins identified 
by mass spectrometry.HEK293T cells transfected with Keap1-V5, or mock 
transfected were lysed and Keap1-V5 was immunopurified. Samples taken 
before immunopurification (IN; input), after immunopurification (FT; flow 
through) and proteins co-purified with agarose beads eluted from the beads 
(IP) were separated by SDS-PAGE. Western blotting was performed for a 
selection of known Keap1 binding partners. Representative images shown 
from two biological repeats. 
 
4.3.2 LC-MS/MS analysis of putative Keap1-V5 binding partners 
Using a Protein Pilot search, we were able to identify 1,449 proteins co-
purified with Keap1-V5 from HEK293T cells treated with the vehicle dH2O, 
which were present in at least one of six biological repeats. Proteins such as 
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keratins which are likely to be skin derived proteins introduced during sample 
preparation, were removed. The list of putative Keap1-binding proteins was 
further refined by excluding proteins identified in <2 of six biological repeats 
and by comparing the number of peptides identified for a given protein in the 
Keap1-V5 transfected samples with the number identified in the mock 
transfected control (Fig 4.6). Proteins present in the mock transfected control 
are likely to bind to the anti-V5 agarose beads non-specifically, as opposed 
to Keap1-V5. For some proteins, however, more peptides were present in 
Keap1-V5 transfected samples compared to mock transfected controls. 
These proteins were retained in the data set if the ratio of peptides in Keap1-
V5 transfected samples to mock transfected controls was ≥ 1.5 (Fig 4.6).  
 
 
 
Figure 4.6. Flow diagram highlighting the number of proteins retained 
for further analysis of potential Keap1-interacting partners.(Following co-
purification with Keap1-V5 from HEK293T cells.) 
 
1,449 
• All proteins co-purified with Keap1-V5 from HEK293T cells 
treated with dH2O present in one out of six biological repeats 
1,438 
• Exclusion of keratins as are likely to be skin-derived and 
introduced during sample preparation 
1,160 
• Exclusion of proteins identified in less than two out of six 
biological repeats    
1,054 
• Exclusion of proteins present in mock control if the averge 
number of peptides for an individual protein was ≤ 1.5 
Number of proteins Exclusion criteria 
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4.3.3 Identification of proteins with Keap1 binding motif 
 
Due to the vast number (1,054) of proteins co-purified with Keap1-V5 and 
identified by MS, and despite our exclusion of likely false positives, it is likely 
that a proportion of the remaining proteins are present in the data set due to 
an interaction with other Keap1-binding partners. Notwithstanding the fact 
that such proteins may have important roles in regulating the function of 
Keap1, we focussed subsequent investigations on proteins that were more 
likely to be direct binding partners of Keap1. During the course of this 
investigation, Hast et al. (2013) published a Keap1 interactome using a 
similar methodology to our own, involving the transfection of HEK293T cells 
with Keap1-FLAG followed by affinity purification and LC-MS/MS analysis. 
Comparison of our data set (1,054 proteins) with that of Hast et al. (2013) 
revealed a considerable (34 %) overlap in the proteins identified (Fig 4.7A). 
Moreover, Hast et al. (2013) showed that the ETGE-like motif containing 
proteins that were identified and validated in their study required the ETGE-
like motif to bind to Keap1. Furthermore, proteins containing ETGE-like 
motifs can compete with Nrf2 to bind to Keap1, resulting in up-regulation of 
Nrf2 signalling (Camp et al. 2012, Ma et al. 2012, Hast et al. 2013). 
Therefore, for the analysis of our data set, we focused our attention on 
proteins which contained an ETGE-like Keap1 binding motif 
(ETGE/ESGE/STGE). 44 proteins containing at least one of such motifs were 
commonly identified in our data set and that of Hast et al. (2013) (Fig 4.7B), 
and 11 solely in our analysis, and further analysis was focussed on these 
proteins (see appendix 5 for full list).  
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Figure 4.7. Venn diagram comparing our data with that of Hast et al. 
2013 Comparison of total number of proteins identified in both data sets (A) 
and those identified containing an ETGE-like motif (ETGE/ESGE/STGE) (B). 
UniProt IDs were converted to DAVID gene IDs in order to facilitate 
comparison to the data set output of a search for proteins containing an 
ETGE/ESGE/STGE motif (http://www.genome.jp/tools/motif/). UniProt IDs 
taken directly from supplementary material from Hast et al. (2013). 
 
To identify proteins with ETGE-like motifs, the UniProt IDs from our data set 
and the data set of Hast et al. (2013), and the gene ID output from the 
programme used to identify proteins with ETGE-like motifs 
(http://www.genome.jp/tools/motif/) were converted to DAVID gene IDs using 
DAVID Bioinformatics Resources 6.7 (Huang da et al. 2009b, Huang da et al. 
2009a). Therefore, discrepancies between the total numbers of proteins in 
either data set are due to inconsistencies in the conversion of gene ID 
values. 
 
4.3.4 Network and pathway analysis 
 
Having identified 55 proteins containing Keap1 binding motifs in our data set, 
44 of which were also identified following Keap1-FLAG IP from HEK293T 
cells byHast et al. (2013), we subjected these proteins to network and 
pathway analysis using Ingenuity (see appendix 5 for details of proteins used 
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in this analysis). Nrf2, which was not identified in the MS dataset was also 
added to the list of proteins used in these analyses, as it is a well-known 
Keap1 binding partner, and relevant to the focus of this thesis. Additionally, 
Keap1 was included in these analyses, as it is the focal point of this study. 
Network and pathway analysis were performed to determine whether any of 
the 55 putative Keap1 binding partners have previously been shown to 
interact with Keap1, either directly or indirectly, and to identify their cellular 
functions.  
 
The network analysis software identifies known interactions between proteins 
in the inputted data set to create a small network, and adds in molecules 
from a database to specifically connect two or more small networks. The 
functions shown (Table 4.5) are the top 3 functions associated with the 
proteins in the network. The top 3 represented networks (in order of their 
significance) are shown in Table 4.5. The score given to the network is based 
on a Fishers Exact Test p-value calculation which calculates the likelihood 
that molecules that are part of a network are found there by chance. 
 
The 55 inputted proteins were found to be significantly associated with 
networks related to the cell cycle, DNA replication and repair, cell death and 
cell survival (Table 4.5). Network 1 does not contain Keap1, or Nrf2, but does 
contain PGAM5, a known Keap1 binding partner (Fig 4.8). Therefore, despite 
containing ETGE-like binding motifs, it is possible that some of the proteins 
selected for network and pathway analysis may have been co-purified with a 
Keap1 binding partner, such as PGAM5, and therefore not be a direct binding 
partner of Keap1. Further work will be needed to address this issue. 
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Alternatively, the proteins identified in this network could be novel Keap1-
binding partners with previously unknown links to established Keap1-
interacting partners. Network 2 contains Keap1, Nrf2 (NFE2L2) and p62 
(SQSTM1) and a number of proteins co-purified with Keap1 in this study that 
have not previously been linked to Keap1 (Fig 4.9). Network 3 does not 
appear to contain any known Keap1 binding proteins (Fig 4.10). The focus of 
this network is p53, a tumour suppressor protein involved in apoptosis and 
cell survival, the mutation of which has been associated with numerous 
cancers (Muller and Vousden 2014). Identifying a direct interaction between 
Keap1 and a protein within this network would unequivocally link the Nrf2 cell 
defence pathway and the p53-mediated cell survival pathway.  
Network Functions Focus 
molecules 
Score 
1 
Cell cycle 
DNA replication, recombination 
and repair 
Cell death and survival 
18 35 
2 
Cell death and survival 
(Cancer, Respiratory disease) 
13 23 
3 
Cell cycle 
Cell growth and proliferation 
Connective tissue 
development and function 
13 23 
Table 4.5.Network analysis of putative Keap1 interacting proteins 
containing ETGE-like Keap1 binding motif. Proteins co-purified with 
Keap1-V5 from HEK293T cells expressing Keap1-V5 containing ETGE-like 
motifs, plus Nrf2 and Keap1, were subjected to Ingenuity network analysis. 
Showing the three most represented networks in order of significance. Focus 
molecules is the number of proteins from the inputted data set (55 in total) in 
that network, the score is generated using a right-tailed Fishers Exact Test p-
value calculation, which calculates the likelihood that that inputted proteins 
that are part of a network are found there by chance (the higher the score, 
the more significant the network representation). 
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Figure 4.8. Network 1 identified through Ingenuity network analysis of 
putative Keap1 interacting partners. Of the proteins co-purified with 
Keap1-V5 from HEK293T cells, those containing ETGE-like motifs, plus Nrf2 
and Keap1 and were subjected to network analysis using Ingenuity. This 
assigns the proteins in the data set to networks in which they are known to 
be involved, based on known interactions. Showing the most significantly 
represented network. Proteins highlighted in grey are present in the inputted 
data set, those in white are in the Ingenuity database in that network, but not 
present in the inputted data set. Solid and dotted grey lines indicate direct 
and indirect interactions, respectively. Arrows indicate the direction of the 
interaction. Different shapes indicate different molecule functions. See 
appendix 6 for figure legend regarding molecule shapes. 
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Figure 4.9. Network 2 identified through Ingenuity network analysis of 
putative Keap1 interacting partners. Of the proteins co-purified with 
Keap1-V5 from HEK293T cells, those containing ETGE-like motifs, plus Nrf2 
and Keap1 and were subjected to network analysis using Ingenuity. This 
assigns the proteins in the data set to networks in which they are known to 
be involved, based on known interactions. Showing the second most 
significantly represented network. Proteins highlighted in grey are present in 
the inputted data set, those in white are in the Ingenuity database in that 
network, but not present in the inputted data set. Solid and dotted grey lines 
indicate direct and indirect interactions, respectively. Arrows indicate the 
direction of the interaction. Different shapes indicate different molecule 
functions. See appendix 6 for figure legend regarding molecule shapes. 
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Figure 4.10. Network 3 identified through Ingenuity network analysis of 
putative Keap1 interacting partners. Of the proteins co-purified with 
Keap1-V5 from HEK293T cells, those containing ETGE-like motifs, plus Nrf2 
and Keap1 and were subjected to network analysis using Ingenuity. This 
assigns the proteins in the data set to networks in which they are known to 
be involved, based on known interactions. Showing the third most 
significantly represented network. Proteins highlighted in grey are present in 
the inputted data set, those in white are in the Ingenuity base in that network, 
but not present in the inputted data set. Solid and dotted grey lines indicate 
direct and indirect interactions, respectively. Arrows indicate the direction of 
the interaction. Different shapes indicate different molecule functions. See 
appendix 6 for figure legend regarding molecule shapes. 
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The pathway analysis indicated that many of the proteins in this data set are 
not involved in similar cellular pathways (Table 4.6). The most significantly 
represented pathway is that of cell cycle control and chromosomal replication 
(pathway 1), which relates well with the network analysis (Table 4.5). 
However, this pathway is only represented by three proteins within the 
relatively small data set. As would be expected, the Nrf2-mediated oxidative 
stress response is represented by the presence of Keap1, Nrf2 (NFE2L2) 
and p62 (SQSTM1) (pathway 7). Furthermore, there is substantial 
representation of cell survival/apoptosis pathways (pathways 7, 8, 10, 11 and 
14) and DNA repair pathways (pathways 13 and 15). Interestingly, there are 
a number of pathways associated with the biosynthesis of nucleic acids 
(pathways 2, 3 and 4), as well as transcription and translation (pathways 5, 6 
and 9 respectively). In such a small data set, the number of proteins 
associated with each of the above pathways is low, however the analysis 
does highlight the diverse array of pathways that putative Keap1-interacting 
proteins may be associated with. In particular, it highlights the close 
association of Keap1 with cell defence and cell survival pathways. 
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Table 4.6.Pathway analysis of putative Keap1-interacting proteins 
containing an ETGE-like Keap1 binding motif. Proteins co-purified with 
Keap1-V5 from transfected HEK293T cells containing ETGE-like Keap1 
binding motifs, plus and Nrf2 and Keap1, were subjected to Ingenuity 
pathway analysis. This assigns the proteins to pathways in which they are 
known play a role. Showing the significantly represented pathways, the p-
value (right-tailed Fishers Exact Test) represents the likelihood that that 
inputted proteins that are part of a pathway are found there by chance. 
 
Pathway P value Inputted proteins 
represented in 
pathway 
1 
Cell Cycle Control of 
Chromosomal Replication 
0.0001 MCM3,RPA1,MCM4 
2 
Pyrimidine Ribonucleotides 
De Novo Biosynthesis 
0.0033 CAD,CTPS1 
3 
Uridine-5'-phosphate 
Biosynthesis 
0.0063 CAD 
4 Diphthamide Biosynthesis 0.0095 EEF2 
5 
Regulation of eIF4 and 
p70S6K Signalling 
0.0102 EIF3G,EIF3I,EIF4G1 
6 EIF2 Signalling 0.0170 EIF3G,EIF3I,EIF4G1 
7 
NRF2-mediated Oxidative 
Stress Response 
0.0186 
KEAP1,SQSTM1,NFE
2L2 
8 mTOR Signalling 0.0200 EIF3G,EIF3I,EIF4G1 
9 
NAD Phosphorylation and 
Dephosphorylation 
0.0309 NNT 
10 Apoptosis Signalling 0.0316 LMNA,DFFA 
11 Death Receptor Signalling 0.0339 LMNA,DFFA 
12 
Cleavage and 
Polyadenylation of Pre-
mRNA 
0.0372 CPSF2 
13 
DNA Double-Strand Break 
Repair by Homologous 
Recombination 
0.0437 RPA1 
14 Granzyme B Signalling 0.0490 DFFA 
15 
Mismatch Repair in 
Eukaryotes 
0.0490 RPA1 
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4.3.5 Validation of Keap1-interacting partners using Y2H 
Having identified a number of potential Keap1 binding partners, a high-
throughput method for the validation of the interactions was necessary. Y2H 
is a method whereby many proteins can be screened for interactions 
simultaneously, and with various stringencies (see Section 4.2.15 for details 
of how Y2H is used to identify protein-protein interactions). In order to 
perform Y2H, it was necessary to acquire plasmids containing the gene 
sequences for the proteins of interest which could be used to transform 
yeast. Constructs for a selection of the putative Keap1 binding proteins in 
pDONR gateway vectors were obtained from a collaborator (Dr. Jon 
Woodsmith, Max-Planck Institute for Molecular Genetics, Berlin, Germany), 
however not all of the 55 proteins containing ETGE-motifs were available 
(see appendix 7 for the details of the constructs obtained). Once KOD PCR 
had been performed to determine that the DNA products were of the correct 
molecular weight (data not shown), gap repair cloning was used to insert the 
constructs into vectors which would be expressed in yeast cells as bait- i.e. 
they would be expressed bound to the DNA binding domain of the Gal4 
transcription factor. In this study, Keap1 was used as prey, due to it 
promoting auto-activation when used as bait (data to be presented in thesis 
of Amy Ponsford). Following the transformation of yeast with the appropriate 
vector, YCPCR was performed to further confirm the insertion of the correct 
construct size (data not shown). Those showing incorrect YCPRC product 
were not continued in the screen. Those with the correct YCPCR product 
size and that did not exhibit auto-activation capabilities (data not shown), 
were continued in the screen (see Table 4.7). 
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Location  Gene Name UniProt ID Protein Name 
-* AP3B1 O00203 AP-3 complex subunit beta-1 
B7 AP3D1 O14617 AP-3 complex subunit delta-1 
B3 ATP6V0A2 Q9Y487 
V-type proton ATPase 116 kDa 
subunit a isoform 2 
D3 CTPS P17812 CTP synthase 1 
-** DFFA O00273 
DNA fragmentation factor 
subunit alpha 
C7 DHX8 Q14562 
ATP-dependent RNA helicase 
DHX8 
B2 DPP3 Q9NY33 Dipeptidyl peptidase 3 
-* EEF2 P13639 Elongation factor 2 
D6 EFTUD1 Q7Z2Z2 
Elongation factor Tu GTP-
binding domain-containing 
protein 1 
B9/C2 EFTUD2 Q15029 
116 kDa U5 small nuclear 
ribonucleoprotein component 
C12/C4/D2 EIF3G O75821 
Eukaryotic translation initiation 
factor 3 subunit G 
D2/D4 EIF3I Q13347 
Eukaryotic translation initiation 
factor 3 subunit I 
C6 FLNA P21333 Filamin-A 
D10 GRWD1 Q9BQ67 
Glutamate-rich WD repeat-
containing protein 1 
B12 HBS1L Q9Y450 HBS1-like protein 
D9 HCFC1 P51610 Host cell factor 1 
D11/E10/D5 HNRNPH1 P31943 
Heterogeneous nuclear 
ribonucleoprotein H1 
B6/B1 HNRNPH3  P31942 
Heterogeneous nuclear 
ribonucleoprotein H3 
B11 HSPA9 P38646 Stress-70 protein, mitochondrial 
C9 LETM1 O95202 
LETM1 and EF-hand domain-
containing protein 1, 
mitochondrial 
C11/E8/D1 LMNA P02545 Prelamin-A/C 
B10 MAD2L1 Q13257 
Mitotic spindle assembly 
checkpoint protein MAD2A 
B5/C5 MCM3 P25205 
DNA replication licensing factor 
MCM3 
-** NAP1L1 P55209 
Nucleosome assembly protein 
1-like 1 
-** NCAPH Q15003 Condensin complex subunit 2 
C3 NNT Q13423 
NAD(P) transhydrogenase, 
mitochondrial 
B4 PPIA P62937 
Peptidyl-prolyl cis-trans 
isomerase A 
B8 PRKAR2A P13861 
cAMP-dependent protein kinase 
type II-alpha regulatory subunit 
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Table 4.7. Details of clones obtained for Y2H screen against Keap1. 
Those in bold type were not successfully cloned into yeast bait vectors (i.e. 
incorrect YCPRC product size) (*), or exhibited auto-activation capabilities 
(**), therefore were not used in the Y2H screen. All proteins contain an 
ETGE-like motif (ETGE/ESGE/STGE). Location column refers to Figures 
4.11 and 4.12). 
 
Yeast containing the constructs of interest (as bait) were mated against the 
following preys: Keap1, Nrf2 and p62, in order to examine the potential for 
the proteins to interact with Keap1 directly, or indirectly through Nrf2 or p62. 
Positive controls were used as follows (Fig 4.11):  
Keap1 (prey) + p62 (bait), Keap1 (prey) + Cul3 (bait) 
p62 (prey) + p62 (bait)  
Nrf2 (prey) + MafG (bait) 
 
The Y2H screens were carried out on two different selective medias (SD-
WLA and SD-WHL(AT)). The growth of colonies on both medias indicates the 
activation of two different reporter genes by the Gal4 transcription factor 
(ADE2 and HIS3, respectively). Positive interactions identified through this 
Y2H screen are shown in Figure 4.11 and outlined in Table 4.8. The 
functions of the proteins positively identified as protein interactions are 
D8/D7 PSMD3 O43242 
26S proteasome non-ATPase 
regulatory subunit 3 
E11/E9/C2 RIC8A Q9NPQ8 Synembryn-A 
C8 RPA1 P27694 
Replication protein A 70 kDa 
DNA-binding subunit 
-* SLK Q9H2G2 
STE20-like serine/threonine-
protein kinase 
A12 SQSTM1 Q13501 Sequestosome/p62 
-** WDR1 O75083 
WD repeat-containing protein 
1 
C10 YBX1 P67809 
Nuclease-sensitive element-
binding protein 1 
E12 ZW10 O43264 
Centromere/kinetochore protein 
zw10 homolog 
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detailed in Table 4.9. Proteins identified through activation of both ARE2 and 
HIS3 reporter genes, in two out of two biological repeats were considered 
true interactions. 
 
Prey Location Bait 
Keap1 
A8 EIF3J 
A9 Nrf2 
A11 Cul3 
A12 p62 
B1 HNRNPH3 
B5, C5 MCM3 
B10 MAD2L1 
B12 HSB1L1 
C1, E11, E12 RIC8A 
C4 EIF3G 
P62 
A12 p62 
B1 HNRNPH3 
C1 RIC8A 
C4, C12, D2 EIF3G 
D2 PSMD3 
Nrf2 B10 MafG 
 
Table 4.8. Proteins identified as positive binding partners in Y2H screen 
from two biological repeats. Those in bold type are previously known 
interactions and were used as positive controls in the assay. 
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Figure 4.11.Y2H matrix style mating. Yeast were transferred onto selective 
media (SD-WLA and SD-WHL(AT)) and incubated at 30 °C for up to 10 days. 
Photographs were taken at regular intervals. The presence of yeast colonies 
indicates the induction of the ADE2 reporter (SD-WLA) and the HIS3 reporter 
(SD-WHL(AT)), each under the control of the Gal2p and Gal1pGal4 
promoters respectively. A red box around yeast colonies indicates a protein 
interaction. The plates shown are representative of two biological repeats. 
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Protein Function 
EIF3J/EIF3G Component of the eukaryotic translation initiation factor 3 
(eIF-3) complex, required for the initiation of protein 
synthesis. EIF-3 complex associates with 40S ribosome, 
facilitates recruitment of subunits to form 43Spre-initiation 
complex (43S PIC). The complex stimulates mRNA 
recruitment to the 43S PIC and scanning of mRNA for 
AUG recognition. Complex required for disassembly and 
recycling of post-termination ribosomal complexes, 
prevents premature joining of the 40S and 60S ribosomal 
subunits prior to initiation.eIF-3 complex is composed of 
13 subunits: EIF3A, EIF3B,EIF3C, EIF3D, EIF3E, EIF3F, 
EIF3G, EIF3H, EIF3I, EIF3J, EIF3K,EIF3L and EIF3M.  
HBS1L A member of the GTP-binding elongation factor family. It 
is expressed in multiple tissues with the highest 
expression in heart and skeletal muscle.  
HNRNPH3 Involved in splicing process and participates in early heat 
shock-induced splicing arrest. 
MAD2L1 Component of the spindle-assembly checkpoint that 
prevents the onset of anaphase until all chromosomes are 
properly aligned at the metaphase plate. Required for the 
execution of the mitotic checkpoint which monitors the 
process of kinetochore-spindle attachment and inhibits 
the activity of the anaphase promoting complex by 
sequestering CDC20 until all chromosomes are aligned at 
the metaphase plate. 
MCM3 A component of MCM2-7 complex (MCM complex) which 
is the putative replicative helicase essential for 'once per 
cell cycle' DNA replication initiation and elongation in 
eukaryotic cells. Required for DNA replication and cell 
proliferation. 
PSMD3 A member of the proteasome subunit S3 family that 
functions as one of the non-ATPase subunits of the 19S 
regulator lid. The 26S proteasome is a multi-catalytic 
proteinase complex with a highly ordered structure 
composed of 2 complexes, a 20S core and a 19S 
regulator. The 19S regulator is composed of a base, 
which contains 6 ATPase subunits and 2 non-ATPase 
subunits, and a lid, which contains up to 10 non-ATPase 
subunits. 
 
RIC8A Guanine nucleotide exchange factor (GEF), which can 
activate some G-alpha proteins. Involved in regulation of 
microtubule pulling forces during mitotic movement of 
chromosomes by stimulating G(i)-alpha protein, possibly 
leading to release G(i)-alpha-GTP and NuMA proteins 
from the NuMA-GPSM2-G(i)-alpha-GDP. Also acts as an 
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activator for G(q)-alpha (GNAQ) protein by enhancing the 
G(q)-coupled receptor-mediated ERK activation. 
 
Table 4.9. Function of proteins identified as novel Keap1-binding 
partners in Y2H screen. Protein function descriptions are taken directly from 
the NCBI Entrez Protein database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein). 
 
4.3.6 β-Galactosidase Reporter Assay 
In order to further validate the interactions identified in Section 4.3.5, we used 
a third reporter assay, the β-Galactosidase reporter assay. Following diploid 
selection, the yeast are transferred onto filter paper and incubated at 37 °C in 
the presence of X-gal. If the Gal4 transcription factor is functional (i.e. the BD 
and AD are brought together), the X-gal will be catalysed into colourless 
galactose and 4-chloro-3-brom-indigo, which is blue on the filter paper, 
indicating a protein interaction. As in Section 4.3.5, all preys were screened 
against Keap1, p62 and Nrf2 baits. The data do not indicate any interactions 
that were not identified in the previous mating screen (Fig 4.11) but does 
confirm the novel Keap1-interacting proteins identified in Section 4.3.5, 
including EIF3J (A7),HNRNPH3 (B1), MAD2L1 (B10), HBS1L1 (B12) 
andRIC8A (E11) (Fig. 4.11, 12). In addition, strong blue colour is seen with 
positive control matings, such asKeap1 and p62 (top panel A12), p62 and 
p62 (middle panel A12) and Nrf2 with MafG (bottom panel, B10). 
  Chapter 4 
- 181 - 
 
 
Figure 4.12.β-Gal Reporter assay. Following diploid selection, yeast were 
transferred onto filter paper, which was laid on top of additional filter paper 
covered in β-Gal reagent and incubated at 30 °C for 24 hr. Photographs were 
taken of the colour changes over this time period. Blue indicates the 
induction of the LacZ gene in yeast by the Gal4 transcription factor, 
catalysing the hydrolysis of X-Gal to a colourless galactose and 4-chloro-3-
brom-indigo, which is blue. The red dotted box around a blue circle indicates 
a protein-protein interaction. One biological repeat. 
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4.3.7 Comparison of Keap1 interactome composition following 
exposure of cells to selected Nrf2 inducers 
In Chapter 2, HEK293T cells were transfected with Keap1-V5 and treated 
with various Nrf2 inducing compounds, before Keap1 was immunopurified, 
subjected to trypsin digestion and LC-ESI-MS/MS analysis to identify 
modifications of cysteine residues. These data permit us to investigate the 
different proteins co-purified with Keap1-V5 following the treatment of cells 
with Nrf2-inducing compounds. For this, we have focussed on DNCB, CDDO-
Me and Dex-mes, as they are all electrophilic compounds and exposed to 
cells using the same vehicle, DMSO. The other Nrf2-inducing compounds 
used in Chapter 2 (BSO and H2O2) are not electrophilic and the vehicles 
used were dH2O and cell growth media respectively, therefore including 
these compounds in the analysis described here would have introduced 
additional variables. In order to compare the proteins that were co-purified 
with Keap1-V5 following each treatment (DMSO, DNCB, CDDO-Me, Dex-
Mes), the total list of proteins co-purified with Keap1-V5 in ≥ 4 out of 6 
biological repeats was compared to the list of proteins purified following mock 
transfection. If a protein was identified in both the mock transfected samples 
and those transfected with Keap1-V5, it was removed from the list if the ratio 
of the number of peptides in transfected:mock was ≥1.5. The proteins 
remaining were compared using a Venn diagram(Oliveros 2007) to identify 
the overlap or differences in proteins co-purified with Keap1-V5 following the 
treatment of HEK293T cells with each Nrf2 inducing compound (Fig 4.15). 
Note that the proteins used in this study were not limited to only those 
containing ETGE-like motifs.  
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Figure 4.13. Venn diagram comparison of proteins co-purified with 
Keap1-V5 following treatment of cells with Nrf2 inducing electrophiles. 
The total list of proteins co-purified in ≥ 4/6 biological repeats was compared 
to the list of proteins purified following mock transfection. If the protein was 
identified in both the mock transfected samples and following transfection of 
Keap1-V5, proteins were removed from the list if the ratio of the average 
number of peptides in transfected:mock was ≥1.5. The proteins remaining 
were compared using a Venn diagram programme by Oliveros (2007). 
 
Of these proteins, 203 of those identified following treatment with all 
compounds were also identified following treatment with the vehicle control 
(DMSO), and thus further investigation of these may reveal partners which 
are constitutively bound to Keap1 and unaffected by Nrf2 induction, or the 
presence of electrophiles(Fig 4.13) (see appendix 8 for details of proteins in 
each Section). Ingenuity-based pathway analysis of these 203 proteins 
reveals the most significantly represented pathways by these proteins (Table 
4.10). The pathways represented by this data set include EIF2 signalling, 
mTOR signalling, the protein ubiquitination pathway, DNA double strand 
break repair, the Nrf2-mediated oxidative stress response, as well as 
nucleotide biosynthetic pathways.  
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Pathway P-value Molecules in the pathway 
EIF2 Signalling 7.94E-36 RPL24,RPL22,RPL27A,RPS18,
RPLP2,EIF4G1,EIF2S1,EIF2A,
RPS7,RPS20,UBA52,EIF3D,RP
S13,RPL23A,RPS9,EIF5,EIF3A,
RPL13,PABPC1,RPL12,RPL23,
RPL21,RPL9,RPL10A,EIF3F,R
PL28,RPS26,RPL26L1,EIF4A3,
EIF4A1,EIF3I,RPL10,RPL5,RPS
15A,RPL13A,RPSA 
Regulation of eIF4 and 
p70S6K Signalling 
2.00E-15 PABPC1,RPS18,EIF4G1,EIF2S
1,EIF2A,RPS7,EIF3F,PPP2R1A
,RPS20,EIF3D,RPS13,RPS26,E
IF4A3,RPS9,EIF4A1,EIF3A,EIF
3I,RPS15A,RPSA 
RAN Signalling 2.00E-10 KPNB1,CSE1L,KPNA2,TNPO1,
RANGAP1,XPO1,IPO5 
mTOR Signalling 2.14E-10 RPS18,EIF4G1,RPS7,EIF3F,PP
P2R1A,RPS20,EIF3D,RPS13,R
PS26,EIF4A3,EIF4A1,RPS9,EIF
3A,EIF3I,RPS15A,RPSA 
Protein Ubiquitination 
Pathway 
3.89E-09 USP9X,HSPA9,PSMD3,HSPD1,
DNAJA1,HSPA5,PSMC5,PSMD
11,HSP90AB1,PSMD2,PSMD12
,HSP90AA1,PSMD14,SUGT1,P
SMC2,PSMC3,DNAJC7 
tRNA Charging 7.59E-09 LARS,RARS,YARS,VARS,MAR
S,IARS,EPRS,QARS 
Caveolar-mediated 
Endocytosis Signalling 
1.51E-04 ARCN1,FLNA,COPA,PTPN1,C
OPB1,COPG1 
Purine Nucleotides De 
Novo Biosynthesis II 
2.09E-04 ADSL,GMPS,GART 
Oxidized GTP and dGTP 
Detoxification 
3.72E-04 DDX6,RUVBL2 
Telomere Extension by 
Telomerase 
5.62E-04 HNRNPA1,XRCC6,XRCC5 
Tetrahydrofolate Salvage 
from 5,10-
methenyltetrahydrofolate 
1.20E-03 MTHFD1,GART 
Aldosterone Signalling in 
Epithelial Cells 
1.55E-03 HSP90AB1,HSPA9,HSP90AA1,
HSPD1,DNAJA1,HSPA5,DNAJ
C7 
Mitotic Roles of Polo-Like 
Kinase 
5.37E-03 PPP2R1A,HSP90AB1,HSP90A
A1,CDK1 
Remodelling of Epithelial 
Adherens Junctions 
6.31E-03 TUBA1B,TUBB6,TUBB4B,TUB
B 
14-3-3-mediated Signalling 9.77E-03 TUBA1B,TUBB6,TUBB4B,PDC
D6IP,TUBB 
DNA Double-Strand Break 
Repair by Non-Homologous 
1.02E-02 XRCC6,XRCC5 
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End Joining 
Acetyl-CoA Biosynthesis III 
(from Citrate) 
1.12E-02 ACLY 
Asparagine Biosynthesis I 1.12E-02 ASNS 
NRF2-mediated Oxidative 
Stress Response 
1.45E-02 PRDX1,CCT7,SQSTM1,DNAJA
1,PTPLAD1,DNAJC7 
Breast Cancer Regulation 
by Stathmin1 
2.00E-02 TUBA1B,PPP2R1A,TUBB6,TUB
B4B,TUBB,CDK1 
Unfolded protein response 2.14E-02 HSPA9,HSPA5,EIF2A 
Palmitate Biosynthesis I 
(Animals) 
2.24E-02 FASN 
Uridine-5'-phosphate 
Biosynthesis 
2.24E-02 CAD 
Fatty Acid Biosynthesis 
Initiation II 
2.24E-02 FASN 
Endoplasmic Reticulum 
Stress Pathway 
2.24E-02 EIF2S1,HSPA5 
Gap Junction Signalling 2.69E-02 DBN1,TUBA1B,TUBB6,TUBB4
B,TUBB 
Glycolysis I 2.88E-02 PGK1,GAPDH 
Germ Cell-Sertoli Cell 
Junction Signalling 
3.09E-02 TUBA1B,TUBB6,CFL1,TUBB4B
,TUBB 
Gluconeogenesis I 3.16E-02 PGK1,GAPDH 
Diphthamide Biosynthesis 3.31E-02 EEF2 
PRPP Biosynthesis I 3.31E-02 PRPS1 
NADH Repair 3.31E-02 GAPDH 
5-aminoimidazole 
Ribonucleotide Biosynthesis 
I 
3.31E-02 GART 
Inosine-5'-phosphate 
Biosynthesis II 
3.31E-02 ADSL 
Hypusine Biosynthesis 3.31E-02 EIF5A 
Pyrimidine Ribonucleotides 
De Novo Biosynthesis 
3.63E-02 CAD,CTPS1 
PPARα/RXRα Activation 3.72E-02 CAND1,HSP90AB1,FASN,CKA
P5,HSP90AA1 
Proline Biosynthesis I 4.37E-02 ALDH18A1 
Sertoli Cell-Sertoli Cell 
Junction Signalling 
4.47E-02 TUBA1B,TJP2,TUBB6,TUBB4B,
TUBB 
PI3K/AKT Signalling 4.68E-02 CDC37,PPP2R1A,HSP90AB1,H
SP90AA1 
Table 4.10. Pathway analysis proteins co-purified with Keap1-V5 
following treatment of cells with Nrf2 inducers. Proteins were co-purified 
with Keap1-V5 from transfected HEK293T cells treated with DMSO, DNCB, 
Dex-mes or CDDO-Me. Those identified in ≥4/6 biological repeats and with 
the ratio of the average number of peptides in transfected:mock≥1.5 and 
present following treatment with all compounds or vehicle control were 
subjected to Ingenuity pathway analysis. Shown in order of significance. 
  Chapter 4 
- 186 - 
 
The data demonstrate that there are proteins co-purified with Keap1 which 
are unique to each treatment; 14 for DNCB, 29 for CDDO-Me and 61 for Dex-
Mes (Fig 4.13). Ingenuity network analysis of these individual data sets 
shows that the proteins are associated with diverse cellular functions. The 
proteins purified from HEK293T cells expressing Keap1-V5, and unique to 
DNCB treatment, appear to be related primarily to cell death and survival and 
DNA repair, indicating toxicity within the cell (Table 4.11). Proteins co-purified 
with Keap1-V5 unique to dex-mes treatment are also associated with 
networks involved in cell death and survival as well as cellular assembly and 
organisation, and various disease states (Table 4.12). On the other hand, 
proteins co-purified with Keap1-V5 from cells following treatment with CDDO-
Me are associated with networks that have roles in cancer and lipid 
metabolism, both of which are associated with the Nrf2 signalling pathway 
(Table 4.13). Further investigation into these interactions may give some 
insight into the changes in the Keap1 complex that occur following Nrf2 
induction and how this differs between electrophiles. 
 
DNCB Network 
Focus 
Molecules 
Score 
Cell death and survival 
Cellular compromise,  
DNA replication, recombination and repair 
11 26 
Cell cycle, 
Cellular movement,  
Cancer 
1 3 
Cancer,  
Organismal injury and abnormalities, 
Renal and urological disease 
1 2 
Table 4.11. Network analysis of proteins co-purified with Keap1-V5 from 
cells following DNCB treatment only. Showing the top three significantly 
represented networks. 
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Dex-mes Network 
Focus 
Molecules 
Score 
Cell death and survival, Developmental 
disorders, Gastrointestinal disease 
13 23 
Cell to cell signalling and interaction, 
Cellular assembly and organisation, 
Tissue development 
13 21 
Dermatological conditions,  
Infectious disease,  
Inflammatory disease 
10 16 
Table 4.12. Network analysis of proteins co-purified with Keap1-V5 from 
cells following dex-mes treatment only. Showing the top three significantly 
represented networks. 
 
CDDO-MeNetwork 
Focus 
Molecules 
Score 
Cancer,  
Neurological disease,  
Cellular development 
11 22 
Lipid metabolism,  
Molecular transport,  
Small molecule biochemistry 
12 22 
Cellular assembly and organisation, 
Cellular function and maintenance 
1 2 
Table 4.13. Network analysis of proteins co-purified with Keap1-V5 from 
cells following CDDO-Me treatment only. Showing the top three 
significantly represented networks. 
 
Interestingly, only two proteins were co-purified with Keap1 following 
treatment with all three electrophiles but not with vehicle control (Fig 4.13). 
These are Serine/arginine-rich splicing factor 10 (SRSF10) and 
heterogeneous nuclear ribonucleoprotein Q (hnRNP Q). SRSF10 is a 
repressor of pre-mRNA splicing during M-phase of the cell cycle and after 
heat shock. It is located within the cytosol and nuclear speckles, the common 
localisation for proteins involved in transcription and pre-mRNA processing 
(details from www.uniprot.org). hnRNP is also implicated in mRNA 
processing, and is a component of a complex which promotes mRNA 
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stability. Additionally, it is a component of the gamma (γ) interferon-activated 
inhibitor of translation (GAIT) complex which mediates interferon-γ-induced 
transcript-selective translation inhibition in inflammation processes. It is 
localised in cytoplasmic granules containing untranslated mRNAs, and in the 
nucleus (details from www.uniprot.org). Interestingly, another hnRNP protein 
(hnRNPH3) was identified as a potential Keap1 binding partner by MS and 
validated by the Y2H assay. It is worth noting that whilst hnRNPH3 contains 
an ETGE-like motif, neither hnRNP Q nor SRNF10 do. Further investigation 
of the Keap1-binding complex and how it changes in response to Nrf2-
inducing compounds may provide insights into the mechanisms by which 
different inducers provoke Nrf2 activation.  
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4.4  DISCUSSION 
 
As the manipulation of the Nrf2 pathway is considered a promising 
therapeutic strategy, furthering our understanding of its activation and 
regulation is vital. By investigating the proteins which are involved in the 
Keap1/Nrf2 complex, we can develop a more detailed picture of the 
molecular interactions which can be targeted to modulate Nrf2 activity, or to 
fine-tune Nrf2-related therapeutic interventions. As we have previously used 
MS methods to identify p62 as a novel Keap1 binding partner, and data 
obtained in Chapter 2 were available for the analysis of proteins which are 
co-purified with Keap1-V5 from cells, we took an unbiased approach to 
identify novel Keap1 binding partners and investigate the biological roles 
played by proteins which interact with Keap1.  
 
The MS analysis of proteins co-purified with Keap1 from HEK293T cells 
identified upwards of 1,000 potential interacting partners. Further validation 
was concentrated on proteins which contain an ETGE-like Keap1-binding 
motif. Network analysis of such proteins revealed that whilst a number of the 
proteins identified have not been shown to bind directly to Keap1, some 
interact with other known Keap1 binding partners, such as PGAM5. However, 
the presence of an ETGE-like motif within these proteins indicates that they 
are likely to bind to Keap1 directly. Pathway analysis demonstrated that 
many of the putative Keap1-interacting proteins identified have been linked to 
cell survival pathways, supporting a link to p53 signalling. This supports 
observations of an association between p53 and Nrf2, whereby in conditions 
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of low ROS exposure, p53 and Nrf2 up-regulate the expression of antioxidant 
genes yet with extended ROS exposure, p53 is up-regulated. This mediates 
the expression of pro-oxidant genes augmenting p53-mediated apoptosis, 
whilst Nrf2 is suppressed (Chen et al. 2012). It is plausible that a protein 
interacts with p53 and Keap1, and that the interaction is altered under 
conditions of stress, facilitating the co-regulation of both pathways.  
 
Y2H screening allowed the validation of a number of candidate Keap1-
binding proteins. This assay verified potential Keap1-binding partners which 
contain ETGE-like motifs, including EIF3J/G, HBS1L, HNRNPH3, MAD2L1, 
MCM3, RIC8A, as well as PSMD3 as a potential p62-binding partner. 
PSMD3 is a non-ATPase member of the 19S regulator lid of the 26S 
proteasome. The lid of the 26S proteasome is responsible for the recognition 
of poly-ubiquitinated proteins (Thrower et al. 2000), therefore, it is possible 
that p62/Keap1 interact with the proteasome via PSMD3, to facilitate the 
degradation of ubiquitinated proteins, such as Nrf2. Proteins of the EIF3 
complex, have been shown to interact with the 19S proteasomal lid (Sharon 
et al. 2006). In this Y2H screen, EIF3G was shown to interact with Keap1 and 
p62. Additionally, EIF3J, another subunit of the EIF3 complex, was screened 
against Keap1 as it has previously been identified as an Nrf2 binding partner 
using this assay (data to be presented in thesis of Amy Ponsford). EIF3J and 
EIF3G are subunits of the eukaryotic initiation factor 3 complex (EIF3), and 
participate in the initiation of transcription by aiding the recruitment of protein 
and mRNA to the 40S ribosome (Zhou et al. 2008).  
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HNRNPH3, verified in the Y2H screen as a Keap1-interacting partner would 
be worth investigating further, especially as an additional HNRNP protein 
(HNRPN Q) was identified as one of two proteins co-purified with Keap1, 
following treatment with Nrf2-inducing electrophiles. Following heat shock, 
pre-mRNA splicing (performed by HNRNP proteins) is transiently inhibited to 
prevent the synthesis of abnormal proteins (Yost and Lindquist 1986, Yost 
and Lindquist 1988). This is facilitated by HNRNP proteins leaving the 
HNRNP complex, and it is possible that under these conditions an 
association with Keap1 occurs, leading to concomitant activation of Nrf2 cell 
defence signalling.  
 
Our Y2H validation of MCM3 as a Keap1 binding partner further supports the 
observations by Hast et al. (2013). They showed that the ETGE motif in 
MCM3 facilitates this interaction. As part of the MCM complex, MCM3 
ensures that DNA replication occurs only once per cell cycle (Takei and 
Tsujimoto 1998). MCM3 is primarily a nuclear protein, its localisation 
facilitated via an interaction with Map80 and an NLS (Takei and Tsujimoto 
1998). Therefore, due to the cytoplasmic localisation Keap1 (Watai et al. 
2007), this interaction is only likely to occur if Keap1 enters the nucleus, 
perhaps under stress conditions, as it has been reported to do (Sun et al. 
2007).  
 
MAD2L1 was also previously identified as a Keap1-binding protein by Hast et 
al. (2013) who showed that when ectopically expressed in cells, MAD2L1 
activates Nrf2-mediated transcription, dependent on the presence of its 
  Chapter 4 
- 192 - 
 
ESGE motif. Further investigation into the functional effect this protein has on 
the Nrf2 pathway, and the underlying molecular mechanisms, is therefore 
warranted. An interaction between Keap1 and either MAD2L1 or MCM3 
would directly link the Nrf2 pathway with the p53 pathway, as shown in Fig 
4.9. 
 
HBS1L is a member of the GTP-binding elongation factor family, thus is 
involved in protein synthesis. Polymorphisms within the HBS1L gene have 
been associated with fetal haemoglobin levels and sickle cell disease 
(Stadhouders et al. 2014). Interestingly, fetal haemoglobin levels have been 
shown to be induced by Nrf2-activating compounds (e.g. tBHQ) (Macari and 
Lowrey 2011), therefore it is plausible that an interaction between HBS1L 
and Keap1 impacts the regulation of fetal haemoglobin levels in the cell. 
 
RIC8A is a guanine nucleotide exchange factor, which localises to the cell 
membrane, via an interaction with neural cell adhesion molecule (NCAM)-
180 (Amoureux et al. 2012). As Keap1 interacts with the actin cytoskeleton, 
potentially tethering it adjacent to the cell membrane, it is possible that these 
proteins co-localise. This interaction would benefit from further investigation. 
 
Additional proteins identified as potential Keap1 binding partners which 
require further investigation include those with ETGE-like motifs which were 
not screened using Y2H in this study. These proteins were not screened for 
one of three reasons. Firstly, the constructs obtained for the screen were 
obtained from a collaborator, and not all putative Keap1-interacting partners 
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were available. Secondly, some constructs were not successfully introduced 
into yeast bait vectors or cells. Lastly, some proteins exhibited auto-activation 
capabilities and thus could not be used in the screen. One example is SLK 
which was not used in our screen but was identified as a Keap1-binding 
partner by Hast et al. (2013), who showed that the over-expression of SLK in 
cells activates Nrf2-mediated transcription, independently of its ETGE motif. 
SLK is a kinase primarily expressed in the kidneys, which is induced during 
development and in recovery from acute renal failure, and which promotes 
apoptosis via p53 activation (Cybulsky et al. 2009). Therefore, further 
investigation of the interplay between this protein and the Keap1/Nrf2 
pathway would be worthwhile  
 
The dataset used for this analysis was not originally generated with the 
intention of identifying novel Keap1-binding partners. It was obtained 
following the treatment of Keap1-V5 expressing HEK293T cells with various 
Nrf2 inducers, to investigate the modification of Keap1 cysteine residues. For 
this reason, the data used for the studies shown in this chapter were derived 
from cells treated with 55 mM NEM for 5 min prior to lysis, to cap all Keap1 
cysteine residues, and aid the analysis of their modification state. Although 
this is unlikely to affect the basal Keap1-interactome, were this experiment 
designed specifically to identify Keap1 binding partners, this treatment would 
be excluded. As for the investigation into the change in Keap1-interactome 
following treatment with Nrf2-inducing electrophiles, all cells used for this 
analysis were treated with NEM, which is a constant factor among all 
samples. Should this experiment be repeated, NEM would be excluded.  
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Analysis of the proteins that are enriched following the purification of Keap1-
V5 from cells treated with different electrophilic Nrf2-inducing agents reveals 
distinct proteins associated with Keap1, which contribute to various cellular 
networks and functions. It is worth considering that the data sets used for 
network/pathway analyses are small, therefore pathways can appear to be 
significantly represented, when only one or two proteins in the data set are 
associated with that network/pathway. The focus of this work was to identify 
the type of functions associated with co-purified proteins, and not to make 
general conclusions regarding which pathways are significantly represented. 
 
In conclusion, we have identified a number of proteins which may be 
potential Keap1-interacting partners, some of which are in agreement with 
previously published data. Whilst we focussed on proteins containing ETGE-
like Keap1 binding motifs, a number of proteins identified did not contain this 
motif but would be worth investigating further. We show that Keap1-
interacting proteins containing ETGE-like motifs are involved in a diverse 
array of cellular functions, but there appears to be a clear focus on cell 
survival, cell death and DNA replication. Additionally, we show that there 
appears to be differences in the proteins which associate with Keap1 
following Nrf2 induction in cells with various electrophiles, which requires 
further investigation.  
 
It will be important to validate these interactions further and determine the 
functional effects of the interaction of these proteins with Keap1. Further 
validation could be carried out as follows: 
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 Confirm co-purification of proteins with Keap1-V5 from cells, or of 
endogenous Keap1 with epitope-tagged protein of interest, by western blot  
 Confirm protein co-localisation in cells using fluorescent microscopy 
 Validate protein interaction in different cell lines 
 siRNA-mediated knock-down, or ectopic expression of the protein of 
interest, and examination of the consequences for Keap1/Nrf2 protein 
levels and Nrf2 activity 
These investigations may reveal proteins which are potential therapeutic 
targets to manipulate Nrf2 levels, without the use of potentially toxic 
electrophiles. 
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5.1  INTRODUCTION 
 
Diseases associated with oxidative stress and the dysregulation of the Nrf2 
pathway are a major public health concern. Additionally, ADRs, one of the 
prevailing reasons for drug attrition, have been associated with chemically 
reactive, Nrf2-inducing compounds. It is therefore important to develop novel 
therapeutic agents, and enhance the safety of current medicines to improve 
patient wellbeing. These developments will be informed by furthering our 
understanding of the molecular mechanisms underlying Nrf2 activation. This 
thesis has focused on the mechanisms whereby electrophiles and oxidants 
can induce Nrf2 via covalent or non-covalent interactions with Keap1. 
Additionally, studies presented here have aimed to reveal Keap1’s 
interactions with other proteins, which may regulate the activity of Nrf2 and 
could therefore be promising therapeutic targets.  
 
5.2  SUMMARY OF THE WORK PRESENTED IN THIS THESIS 
 
Previous work in our lab has shown that the depletion of GSH can induce 
Nrf2 in the absence of covalent modification of Keap1 (Chia et al. 2010), thus 
we hypothesised that GSH depletion causes changes in the redox state of 
the cell, allowing ROS to accumulate and thus, the oxidation of Keap1 
cysteine residues. Due to the difficulty in directly detecting oxidation states in 
cysteine-rich proteins such as Keap1, we developed an MS method which 
allowed us to detect reversible and irreversible modifications of Keap1 
cysteines, following the treatment of cells with Nrf2 inducing compounds. We 
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showed that some Nrf2 inducers promote the formation of reversible and/or 
irreversible redox modifications of Keap1 which could be due to thiol 
oxidation, although this is not dependent on GSH depletion. Whilst we were 
unable to provide evidence for the direct oxidation of Keap1 cysteine 
residues, or that the oxidation of Keap1 cysteine residues is 
necessary/sufficient for the activation of Nrf2, it remains a plausible 
mechanism which requires further investigation.  
 
TPs are extremely potent inducers of the Nrf2 pathway, and there is interest 
in these compounds as therapeutic agents, for the treatment of a variety of 
diseases. We hypothesised that the activation of Nrf2 by this class of 
compound occurs via the covalent modification of Keap1 cysteine residues. 
In keeping with this, we have shown that a chemically-tuned TP (CDDO-
Epoxide) can covalently modify Keap1 cysteine residues known to be 
important for the ability of Keap1 to repress Nrf2. We have also shown, using 
in silico modelling, that the ability of a series of TPs to interact with Keap1 
non-covalently in cysteine-containing pockets correlates with their potency as 
inducers of Nqo1, which is regulated by Nrf2. Non-covalent modification of 
Keap1 by TPs is therefore a potential mechanism of Nrf2 activation, however 
requires further investigation before we can extrapolate this data to other 
Nrf2-inducing compounds. 
 
A detailed understanding of the mechanisms that regulate the Nrf2 cell 
defence pathway is dependent on an appreciation of a number of molecular 
aspects. This includes protein-protein interactions which may affect the ability 
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of the pathway to function. These interactions can be examined by combining 
experimental work with computational pathway analysis. Using this approach, 
we have investigated 55 proteins containing a Keap1-binding motif that were 
co-purified with Keap1-V5 from HEK293T cells. Network analysis of these 
proteins identified links between the Keap1/Nrf2 pathway and the p53 
pathway. Furthermore, we have identified potential Keap1 binding partners 
(HNRNPH3, EIF3G, MCM3, HBS1L, RIC8A and PSMD3) which require 
further validation of their functional effects on the Nrf2 pathway.  
 
5.3  FUTURE DIRECTIONS 
 
The experiments described here were performed on recombinant Keap1 
protein and cell lines transfected with epitope-tagged Keap1. Although 
necessitated by the low abundance of endogenous Keap1 in most cell lines, 
ectopically expressing a protein may divert the cell/protein environment away 
from that of a physiological state, the functional consequences of which are 
yet to be established. Additionally, in vitro systems and commonly-used liver 
cell lines (e.g. HepG2) do not have drug metabolising capabilities (Wilkening 
et al. 2003). This makes the identification of Keap1 cysteine modifications by 
reactive drug metabolites difficult, in such platforms. The use of primary 
hepatocytes, or a transgenic animal expressing tagged Keap1, which can be 
purified and subjected to MS following treatment with Nrf2 inducers, would 
inform how we extrapolate data obtained in vitro and in cell models, to in vivo 
settings. Further experimental and computational assessment of the Keap1 
cysteine residues located on solvent-accessible surfaces of Keap1, will be 
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aided by defining its full crystal structure, thus highlighting those most likely 
to be modified by Nrf2 activators.  
 
As an alternative to experimentally enriching Keap1 from cells, chemically-
adapted electrophiles could be used, to enable the affinity enrichment of 
proteins modified by such compounds (Dennehy et al. 2006, Shin et al. 
2007). This is a method that has been used to identify protein targets, 
including IKK and JAK1, of biotin-tagged TPs (Yore et al. 2011). It is not 
presently clear what effect the affinity tag has on the reactivity of the 
electrophile. Additionally, low-abundance proteins such as endogenous 
Keap1, may still prove difficult to detect using this approach. The use of 
chemical probes, such as dimedone which specifically alkylates cysteine 
sulphenic acid (S-OH) (Nelson et al. 2010), would be a promising avenue to 
consider regarding THE investigation of oxidised cysteine residues. 
 
The use of multiple reaction monitoring (MRM), whereby MS analysis is 
focussed on pre-defined target ions, such as specific peptides that are 
expected to be modified by a chemical entity, has permitted increased 
sensitivity and specificity in detecting modified proteins in cells, or tissues 
(Kitteringham et al. 2009). This approach reduces background signals, 
increasing the signal-to-noise ratio, giving more sensitive detection of 
modified peptides (Unwin et al. 2005), and can be guided by in vitro analysis 
to identify peptides of interest in in vivo assays. Further research is required 
to determine whether this approach will be sensitive enough to detect the 
modification of an endogenous protein of such low abundance as 
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Keap1.However, advances in sampling rate, sensitivity and the resolution of 
mass spectrometers are increasingly enabling the detection of modified 
endogenous proteins (Koen et al. 2006, Shin et al. 2007).  
 
The importance of non-covalent interactions between Nrf2 inducers and 
Keap1 cysteine-containing pockets will be facilitated by detailed in silico 
molecular modelling, using the crystal structures of Keap1 domains, or the 
full length protein if/when it becomes available. Non-covalent interactions are 
more readily reversible, thus Keap1 could theoretically be recycled, and not 
require de novo synthesis in order to regenerate fully-functional protein, as 
would likely be the case following irreversible modification of Keap1. 
 
The identification of novel Keap1 binding partners in this study supports, and 
adds, to the findings of Hast et al. (2013), and the Nrf2-interactome described 
by Papp et al. (2012). Further validation of the binding partners identified 
here is required. For example, it will be important to investigate whether 
these interactions are cell-type specific. The functional effect the interaction 
may have on the Nrf2 pathway, and its regulation, also requires investigation. 
This can be facilitated by over-expression or siRNA-mediated knock-down of 
the proteins of interest, and analysis of the effect on Keap1 protein levels and 
the basal/inducible activity of Nrf2. 
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5.4 CONCLUDING REMARKS 
 
The main aims of this thesis were to further our understanding of the 
mechanisms whereby Keap1 regulates the activity of Nrf2, in particular by 
investigating its molecular interactions with Nrf2-inducing compounds or 
other cellular proteins. Such information is vital to inform the design and 
development of safe and efficacious Nrf2-inducing compounds, which may 
have therapeutic value in numerous disease contexts. As an example, the 
modelling approach used here could be exploited to screen compound 
libraries for their ability to bind non-covalently to Keap1 in silico and induce 
Nrf2 in cells, to identify novel candidate Nrf2-modulating therapeutic agents. 
Furthermore, determining the ability of existing and new drugs to modulate 
the functions of Keap1, Nrf2 and/or their interacting proteins, may reveal new 
pharmacological mechanisms, or explain specific off-target effects.  
 
An increased understanding of Nrf2 signalling, in conjunction with 
investigations into the variation in its basal and inducible activity between 
individuals, will aid the stratification of medicine targeting this pathway, 
thereby improving patient wellbeing. Additionally, screening individuals for 
polymorphisms in the genes encoding Keap1 or Nrf2, which have been 
associated with various diseases (Wong et al. 2011, Hartikainen et al. 2012, 
Shimoyama et al. 2014), may allow the identification of at-risk patients. This 
could potentially allow for clinicians to develop strategies to prevent or slow 
the onset and/or progression of disease.
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Appendix 1 
Table showing mass of GSTP1 cysteine-47 with addition of CDDO-Me (+ 505 
amu) and CDDO-Epoxide (+ 521 amu) 
 
Peptide Residue Mass Mass:charge ratio + TP 
singe double triple 
ASCLYGQLPK 47 1079.28 1584.28 793.14 529.09 
ASCLYGQLPK 47 1079.28 1600.28 801.14 534.43 
 
 
 
 
 
 
Appendix 2 
Table showing mass of Keap1 cysteine containing peptides identified as 
modified with addition of CDDO-Epoxide (+ 521 amu) 
Peptide Residue Mass Mass:charge ratio + TP 
singe double triple 
YDCPQR 257 780.32 1301.62 651.81 434.87 
CHALTPR 273 796.40 1317.70 659.81 440.23 
CEILQADAR 288 1017.49 1538.79 77.04 513.93 
IGVGVIDGH…VER 434 2755.36 3276.66 1639.33 1093.22 
LNSAECYYPER 489 1343.58 1864.88 933.44 622.63 
SGVGVAVTMEPCR 613 1304.62 1825.92 913.96 609.64 
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Appendix 3 
Table showing mass of Keap1 cysteine containing peptides with addition of 
IAA (184.9 amu) 
Peptide Residue Mass Mass:charge ratio + IAA 
single double triple 
CPEGAGDAVM…TECK 23, 38 1730.70 1915.66 958.83 639.55 
LSQQLCDVTLQVK 77 1473.79 1658.75 830.37 553.92 
CVLHVMNGAV…DSVVR 151 2133.05 2318.01 1160.01 773.67 
ACSDFLVQQLDP…HQR 170, 196 3587.71 3957.63 1979.82 1320.21 
QEEFFNLSHCQLATLISR 226 2135.05 2320.01 1161.00 774.34 
CESEVFHACIDWVK 241, 249 1664.73 2034.65 1018.33 679.22 
YDCPQR 257 780.32 965.28 483.64 322.76 
CHALTPR 273 796.40 981.36 491.68 328.12 
CEILQADAR 288 1017.49 1202.45 602.23 401.82 
CK 297 2598.36 2783.32 1392.66 928.77 
DYLVQIFQELTL…VPCR 319 1647.88 1832.84 917.42 611.95 
SGLAGCVVGGL…VGGR 368 3558.45 3928.37 1965.19 1310.46 
NNSPDGNTDSS.…VPR 395, 406 2755.36 2940.32 1471.16 981.11 
IGVGVIDGHIYAV.…VER 434 1343.58 1528.54 765.27 510.51 
LNSAECYYPER 489 2995.36 3365.28 1683.64 1122.76 
SGAGVCVLHNCI…VER 513, 518 3538.55 3723.51 1862.76 1242.17 
IYVLGGYDGHTFL…VTR 583 1304.62 1489.58 745.79 497.53 
SGVGVAVTMEPCR 613 1051.41 1421.33 711.66 474.78 
QIDQQNCTC 622, 624 1730.70 1915.66 958.83 639.55 
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Appendix 4 
Structure of TP compounds taken from published literature by Dinkova-
Kostova et al. (2005) with concentration at which Nqo1 activity is doubled 
(CD) in Hepa1c1c7 cells. 
Name Structure Nqo1 CD (nM) 
TP-225 
 
0.28 
TP-224 
 
1 
TP-155 
 
1 
TP-151 
 
2.3 
TP-223 
 
2.3 
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TP-226 
 
6.9 
TP-190 
 
18 
TP-222 
 
22 
TP-162 
 
100 
TP-191 
 
220 
TP-82 
 
280 
TP-156 
 
1500 
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TP-69 
 
1800 
TP-46 
 
3900 
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Appendix 5. 
Table of ETGE-like motif containing proteins identified in Keap1-V5 and mock 
transfected HEK293T cells 
UniProt Protein Name Average peptides Motif 
Keap1-V5 Mock 
Q15029 
116 kDa U5 small nuclear 
ribonucleoprotein component 8.6 0 
ESGE 
O43242 
26S proteasome non-ATPase 
regulatory subunit 3 9.5 4.0 
 STGE 
P08195 
4F2 cell-surface antigen heavy 
chain  2.8 2.0 
STGE 
Q02952 A-kinase anchor protein 12 2.3 0 
ETGE, 
ESGE 
Q86XL3 
Ankyrin repeat and LEM 
domain-containing protein 2  2.0 0 
ETGE 
O00203 AP-3 complex subunit beta-1  1.7 0 ESGE 
O14617 AP-3 complex subunit delta-1 5.3 0 STGE 
Q9P2R6 
Arginine-glutamic acid 
dipeptide repeats protein 3.4 3.0 
ETGE 
Q14562 
ATP-dependent RNA helicase 
DHX8  5.3 0 
ETGE 
P27708 CAD protein  47.3 3.0 STGE 
P13861 
cAMP-dependent protein 
kinase type II-alpha regulatory 
subunit  3.2 0 
ESGE 
O43264 
Centromere/kinetochore 
protein zw10 homolog  3.3 0 
STGE 
Q9P2I0 
Cleavage and polyadenylation 
specificity factor subunit 2  2.0 0 
ETGE 
Q07021 
Complement component 1 Q 
subcomponent-binding protein, 
mitochondrial 5.8 2.0 
STGE 
Q15003 Condensin complex subunit 2 5.2 0 STGE 
P17812 CTP synthase 1 3.7 1.0 STGE 
Q96N67 
Dedicator of cytokinesis 
protein 7 4.0 0 
STGE 
Q9NY33 Dipeptidyl peptidase 3  4.2 0 ETGE 
O00273 
DNA fragmentation factor 
subunit alpha 1.5 0 
ESGE 
P25205 
DNA replication licensing 
factor MCM3  15.5 0 
ETGE 
P33991 
DNA replication licensing 
factor MCM4  5.0 1.0 
STGE 
P13639 Elongation factor 2  32.0 6.3 ESGE 
Q7Z2Z2 
Elongation factor Tu GTP-
binding domain-containing 
protein 1 4.0 0 
ETGE 
O75821 
Eukaryotic translation initiation 
factor 3 subunit G  4.2 0 
STGE 
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Q13347 
Eukaryotic translation initiation 
factor 3 subunit I 5.7 2.0 
STGE 
Q04637 
Eukaryotic translation initiation 
factor 4 gamma 1  29.0 1.0 
ESGE 
P21333 Filamin-A 9.7 3.0 ETGE 
Q9BQ67 
Glutamate-rich WD repeat-
containing protein 1  2.3 0 
ETGE 
Q9Y450 HBS1-like protein 9.3 0 STGE 
P31943 
Heterogeneous nuclear 
ribonucleoprotein H  14.3 7.0 
STGE 
P31942 
Heterogeneous nuclear 
ribonucleoprotein H3  7.7 4.3 
STGE 
P51610 Host cell factor 1  1.7 0 STGE 
O95202 
LETM1 and EF-hand domain-
containing protein 1, 
mitochondrial  2.2 0 
ETGE 
Q13257 
Mitotic spindle assembly 
checkpoint protein MAD2A 3.0 0 
ESGE 
Q13423 
NAD(P) transhydrogenase, 
mitochondrial  2.5 0 
ESGE 
Q96TA1 Niban-like protein 1  2.5 0 ETGE 
P67809 
Nuclease-sensitive element-
binding protein 1 5.4 1.5 
ESGE 
P55209 
Nucleosome assembly protein 
1-like 1  6.0 2.0 
ETGE 
P62937 
Peptidyl-prolyl cis-trans 
isomerase A  4.4 0 
STGE 
Q15149 Plectin 19.2 0 STGE 
P02545 Prelamin-A/C  2.3 0 STGE 
O15027 
Protein transport protein 
Sec16A 3.0 0 
ESGE 
Q92900 
Regulator of nonsense 
transcripts 1 9.2 0 
ETGE 
P27694 
Replication protein A 70 kDa 
DNA-binding subunit  6.3 2.0 
ESGE 
Q14684 
Ribosomal RNA processing 
protein 1 homolog B 2.0 1.5 
STGE 
Q13501 Sequestosome-1 3.3 0 STGE 
Q96HS1 
Serine/threonine-protein 
phosphatase PGAM5, 
mitochondrial  30.0 4.0 
ESGE 
Q9H2G2 
STE20-like serine/threonine-
protein kinase  2.7 0 
ETGE 
P38646 
Stress-70 protein, 
mitochondrial  13.3 4.0 
ETGE 
Q9NPQ8 Synembryn-A  1.8 0 ETGE 
Q6PGP7 
Tetratricopeptide repeat 
protein 37 5.7 0 
ETGE 
Q8NI27 THO complex subunit 2  2.7 0 ETGE 
Q9Y487 
V-type proton ATPase 116 kDa 
subunit a isoform 2 10.7 0 
ETGE 
O75083 WD repeat-containing protein 1  2.0 0 ETGE 
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Appendix 6. 
Figure detailing the shapes representing different molecules shown in 
Ingenuity pathways and what they represent. Taken directly from: 
http://ingenuity.force.com/ipa/articles/Feature_Description/Legend 
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Appendix 7. 
List of constructs received from Dr Jon Woodsmith, Max-Planck Institute for 
Molecular Genetics, Berlin, Germany for Y2H screen. Includes details of 
location of construct on 96 well plate, gene symbol and ID, the pDONR 
vector the constructs is in and the length of the intern in nucleotides (nt) 
Plate Row Column Symbol GeneID Vector Length(nt) 
1 A 5 PPIA 5478 pDONR221 536 
1 A 8 PSMD3 5709 pDONR221 1643 
1 A 9 DFFA 1676 pDONR221 913 
1 A 10 EFTUD2 9343 pDONR221 2957 
1 A 12 HNRNPH1 3187 pDONR221 1388 
1 B 1 NAP1L1 4673 pDONR221 1214 
1 B 5 HNRNPH3 3189 pDONR221 686 
1 B 8 EIF3G 8666 pDONR221 1001 
1 B 10 EIF3I 8668 pDONR221 889 
1 B 11 RIC8A 60626 pDONR221 1682 
1 C 10 GRWD1 83743 pDONR221 1341 
1 D 1 NCAPH 23397 pDONR221 2226 
1 E 3 HNRNPH1 3187 pDONR221 1350 
1 E 5 YBX1 4904 pDONR221 975 
1 E 6 YBX1 4904 pDONR221 975 
1 E 9 AP3B1 8546 pDONR221 3285 
1 F 1 LETM1 3954 pDONR221 2220 
1 F 7 MCM3 4172 pDONR221 2427 
1 G 7 DFFA 1676 pDONR223 996 
1 G 12 NAP1L1 4673 pDONR223 1176 
1 H 2 GRWD1 83743 pDONR223 1341 
1 H 5 WDR1 9948 pDONR223 1821 
1 H 6 DPP3 10072 pDONR223 2214 
1 H 11 WDR1 9948 pDONR223 1821 
2 A 5 EFTUD2 9343 pDONR223 2919 
2 A 7 MAD2L1 4085 pDONR223 618 
2 B 8 PPIA 5478 pDONR223 498 
2 B 9 NNT 23530 pDONR223 624 
2 C 11 EIF3I 8668 pDONR223 978 
2 D 4 PRKAR2A 5576 pDONR223 1149 
2 E 1 HBS1L 10767 pDONR223 2055 
2 E 2 LETM1 3954 pDONR223 2220 
2 E 11 LMNA 4000 pDONR223 1719 
2 F 1 AP3D1 8943 pDONR223 2229 
2 F 2 MCM3 4172 pDONR223 2427 
2 F 5 AP3B1 8546 pDONR223 3285 
2 F 10 EIF3G 8666 pDONR223 963 
2 G 3 PSMD3 5709 pDONR223 1605 
2 G 4 HSPA9 3313 pDONR223 2040 
2 G 11 DHX8 1659 pDONR223 3650 
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2 H 12 HCFC1 3054 pDONR223 1292 
3 A 2 NCAPH 23397 pDONR223 2231 
3 A 5 EFTUD1 79631 pDONR223 2609 
3 B 4 LMNA 4000 pDONR223 2000 
3 B 7 ATP6V0A2 23545 pDONR223 2576 
3 B 8 DPP3 10072 pDONR223 2219 
3 B 12 CTPS 1503 pDONR223 1781 
3 C 4 FLNA 2316 pDONR223 2522 
3 C 5 RPA1 6117 pDONR223 1856 
3 D 1 EEF2 1938 pDONR223 2577 
3 D 10 RIC8A 60626 pDONR223 1593 
3 E 1 NNT 23530 pDONR223 3261 
3 E 3 SLK 9748 pDONR223 3615 
3 E 6 ZW10 9183 pDONR223 2019 
3 E 10 HNRNPH3 3189 pDONR221 996 
 
Appendix 8. 
Details of Venn diagram comparison of proteins co-purified with Keap1-V5 
following treatment of cells with Nrf2 inducing electrophiles.
 
 
 
 
 
DMSO 
(8) 
DMSO, 
CDDO-
Me (15) 
DMSO, 
DNCB, 
Dex-
mes (3) 
DNCB 
(14) 
DNCB, 
CDDO-
Me (3) 
CDDO-
Me, 
Dex-
mes (2) 
DNCB, 
Dex-
mes (1) 
Q92667 P62191 Q7Z434 O15067 P30041 O75494 Q9NY33 
Q9HAV0 Q8N163 Q16186 P12277 P49588 O60506  
Q12756 Q6P996 P67809 P55072 Q9H0U4   
P51116 P57678  Q01844    
Q99627 P35250  Q9H2G2    
O95456 Q13085  Q9Y3F4    
P62140 P06733  P05091    
P62805 Q92615  P30837    
 Q9HC35  P19338    
 Q8TD19  P22234    
 P57737  P32119    
 P09543  O00273    
 P45974  Q6PKG0    
 O75179  P62913    
 Q07866      
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DMSO, 
Dex-mes 
(19) 
DMSO, CDDO-Me, Dex-mes (277) 
 
CDDO-
Me (29) 
Dex-
mes 
(61) 
 
P49207 Q02978 O43776 Q14498 Q9Y4C2 Q96J01 Q9NZB2 
P06132 P61313 Q01085 Q07666 Q6NXE6 P30520 P40616 
P62318 P63010 Q8TEQ6 Q13526 P56134 O14929 P61962 
Q9Y4R8 O76003 P41250 Q01081 Q9BTW9 Q71DI3 Q5VT66 
Q9BQ67 P46459 P55209 Q9UHD1 O15160 P62937 P11498 
Q8WWM7 P20042 P10768 O96008 P16152 Q13642 Q9UN86 
Q15785 Q9Y5B9 P52789 Q9UBQ7 Q92974 Q0VDF9 P61586 
P62873 Q96QK1 Q86Y56 Q15185 Q9NZL4 O00159 Q9H3K6 
P51148 Q8N1F7 P61619 Q14318 O43491 Q9P2R3 Q01650 
P27348 O43592 Q9UQE7 P14868 P84098 Q7L5N1 P30626 
P61019 P05023 Q9Y224 Q9UGI8 Q9ULC4 O75436 Q8NE71 
P55265 O75694 Q14562 Q13155 P61201 Q15750 P35613 
P36776 O75643 P50502 O60264 O95573 Q15424 Q9Y241 
Q5BKZ1 P33993 P13489 Q9NTJ3 Q9Y263 P08133 O43347 
Q9Y4L1 Q6P2Q9 O14617 Q13098 Q96L92 O43264 P42766 
Q9BXW7 A5YKK6 P35573 Q9Y5L0 Q8WUM0 P46379 P52434 
Q96PK6 O43390 Q14157 Q9BZE4 O95299 O14579 Q92990 
P60660 Q15365 O95433 P08195 P13807 Q14C86 P35658 
P46087 Q15366 Q14671 Q96EP5 Q99829 Q92905 Q15436 
 O75533 Q15021 P62851 Q8TC07 Q7KZI7 P60468 
 Q02878 O43143 P43686 Q01469 Q9H583 Q9ULX3 
 P51991 P19525 Q8TDN6 Q8WWK9 O75369 Q13423 
 P14618 Q5T4S7 A6NDG6 Q9Y295 O60488 Q7L576 
 P50991 Q13595 O94906 P42677 P62333 P0C0S8 
 Q9UQ35 Q9Y277 Q96FW1 O00170 Q9UHI6 P00387 
 P61978 Q15813 Q00535 P41214 Q6P2E9 Q9Y3T9 
 Q92734 Q08J23 P62280 P55196 P46940 Q9UJV9 
 P78527 Q7L1Q6 P31040 P62266 P61353 O15027 
 P22626 P61011 Q3ZCQ8 P62888 P52597 Q9Y2R9 
 P35579 Q9Y450 P39748 Q9Y5M8  Q9H857 
 Q9BVA1 Q92900 Q9BV20 O75569  P18077 
 Q14145 P15170 P53007 P62841  Q66PJ3 
 P45880 Q14697 Q15758 O75821  Q9NTK5 
 P05388 O94874 Q9NZ01 Q9BRX2  Q99714 
 P25705 Q15029 O95793 Q9BTT0  Q92522 
 P63261 Q4VCS5 P23381 Q9BXP5  Q16795 
 P17844 Q9UJS0 Q9UNM6 P04637  Q9NSD9 
 P62826 P53985 Q08945 O60610  Q13523 
 Q15427 O75131 Q96CS3 P63173  P61964 
 P15880 O94973 O00154 P62633  P30101 
 Q16891 P39656 Q14566 Q8N0X7  P49591 
 P18754 P32322 P61081 Q9NVP1  Q9NRG9 
 P12004 Q9Y3A5 P43487 Q9UJU6  O00165 
 P11142 P52209 Q99700 Q9Y696  Q1KMD3 
 Q13148 P35606 P26368 P51571  O43615 
 P18621 P08240 P51114 Q9BVP2  P62879 
 P50914 Q14683 O95163 P50402  Q6UB35 
 Q13263 P33991 P14923 Q15738  Q96EY7 
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 P09874 P31948 P42167 P61803  P61106 
 P43243 Q8N1G4 Q9Y285 Q9H307  Q6PI48 
 P06576 P48735 Q15555 O00264  O75439 
 Q9H9B4 Q9BQG0 O60678 Q9UBM7  O00425 
 O00571 P33992 Q15003 P21964  O15042 
 P14866 Q99613 Q9Y265 Q9ULT8  Q99879 
 P24752 P41091 P78417 O60716  P14625 
 Q14103 P55084 P50454 Q14160  P35580 
 P62899 Q99459 Q15008 Q08752  P20700 
 P08670 P31930 P27694 Q15056  P62917 
 P62701 P18085 P55884 P84103  P18124 
 Q96C36 Q8IYB3 Q9H078 Q9UBB6  P31942 
 Q08211 P78344 P22087 Q9UBX3  Q66K89 
 P07737 Q9UMS4 P11387 P04792   
 P31943 O14979 P11172 O94979   
 P11177 Q9UBF2 Q14839 Q96EY1   
 Q15233 Q9NUU7 P26639 P51570   
 P27824 Q07065 P41240 P00403   
 Q12931 Q13838 Q9H0A0 Q02543   
 Q12906 Q9BXJ9 P60228 P57088   
 Q00325 P33176 Q14258 Q9Y3U8   
 Q92841      
       
 
 
DMSO, DNCB, CDDO-Me, Dex-mes (203) 
CDDO-Me,Dex-Mes (83) 
 
Q9Y3I0 P23528 P35268 Q8TEX9 P62834 Q13547 
P84077 P62995 P62854 P78371 P50995 P14324 
P46781 Q12904 Q16643 O14654 P14406 Q99460 
P30566 P28288 O15260 P08243 Q8TCT9 P51398 
P00558 Q9P035 P26196 P13010 P51648 Q9UJZ1 
Q14203 Q13501 P46776 P52292 Q86X55 Q6YN16 
Q92499 P06748 P62314 P53396 O43396 Q14126 
P38919 Q99873 P60866 P63241 P25789 P49755 
Q14152 P36542 O75964 P12956 Q96KR1 P51149 
Q92973 Q9HAV4 Q9UNS2 Q9UQ80 Q16576 Q7L0Y3 
Q96I24 P62906 O43684 O94826 P21266 P23526 
Q8WUM4 O94905 Q06830 P26641 Q8NBU5 Q96P70 
Q92621 Q13200 P83731 Q9NR30 Q9UL25 Q8NCA5 
Q9Y2L1 P62829 Q12769 P12236 Q8TC12 Q9UNE7 
O43242 Q9BT78 Q92945 P16615 P58107 P68400 
P54577 P35998 Q9UNX3 Q9NZI8 Q5SRE5 O43747 
P22102 P62244 O00487 P48643 P82675 Q53GQ0 
Q12905 O00299 P46778 P60842 Q14677 P51572 
P26640 P40429 P30050 Q02790 Q9H0S4 P46782 
P11940 Q9BY44 Q9NS69 P53618 P38606 P61026 
Q9Y2Z0 Q9Y230 Q96T76 Q99832 P53992 Q9P2R6 
Q9H3U1 O95373 P31689 P40227 Q14694 O95347 
P49915 P62750 P17980 P35637 P52306 Q7L2H7 
Q14166 P32969 P05387 Q86VP6 Q53H12 Q07955 
  Appendix 
- 217 - 
 
P38646 Q99615 Q15084 Q04637 P52565 Q9Y5V3 
P30153 P29692 P24534 O43175 P46783 Q86UE4 
P48444 Q7Z6Z7 P62277 P54886 P37802 Q92552 
O75534 Q16543 Q9UNF1 P05141 P24539 Q9P2E9 
P25205 P46977 P62987 P49368 Q9NX63 Q9Y262 
Q9Y487 P62081 P08559 Q9Y678 P41227 O14974 
P23246 O15371 Q13347 P41252 O60762 Q7L2E3 
P04844 P18031 P46777 P09651 Q5JTH9 Q5T9A4 
O76094 P62195 P55010 P53621 Q09028 Q15149 
Q9UHB9 Q15717 P23921 P27708 Q96AG4 P35232 
P26599 O00231 P24666 P50990 P17655 P07910 
P46060 O00303 Q9Y5A9 Q9P2J5 P61421 P21796 
Q93008 Q7Z2W4 P62495 O00410 Q13151 P38159 
P11021 Q9UBB4 Q07021 P07900 P62424 P36578 
Q5VYK3 Q15393 P17812 Q7KZF4 Q07020 P40939 
Q9UG63 P06493 P27635 P55060 P04843 Q13435 
P11586 Q14739 P04406 Q9Y490 P62249 Q99623 
P47897 P21333 P78347 Q14974 P42704  
Q14008 Q9UDY2 P46779 P17987   
P54136 Q99729 P08865 P13639   
P56192 P60891 Q71RC2 P08107   
O14980 P62269 P26373 P07814   
Q00341 O00232 P05198 P68104   
P49411 P22695 O76021 Q14204   
Q9BUF5 P68371 P10809 Q96HS1   
Q00610 P07437 P16403 P08238   
P68363 P49327  Q92616   
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